 
  
 
 
 
  Distribution Date:  TBD 
Version Date:  August 21, 2017  
 
TO: PHASE I SITES: U of CA LOS ANGELES (CA006 ), U OF 
SOUTHERN CALIFORNIA (CA011), U of CA SAN FRANCISCO 
(CA136), CALIFORNIA PACIFIC (CA222), U OF COLORADO 
(CO070), H. LEE MOFFITT CANCER CENTER (FL065), U OF MICHIGAN (MI014), OHIO STATE UNIV (OH007), CLEVELAND 
CLINIC (OH027), OREGON HEALTH SCIENCES UNIVERSITY 
(OR010), PROVIDENCE PORTLAND  MC (OR014) , U OF 
TENNESSEE – MEMPHIS (TN030), MD ANDERSON (TX035), U 
OF WASHINGTON (WA020)  
 
PHASE II:  SWOG  
 
FROM:  Danae Campos, Protocol Coordinator (E -mail- [EMAIL_15232]
) 
 
RE: S1221, “Phase I/II Study of the Safety and Efficacy of the AKT 
Inhibitor [COMPANY_004]2141795 in Combination with Dabrafenib and 
Trametinib in Patients with BRAF Mutant Cancer.”  Study Chairs:  
Drs. A. Ribas, B. Chmielowski, R. Lo, and A Algazi.  
 
REVISION #10  
 
Study Chair:  Antoni Ribas, M.D., Ph.D.  
Phone Number:  310/206- 3928  
E-mail:  [EMAIL_15233]  
 IRB Review Requirements 
( √ ) Expedited review allowed 
 
Protocol changes  
( √ ) Informed Consent  changes  
( √ ) Patient notification required (Patients currently receiving [COMPANY_004]2141795 must be reconsented.)  
 
Sites  using the  CIRB as their IRB  of record :  The protocol and/or informed consent 
form changes have been approved by [CONTACT_800833] 30 days 
of the CIRB posting of this notice.  
 
Sites  not using the NCI CIRB:  Per CTMB Guidelines, the protocol updates and/or 
informed consent changes must be approved by [CONTACT_800834] 90 days of 
distribution of this notice. The changes in this revision are effective upon approval by 
[CONTACT_1036]; however,  any changes to eligibility become effective 6 weeks after 
distribution of this notice.  
 
 
REVISION #10  
  
 S1221  
 Revision #10 (contd.)  
 Page [ADDRESS_1105365] been made in the protocol referenced above:  
 
1. Title Page : The version dates of the protocol and model consent form have been updated.  
 
2. ICF:  Page 13, under the section “What are the costs of taking part in this study”, the 
paragraph beginning “If your disease progresses before the new drug supply”, was deleted as there will  be no additional supply of [COMPANY_004]2141795 available after 09/30/2018.  
 
This memorandum serves to notify the NCI and the SWOG Statistical Center.  
 
cc:  PROTOCOL & INFORMATION OFFICE   
Syed Mahmood - [COMPANY_001]  
 
 
 
 
  S1221  
  Page 1 
 Version Date 8/21/17  
 
  
 
PRIVILEGED COMMUNICATION  Activated July 1, 2013  
FOR INVESTIGATIONAL USE ONLY  
 
SWOG  
 
 
 
PHASE I/II STUDY OF THE SAFETY AND EFFICACY OF THE AKT INHIBITOR  [COMPANY_004]2141795 IN 
COMBINATION WITH DAB RAFENIB AND TRAMETINIB  IN PATIENTS WITH BR AF MUTANT CANCER  
 
NCT #01902173  
  
STUDY CHAIRS : AGENTS : 
 Antoni Ribas, M.D., Ph.D. (Medical Oncology)  NCI-Supplied Investigational Agents : 
UCLA Medical Center  Dabrafenib Mesylate (NSC -763760; IND -118705) 
Division of Hematology -Oncology  [COMPANY_004]2141795 (NSC -767034; IND-118705) 
11-934 Factor Building  Trametinib (NSC -763093;  IND-119432)  
[ADDRESS_1105366]   
Los Angeles, CA [ZIP_CODE]   
Phone: 310/206- 3928   
FAX: 310/825- 2493   
E-mail: [EMAIL_15233]  BIOSTATISTICIANS  
   
Alain P. Algazi, M.D. (Medical Oncology)  James Moon, M.S.  
University of [LOCATION_004], San Francisco  Megan Othus, Ph.D.  
[ADDRESS_1105367] North, M3- C102  
Phone:  415/353- 7552  [PO_BOX] 
FAX:  415/353- 7779  Seattle, WA [ZIP_CODE]- 1024  
E-mail:  [EMAIL_15234]  Phone: 206/667- 4623  
 FAX: 206/667- 4408  
Bartosz Chmielowski, M.D., Ph.D. (Medical Oncology)  E-mail: [EMAIL_15235]  
University of [LOCATION_004], Los Angeles  E-mail: [EMAIL_14824] 
David Geffen School of Medicine  
Division of Hematology/Oncology  
[ADDRESS_1105368], PVUB Suite 2333  
Los Angeles, CA  [ZIP_CODE]- 7059  
Phone:  310/586- 2650  
FAX:  310/443- 0477  
E-mail:  [EMAIL_15236]  
 Roger S. Lo, M.D., Ph.D. (Translational Medicine)   
UCLA Medical Center   
Division of Dermatology   
52-[ADDRESS_1105369]   
Los Angeles, CA [ZIP_CODE]   
Phone: 310/825- 5420   
FAX: 310/206- 9878   
E-mail: [EMAIL_15237]  
 
  
 S1221  
 Page 2 
 Version Date 8/21/17  
 
  
 
   
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
PARTICIPANTS  
PHASE I PORTION LIMITED TO THE FOLLOWING:  
CA006 /U OF CA LOS ANGELES  
CA011 /U OF SOUTHERN CALIFORNIA  
CA136 /U OF CA SAN FRANCISCO 
CA222 /CALIFORNIA PACIFIC 
CO070/U OF COLORADO  
FL065/H. LEE MOFFITT CANCER CENTER  
MI014/U OF MICHIGAN  
OH007/OHIO STATE UNIV  
OH027/CLEVELAND CLINIC  
OR010/OREGON HEALTH SCIENCES UNIVERSITY  
OR014/ PROVIDENCE PORTLAND MC NCORP  
TN030/U OF TENNESSEE - MEMPHIS  
TX035/MD ANDERSON  
WA020 /U OF WASHINGTON  
 
PHASE II PORTION:  
 
SWOG /SWOG  
   S1221  
   Page 3 
   Version Date 8/21/17  
 
  
 
TABLE OF CONTENTS  
 Page  
 PARTICIPANTS  ...................................................................................................................................... 2  
SCHEMA  ................................................................................................................................................. 5  
1.0 OBJECTIVES  ............................................................................................................................ 6  
1.1 Primary Phase I Portion Objective  ............................................................................................. 6  
1.2 Primary Phase II Portion Objective  ............................................................................................ 6  
1.3 Secondary Objectives  ................................................................................................................ 6  
1.4 Translational Medicine Objective  ............................................................................................... 6  
2.0 BACKGROUND  ......................................................................................................................... 7  
3.0 DRUG INFORMATION .............................................................................................................. 12 
3.1 Dabrafenib mesylate ([COMPANY_004]2118436B) (NSC -763760) (CTEP IND# 118705)  ........................... 12 
3.2 [COMPANY_004]2141795 ([COMPANY_004]2141795C) (NSC -767034) (CTEP IND #118705)  ...................................... 19 
3.3 Trametinib Dimethyl Sulfoxide ([COMPANY_004]1120212B) (NSC -763093) (IND -119432)  ........................ 23 
4.0 STAGING CRITERIA  (AJCC 7
th Edition, 2010)  ....................................................................... 31 
5.0 ELIGIBILITY CRITERIA  ............................................................................................................ 32 
5.1 Phase I Portion Eligibility Criteria  ............................................................................................... 32 
5.2 Phase II Portion Eligibility Criteria  .............................................................................................. 36 
6.0 STRATIFICATION FACTORS  ................................................................................................... 37 
7.0 TREATMENT PLAN  .................................................................................................................. 37 
7.1 Treatm ent Overview  ................................................................................................................... 37 
7.2 General Concomitant Medication and Supportive Care Guidelines  .......................................... 37 
7.3 Treatment - Phase I  Dabrafenib + [COMPANY_004]2141795 (D+G)  ........................................................... 38 
7.4 Treatment - Phase I  Dabrafenib + Trametinib + [COMPANY_004]2141795 (D + T + G)  ............................. 41 
7.5 Treatment - Phase II Portion of the Study  .................................................................................. 43 
7.6 Guidelines for Administration ..................................................................................................... 43 
7.7 Drug Compliance Documentation  .............................................................................................. 44 
7.8 Full CDUS Reporting Requirements  .......................................................................................... 44 
7.9 Criteria for Removal from Protocol Treatment  ........................................................................... 44 
7.10 Disc
ontinuation of Treatment  ..................................................................................................... 44 
7.11 Follow -Up Period  ........................................................................................................................ 44 
8.0 TOXICITIES TO BE MONITORED AND DOSAGE MODIFICATIONS  .................................... 45 
8.1 NCI Common Terminology Criteria for Adverse Events  ............................................................ 45 
8.2 General Dose Modification Considerations ................................................................................ 45 
8.3 Dose Modifications for Dabrafenib, Trametinib, and [COMPANY_004]2141795  ........................................... 45 
8.4 Dose Modifications for [COMPANY_004]2141795  ......................................................................................... 63 
8.5 Dose Modification Contacts  ....................................................................................................... 64 
8.6 Adverse Event Reporting  ........................................................................................................... 64 
9.0 STUDY CALENDAR  .................................................................................................................. 64 
9.1 Study Calendar – Phase I D+G Portion  ..................................................................................... 65 
9.2 Study Calendar – Phase I D+T +G Portion  ................................................................................ 68 
9.3 Study Calendar – Phase II D+T+G  ............................................................................................ [ADDRESS_1105370] Response  ........................................................................................................................... 76 
10.4 Performance Status  ................................................................................................................... 77 
10.5 Progression- Free Survival .......................................................................................................... 77 
10.6 Time to Death  ............................................................................................................................. 77 
11.0 STATISTICAL CONSIDERATIONS  .......................................................................................... 77 
11.1 Accrual Goals  ............................................................................................................................. 77 
11.2 Evaluation of Dabrafenib + [COMPANY_004]2141795 (D+G)  ....................................................................... 78 
11.3 Evaluation of Dabrafenib + Trametinib + [COMPANY_004]2141795 (D+T+G)  ............................................. 79 
11.4 Analysis of Secondary Endpoints  .............................................................................................. 80 
11.5 Analysis of Translational Medicine Component  ......................................................................... 80 
11.6 Data and Safety Monitoring  ....................................................................................................... 81 
   S1221  
   Page 4 
   Version Date 8/21/17  
 
  
12.0 DISCIPLINE REVIEW  ................................................................................................................ 81 
13.0 REGISTRATION GUIDELINES  ................................................................................................. 81 
13.1 Registration Timing .................................................................................................................... 81 
13.2 Slot Reservation  ......................................................................................................................... 81 
13.3 O PEN Registration Requirements  ............................................................................................. 82 
13.4 Registration Procedures ............................................................................................................. 83 
13.5 Exceptions to SWOG registration policies will not be permitted.  ............................................... 84 
14.0 DATA SUBMISSION SCHEDULE  ............................................................................................ 84 
14.1 Data Submission Requirement  .................................................................................................. 84 
14.2 Master Forms  ............................................................................................................................. 84 
14.3 Data Submission Procedures  .................................................................................................... 84 
14.4 Data Submission Overview and Timepoints  .............................................................................. 85 
15.0 SPECIAL INSTRUCTIONS ........................................................................................................ 87 
15.1 Phase I Portion:  Rapid Reporting  ............................................................................................. 87 
15.2 Phase I Portion:   Mandatory Conference Calls  .......................................................................... 87 
15.3 Phase I Portion:   Mandatory Pharmacokinet ic (PK) Sampling  .................................................. 87 
15.4 Phase I & II Portions:  Mandatory Specimen Submission for Translational Medicine  ............... 88 
16.0 ETHICAL AND REGULATORY CONSIDERATIONS  ............................................................... 89 
16.1 Adverse Event Reporting Requirements .................................................................................... 91 
17.0 BIBLIOGRAPHY  ........................................................................................................................ 96 
18.0 APPENDIX  ................................................................................................................................. 98 
18.1 Determination of Expedited Adverse Event Reporting Requirements  ....................................... 99 
18.2 Translational Medicine  ............................................................................................................... 101 
18.3 Intake Calendar  .......................................................................................................................... 102 
18.4 Strong inducers/inhibitors of CYP3A, CYP2C8, Pgp, Bcrp and possibly 2C8/9 and 2C19  ....... 103 
18.5 [LOCATION_001] Heart Association Classifications  .............................................................................. 106 
18.6 Information on Possible Drug Interactions  ................................................................................. 107 
18.7 Information on Possible Drug Interactions – Patient Wallet Card  .............................................. 109 
18.8 Instr
uctions for Patients for Storage of Trametinib Tablets  ........................................................ 110 
 
 
  
 S1221  
Page 5 
Version Date 8/21/17  
 
  
  
SCHEMA  
 
Phase I p ortion (open to limited institutions  as listed on the Title Page ): 
 
Registration  
   
 
Dabrafenib + [COMPANY_004]2141795  
  
 
 
Assess dosing for triple therapy phase I portion 
  
 
  
Dabrafenib + Trametinib +[COMPANY_004]2141795  
  
 
  
Temporary closure to assess  
dosing for Phase II  portion  
 
 
 
Phase II p ortion (open to all SWOG institutions): 
  
Registration  
   
 
Dabrafenib and Trametinib + [COMPANY_004]2141795  
  
 
A patient may be enrolled to either the Phase I p ortion or the Phase II portion, but not both.  
 S1221  
 Page 6 
Version Date 8/21/17  
 
  
1.0 OBJECTIVES  
 1.1 Primary Phase I Portion Objective  
 
Dabrafenib + [COMPANY_004]2141795  
 
The primary objective of the Phase I Portion will be to assess the safety of dabrafenib in 
combination with [COMPANY_004]2141795 and select the optimal  dose of [COMPANY_004]2141795  for the 
Phase II P ortion in patients with BRAF mutant cancer.  Effective November 15, 2014, this 
trial will not proceed to the Phase  II study  of dabrafenib and [COMPANY_004]2141795 , but will 
moving to an evaluation of triple therapy.  See below ) 
 
Dabrafenib + Trametinib + [COMPANY_004]2141795  
 
The primary objective of the Phase I portion will be to assess the safety of dabrafenib and 
trametinib and [COMPANY_004]2141795 in combination and select the optimal  dose of the 
combination  for the Phase II P ortion  in patients with BRAF mutant cancer.  
 
1.2 Primary Phase II P ortion Objective  
 
The primary objective of the Phase II portion will be to evaluate the objective response 
rate (confirmed and unconfirmed, complete and partial responses) in patients with 
BRAF
V600 mutant metastatic melanoma who  have prev iously -have previously progressed 
on BRAFV600 inhibitor -based therapy (BRAFi), or BRAFi + MEK inhibit or-based therapy 
(MEKi).  
 1.3 Secondary Objectives  
 
a. To estimate overall survival and progression- free survival.  
 
b. To assess the toxicity profile of the recommended Phase II dose.  
 
c. To assess response ( complete and partial, confirmed and unconfirmed)  of 
patients enrolled on each Phase I portion.  
 1.[ADDRESS_1105371]  MAPK- reactivation resistance: Detection of 
BRAF
V600 amplification, BRAFV600 truncation, NRASQ61 mutations and MEK 
mutations, which are the most validated and readily detectable acquired MAPK -
reactivation resistance mechanisms.   Additional analyses to detect other 
mechanisms of resistance, particularly those involving the AKT pathway, will be 
explore d, as will be targeted sequencing of genes in the P13K/AKT pathway.  
 b. All patients participating in the Phase I portions of the study will have a limited PK 
sampling at baseline and at steady state on Days 15 and 29 before taking the 
study drugs on that day. In addition, three patients treated within the second 
cohort of each of the Phase I p ortion s (D+G and D+T+G)  will undergo an intense 
15 day pharmacokinetic (PK) sampling for circulating levels of the study drugs .  
This will be performed to explore potential drug- drug interactions between 
dabrafenib and [COMPANY_004]2141795 leading to changes in the expected exposure with 
either agent compared to prior experience.   
  S1221  
 Page 7 
Version Date 8/21/17  
 
  
2.0 BACKGROUND  
 
The BRAF inhibitors vemurafenib and dabrafenib confer objective response in about half of 
treated patients with BRAFV600 mutant metastatic melanoma, which is mediated by [CONTACT_800835].  Their clinical use is limited by [CONTACT_800836][INVESTIGATOR_014], which typi[INVESTIGATOR_300791] 6 months of 
continuous therapy with dabrafenib or vemurafenib. (1-7) 
 
Resistance to BR AF inhibitors does not follow the common pathways of resistance to other ATP -
competitive targeted kinase inhibitors in that no mutations in the actual target kinase have been described that would make the drug binding ineffective.  Notably, no mutations ha ve been 
described in patient -derived samples that would correspond to the T315I resulting in resistance to 
imatinib in chronic myelogenous leukemia, or the T790M mutation resulting in resistance to gefitinib in non- small cell lung cancer.  (8,9
)  Instead, a variety of mechanistically different 
resistance pathways have been described in subsets of acquired resistant tumor biopsies.  These 
can be divided into two major groups when focusing on mechanisms reported to date in patient -
derived samples:  
 
1. Reactivation of the MAPK pathway :  Despi[INVESTIGATOR_800802], several alterations leading to reactivation of oncogenic signaling through the MAPK pathway result  in acquired resistance to BRAF inhibitors.  Of 
note, the resistant lesions universally maintain the BRAF
V600 mutation.  However, there 
can be other changes in BRAF itself, including amplifications of the mutant BRAFV600 
gene and truncations in the BRAF protein through alternate splicing resulting in increased 
kinase activity due to increased dimerization. (10,11)  Secondary mutations upstream or 
downstream of BRAF would also be predicted to result in resistance, and secondary 
mutations in NRAS and MEK have been described in patient -derived samples. (12,13 )  
However, some patients with a concurrent mutation in BRAFV600 and MEKP124 at baseline 
can still have clinical responses to BRAF inhibitors. (14)  Finally, overexpression of the 
MAPK protein COT without mutations has been suggested to also lead to acquired resistance. (
15)  Overall, data derived from analyzing tumor samples from baseline and 
at the time of acquired resistance, indicate that resistance due to reactivation of the MAP 
kinase pathway is present in 70% of the cases with a known or proposed resistance 
mechanism.  (16)  Most of these resistance mechanisms could be blocked by 
[CONTACT_800837].  Combined BRAF and 
MEK inhibition has been tested in randomized Phase II and Phase III clinical trials using 
the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib. (17,18)  Combination 
therapy substantially increases median PFS compared with dabrafenib alone and the FDA has approved the combination of dabrafenib and trametinib for the first line 
treatment of BRAF mutant melanoma. This combination is generally well tolerated and 
the addition of trametinib to dabrafenib actually reduced the incidence of several significant adverse effects of BRAF  inhibitors. Based on the favorable adverse effect 
profile of dabrafenib with trametinib, triple therapy with dabrafenib, trametinib, and an additional agent may be feasible.  
 
2.  MAPK -independent pathways:   In approximately one-fourth to one- third of the cases of 
acquired resistance, the BRAF inhibitor continues to demonstrate ability to block 
oncogenic BRAFV600 signaling, and the cell adapts to gain MAPK- independent oncogenic 
signaling often leading to overactivation of the PI3K  pathway.  (12,16)  Mechanisms of 
resistance include overexpression or overactivation of receptor tyrosine kinases (RTKs), 
such as the platelet derived growth factor receptor beta (PDGFRb) the insulin- like growth 
factor receptor 1 (IGF -1R), or the epi[INVESTIGATOR_3506] (EGFR). (12,19,20)  
Acquired resistance can also be induced by [CONTACT_800838]3K 
pathway cons tituents including PIK3CA, PTEN, and PHLPP1. (16) Innate resistance to 
BRAF inhibitor therapy can be mediated by [CONTACT_187043] (HGF) binding to the RTK Met.   (
21,22)  These RTKs share a common signaling hub, the PI3K -AKT 
pathway . In preclinical models this signaling can be inhibited by [CONTACT_800839]3K, 
AKT or PI3K+TORC , restoring tumor responses in  the acquired resistance setting.  
 S1221  
 Page 8 
Version Date 8/21/17  
 
  
(19,23- 25)  Unpublished data also suggest  that acquired resistance to dual BRAF and 
MEK inhibition may lead to increased reliance on MAPK -independent pathways during 
drug escape  and combined BRAF, MEK and AKT inhibition demonstrates substantial 
synergy preclinically in treatment -naïve models ( See Rationale for Triple Therapy ). 
 
Clinical Experience with the Combination of Dabrafenib + Trametinib  
 
Data on 247 patients with metastatic melanoma and BRAFV600 mutations participating in the 
Phase I/II study of dabrafenib and trametinib, BRF113220, have been published (Flaherty  et al., 
2012) . 
 
PK 
Coadministration of dabrafenib 150 mg twice daily and trametinib 2  mg once daily resulted in no 
clinically relevant pharmacokinetic drug interactions.   
 
RP2D for the combination of trametinib and dabrafenib 
In the dose escalation portion (Part B) of study BRF113220, the MTD of the combination was not reached, and the RP2D was therefore 150/2 (Flaherty et al. , 2012).  Pyrexia, chills, and nausea 
were the most common reasons cited for dose reductions; pyrexia, chills, and decreased ejection fraction were the most common reasons cited for dose interruptions.  Comprehensive safety data for the combination of dabrafenib and trametinib are presented in Section 3.0
. 
 
Activity of dabrafenib +  trametinib  
In the P hase II portion of study BRF113220, among 162 patients with BRAFV600E or BRAFV600K 
mutation- positive melanoma, were randomized to 3 arms: dabrafenib 150 mg BID + trametinib 2 
mg QD, dabrafenib 150 mg BID + trametinib 1 mg QD, and single- agent dabrafenib 150 mg BID, 
efficacy analyses were performed in the intention- to-treat population, with a median follow -up of 
14.1 months . (17)  All major efficacy endpoints were improved, including PFS, 12- month PFS, 
ORR, and duration of response (see table below).   
 
End Point  
(as assessed by [CONTACT_473])  Dabrafenib 
Monotherapy 
(n=54)  Combination 
150/1  
(n=54)  Combination 
150/2  
(n=54)  
Progression -free Survival – months  
Median (95% CI)  5.8 (4.6- 7.4) 9.2 (6.4- 11.0)  9.4 (8.6- 16.7)  
Progression -free Survival at 12 mo. % 
(95% CI)  9 (3-20) 26 (15- 39) 41 (27- 54) 
CR or PR  
Patients (% [95% CI])  29 (54 [40- 67]) 27 (50 [36- 64]) 41 (76 [62- 86]) 
Duration of response  
Median months (95% CI)  5.6 (4.5- 7.4) 9.5 (7.4- NA) 10.5 (7.4- 14.9)  
 
Safety data for trametinib in combination with [COMPANY_004]2141795  
 
The combination of trametinib and [COMPANY_004]2141795 has been examined in Phase I and Phase II 
clinical trials.  In Phase I testing, the most common adverse events (≥10%) were nausea (26%; 
G3/4 0%), AST elevation (22%; G3/4 9%), fatigue (22%; G3/4 0%), rash (22%; G3/4 0%), 
decreased appetite (17%; G3/4 0%), hypokalemia (17%; G3/4 0%), anemia (13%; G3/4 0%), 
confusional state (13%; G3/4 0%), dry mouth (13%; G3/4 0%), peripheral edema (13%; G3/4 
0%), and vomiting (13%; G3/4 0%). (26)  The recommended  Phase  II dose is trametinib 1.5 mg 
daily with [COMPANY_004]2141795 50 mg daily.   
S1221  
 Page 9 
Version Date 8/21/17  
 
Rationale for triple therapy  
Preclinical Rationale : 
Activating mutations in the PI3K pathway have been described in 22% of tumors that acquired resistance to BRAF inhibitors, most frequently in combination with activating mutations of the 
MAPK pathway. (16) There are emerging data suggesting that the PI3K pathway plays a pi[INVESTIGATOR_800803] 
(Roger Lo, unpublished data).  In preclinical testing, combined BRAF/MEK/AKT inhibition leads to 
profound decreases in BRAF mutant melanoma cell survival.  
 
 
Despi[INVESTIGATOR_800804], the addition of the MEK inhibitor trametinib alone to the BRAF inhibitor dabrafenib after disease progression on dabrafenib alone yields only modest c linical benefits with 
an objective response rate of only 9- 15% and a median progression- free survival of only 3.6 
months. (27)  As a result, the combination of dabrafenib and trametinib after disease progression 
on a BRAF inhibitor has not been FDA approved and the vast majority  of BRAF mutant 
melanoma patients treated with BRAF inhibitor monotherapy have no effective targeted therapy options after disease progression on these agents (median PFS 5- 6 months). (3,4) The current 
study will examine the safety and efficacy of combined BRAF, MEK, and AKT inhibition based on 
preclinical data suggesting that resistance to MAPK inhibitors may be mediated by [CONTACT_800840]3K pathway mutations  and non- mutational activation of the PI3K pathway . (12,16,19-25)  
Phase II testing of this combination in treatment naïve patients is based on data suggesting that 
1. PI3K activity may be essential for the survival of senescent cells after maximal tumor killing from dabrafenib and trametinib and 2. The molecular evolution of surviving tumors in patients with disease progression on BRAF inhibitors may make the addition of additional oncogenic pathway 
inhibitors less effective at the time of progression than at the time of the initiation of BRAF 
inhibitor therapy (Roger Lo, unpublished data).  
Lassen et al.  Molecular Cancer. 2014.  
 S1221  
Page 10  
Version Date 8/21/17  
 
  
 
The rationales for the S1221 treatment arms are summarized below:  
 
   
 
   
 
   
 
   
 
   
 
   
Study outline  
 
Dabrafenib + [COMPANY_004]2141795 :  
Phase I dose escalation will be performed according to a standard 3+3 scheme to identify the 
maximum tolerated dose (MTD) of dabrafenib with [COMPANY_004]795 prior to Phase 1 testing of 
dabrafenib, trametinib, and [COMPANY_004]2141795.  The dabrafenib + [COMPANY_004]795 combination without 
trametinib will not continue to Phase 2 testing under the current protocol.  
 
Dabrafenib + Trametinib + [COMPANY_004]2141795 :  
3 + 3 dose escalation will be performed to identify the MTD of dabrafenib, trametinib, and [COMPANY_004]2141795 in combination.  Phase II testing will then be performed to obtain additional safety  
information and preliminary efficacy data in two populations:  1. Patients with prior disease progression on a BRAF inhibitor alone  or a BRAF + MEK inhibitor combination and 2. Patients 
with no prior exposure to BRAF or MEK inhibitors.   
 
Hypothesis  
 
• The AKT inhibitor [COMPANY_004]795 can be combined safely with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib.  
• In patients with prior disease progression on BRAFi monotherapy or a BRAFi + MEKi 
combination, the addition of [COMPANY_004]795 and trametinib to dabrafenib will increase the overall 
response rate compared with historical controls treated with standard of care chemotherapy.  
• Triple therapy with dabrafenib, trametinib, and [COMPANY_004]795 will increase the overall response 
rate in BRAFi/MEKi naïve patients compared with historical controls treated with dabrafenib 
and trametinib without a PI3K pathway inhibitor.  
 Treatment arm  Prior treatment  Rationale  
D + G Phase  I 
(BRAFV600X solid tumors)  Any Identify MTD.  
 
 
D + T + G Phase  I 
(BRAFV600X melanoma)  
 Any Identify MTD,  
Early response signal.  
D + T + G Phase II 
(BRAFV600X melanoma)  
 Prior PD on BRAFi  or BRAFi + 
MEKi  Allows early assessment of 
benefit (ORR).   
Clinical need: Addition of 
MEKi alone after progression 
on BRAFi only modestly 
beneficial.  
No prior BRAFi or MEKi  Preclinical data suggests 
potential for more durable 
benefit due to targeting of 
senescent cells and 
prevention of emergence of 
resistance due to PI3K 
pathway activation.  
 S1221  
Page 11  
Version Date 8/21/17  
 
  
Inclusion of Women and Minorities  
 This study was designed to include women and minorities, but was not designed to measure 
differences of intervention effects.  The anticipated accrual in the ethnicity/race and sex 
categories is shown in the table below.  
 
Ethnic Category  
Females  Males  Total  
Hispanic or Latino  2 1 3 
Not Hispanic or Latino  32 62 94 
Total Ethnic  34 63 97 
Racial Category  
American Indian or Alaskan Native  2 0 2 
Asian  0 0 0 
Black or African American  0 0 0 
Native Hawaiian or other Pacific Islander  0 0 0 
White  32 63 95 
Racial Category: Total of all Subjects  34 63 97 
 
 
  
  S1221  
 Page 12  
 Version Date 8/21/17  
 
  
3.0 DRUG INFORMATION  
Investigator’s Brochures : 
 For information regarding Investigator ’s Brochures, please refer to SWOG Policy 15.  
 
For this study, dabrafenib mesylate, trametinib,  and [COMPANY_004]2141795 are investigational and are 
being provided under an IND held by [CONTACT_29630].  The Investigator Brochures  
may be obtained by [CONTACT_461480]’s Pharmaceutical Management Branch (PMB) at 240/276-
6575 . 
 
3.1 Dabrafenib mesylate ([COMPANY_004]2118436B ) (NSC -763760) (CTEP IND# 118705) 
 
a. DESCRIPTION  
 
Chemical Name:   N-{3-[5-(2-Amino -4-pyrimidinyl) -2-(1,1-
dimethylethyl) -1,3-thiazol -4-yl]-2-fluorophenyl} -2,6-
difluorobenzene sulfonamide, methanesulfonate 
salt 
 
Other Names :  [COMPANY_004]2118436, [COMPANY_004]2118436A (free base)  
 
Classification :  BRAF inhibitor  
 
CAS Registry Number :  1195768- 06-9 
 
Molecular Formula:  C23H20F3N5O2S2 ·CH 4O3S 
 
Molecular Weight :  615.68 (mesylate salt)  
 
Mode of Action: Dabrafenib mesylate ( [COMPANY_004]2118436B)  is a potent and selective 
BRAF kinase inhibitor. This inhibition suppresses downstream activity of pERK, a biomarker, and has antiproliferative activity against BRAF mutant tumors. The mode 
of action is consistent with ATP -competitive inhibition.  
 
b. TOXI COLOGY  
 
Comprehensive Adverse Events and Potential Risks list (CAEPR) f or 
Dabrafenib mesylate ([COMPANY_004]2118436B, NSC 763760)  
 The Comprehensive Adverse Event and Potential Risks list (CAEPR) provides a single list of reported and/or potential adverse events (AE) associated with an 
agent using a uniform presentation of events by [CONTACT_6764]. In addition to the 
comprehensive list, a subset, the Specific Protocol Exceptions to Expedited 
Reporting (SPEER), appears in a separate column and is identified with bold and 
italicized text. This subset of AEs (SPEER) is a list of events that are protocol 
specific exceptions to expedited reporting to NCI via CTEP- AERS  (except as 
noted below).  Refer to the 'CTEP, NCI Guidelines: Adverse Event Reporting 
Requirements' 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf for further clarification.  Below is the C AEPR for Dabrafenib mesylate 
([COMPANY_004]2118436B).  
 
 S1221  
 Page 13  
Version Date 8/21/17  
 
  
NOTE : Report AEs on the SPEER ONLY IF  they exceed the grade noted in 
parentheses next to the AE in the SPEER.  If this CAEPR is part of a combination protocol using multiple investigational agents and has an AE listed 
on different SPEERs, use the lower of the grades to determine if expedited 
reporting is required.  
Version 2.3, May 20, [ZIP_CODE] 
 
 Adverse Events with Possible  
 Relationship to Dabrafenib mesylate ([COMPANY_004]2118436B)  
 (CTCAE 4.0 Term)  
[n= 1291]   
 Specific Protocol 
Exceptions to 
Expedited Reporting 
(SPEER)  
 
Likely (>20%)  Less Likely 
(<=20%)  Rare but 
Serious (<3%)   
BLOOD AND LYMPHATIC SYSTEM DISORDERS   
 Anemia2,3   Anemia2,3 (Gr 2)  
EYE DISORDERS   
  Eye disorders - 
Other (iritis)4  
  Uveitis4  
GASTROINTESTINAL DISORDERS   
 Abdominal pain   Abdominal pain (Gr 
3) 
 Constipation   Constipation (Gr 3)  
 Diarrhea   Diarrhea (Gr 3)  
Nausea    Nausea (Gr 3)  
  Pancreatitis   
 Vomiting   Vomiting (Gr 3)  
GENERAL DISORDERS AND ADMINISTRATION SITE 
CONDITIONS   
 Chills   Chills (Gr 2)  
 Edema limbs5  Edema limbs5 (Gr 2)  
Fatigue    Fatigue (Gr 3)  
Fever6   Fever6 (Gr 2)  
 Flu like 
symptoms   Flu like symptoms 
(Gr 2)  
 General 
disorders and 
administration 
site conditions  - 
Other 
(hemorrhage)7   
IMMUNE SYSTEM DISORDERS   
  Allergic reaction8  
INFECTIONS AND INFESTATIONS   
 Infections and 
infestations - 
Other 
(nasopharyngitis)   
 S1221  
 Page 14  
Version Date 8/21/17  
 
  
INVESTIGATIONS   
 Creatinine 
increased3  Creatinine 
increased3 (Gr 2)  
 Neutrophil count 
decreased3  Neutrophil count 
decreased3  
(Gr 2)  
 Platelet count 
decreased3  Platelet count 
decreased3 (Gr 2)  
 White blood cell 
decreased3  White blood cell 
decreased3  
(Gr 2)  
METABOLISM AND NUTRITION DISORDERS   
 Anorexia   Anorexia (Gr 2)  
Hyperglycemia3   Hyperglycemia3 (Gr 
2) 
 Hypokalemia3  Hypokalemia3 (Gr 2)  
 Hyponatremia3  Hyponatremia3 (Gr 
2) 
Hypophosphatemia3   Hypophosphatemia3 
(Gr 2)  
MUSCULOSKELETAL AND CONNECTIVE TISSUE 
DISORDERS   
Arthralgia    Arthralgia (Gr 3)  
 Back pain   Back pain (Gr 3)  
 Myalgia   Myalgia (Gr 3)  
 Pain in extremity   Pain in extremity (Gr 
3) 
NEOPLASMS BENIGN, MALIGNANT AND 
UNSPECIFIED (INCL CYSTS AND POLYPS)   
 Neoplasms 
benign, 
malignant and 
unspecified (incl 
cysts and 
polyps) - Other 
(squamous cell 
carcinoma or 
keratoacanthom
a)9  Neoplasms benign, 
malignant and 
unspecified (incl 
cysts and polyps) - 
Other (squamous 
cell carcinoma or 
keratoacanthoma)9 
(Gr 2)  
 Treatment 
related 
secondary 
malignancy (non-
SCC)10   
NERVOUS SYSTEM DISORDERS   
 Dizziness   Dizziness (Gr 2)  
Headache    Headache (Gr 2)  
  Syncope   
 S1221  
 Page 15  
Version Date 8/21/17  
 
  
RENAL AND URINARY DISORDERS   
  Renal and 
urinary disorders 
- Other (renal 
failure)   
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL 
DISORDERS   
 Cough   Cough (Gr 2)  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS   
Alopecia    Alopecia (Gr 2)  
 Dry skin   Dry skin (Gr 2)  
 Hyperhidrosis   Hyperhidrosis (Gr 2)  
 Palmar -plantar 
erythrodysesthes
ia syndrome   Palmar -plantar 
erythrodysesthesia 
syndrome  (Gr 2)  
 Pruritus   Pruritus (Gr 3)  
Rash11   Rash11 (Gr 2)  
 Skin and 
subcutaneous 
tissue disorders - 
Other (abnormal 
hair texture)   Skin and 
subcutaneous 
tissue disorders - 
Other (abnormal 
hair texture) (Gr 2)  
Skin and 
subcutaneous tissue 
disorders - Other 
(hyperkeratosis)    Skin and 
subcutaneous 
tissue disorders - 
Other 
(hyperkeratosis)  
 (Gr 2)  
  Skin and 
subcutaneous 
tissue disorders - 
Other 
(neutrophilic 
panniculitis)12  
Skin and 
subcutaneous tissue 
disorders - Other 
(skin papi[INVESTIGATOR_81875])    Skin and 
subcutaneous 
tissue disorders - 
Other (skin 
papi[INVESTIGATOR_81875]) (Gr 2)  
 S1221  
 Page 16  
Version Date 8/21/17  
 
  
 
  
 
  
 
1 This table will be updated as the toxicity profile of the agent is revised.  
Updates will be distributed to all Principal Investigators at the time of revision.  
The current version can be obtained by [CONTACT_13172] [EMAIL_412].  
Your name, the name [CONTACT_6823], the protocol and the agent should be 
included in the e- mail.  
2 The incidence of anemia is increased when dabrafenib mesylate ([COMPANY_004]2118436B) is used in combination with trametinib dimethyl sulfoxide ([COMPANY_004]1120212B).  
3 The frequencies of these events are based upon laboratory findings rather than 
being due to patient -reported outcomes.  
4 Dabrafenib mesylate ([COMPANY_004]2118436B) has been associated with ocular 
toxicities including chorioretinitis, retinitis, iridocyclitis, iritis,  and uveitis.  
5 Edema limbs (peripheral edema) is a risk associated when dabrafenib 
mesylate ([COMPANY_004]2118436B) is used in combination with trametinib dimethyl 
sulfoxide ([COMPANY_004]1120212B) compared to dabrafenib mesylate ([COMPANY_004]2118436B) 
alone.  
6 Fever (pyrexia) can be associated with hypotension and/or (in rare cases) 
syncope. The frequency of fever and serious febrile events is increased when dabrafenib mesylate ([COMPANY_004]2118436B) is used in combination with trametinib dimethyl sulfoxide ([COMPANY_004]1120212B).  
7 Treatment with dabrafenib mesylate ([COMPANY_004]2118436B) in combination with trametinib dimethyl sulfoxide ([COMPANY_004]1120212B) resulted in an increased incidence and severity of hemorrhagic events compared to patients treated 
with dabrafenib mesylate ([COMPANY_004]2118436B) as a single agent.  Sites of 
hemorrhage may include, but are not limited to, intracranial, reproductive tract, respi[INVESTIGATOR_4352], and gastrointestinal hemorrhage.  
8 Manifestations of allergic reactions (hypersensitivity) to dabrafenib mesylate ([COMPANY_004]2118436B) may include bullous rash (bullous dermatitis).  
9 Squamous cell carcinoma (SCC), including SCC of the skin, SCC in situ 
(Bowen’s disease), and keratoacanthoma have been observed.  
[ADDRESS_1105372] been reported including primary melanoma, 
basal cell carcinoma, and non -cutaneous malignancies.  
11 Rash includes the terms: rash, rash acneiform, rash papular, rash maculo-
papular, and erythema.  
[ADDRESS_1105373] one patient 
treated with dabrafenib mesylate ([COMPANY_004]2118436B)  in combination with the MEK 
inhibitor trametinib dimethyl sulfoxide ([COMPANY_004]1120212B).  
13 Venous thromboembolic events (including deep vein thrombosis and pulmonary embolism) is a risk associated when dabrafenib mesylate 
([COMPANY_004]2118436B) is used in combination with trametinib dimethyl sulfoxide ([COMPANY_004]1120212B).  
 Adverse events reported on Dabrafenib mesylate ([COMPANY_004]2118436B) trials, but for which there is insufficient evidence to suggest that there was a 
reasonable possibility that Dabrafenib mesylate ([COMPANY_004]2118436B ) caused the 
adverse event : 
 BLOOD AND LYMPHATIC SYSTEM DISORDERS  - Blood and lymphatic 
system disorders - Other (agranulocytosis); Blood and lymphatic system 
disorders - Other (pancytopenia); Disseminated intravascular coagulation; Febrile 
neutropenia; Hemolysis  VASCULAR DISORDERS   
 Vascular 
disorders - Other 
(venous 
thromboembolic 
event)13   
 S1221  
 Page 17  
Version Date 8/21/17  
 
  
CARDIAC DISORDERS  - Acute coronary syndrome; Atrial fibrillation; Atrial 
flutter; Heart failure; Left ventricular systolic dysfunction; Mitral valve disease; Myocardial infarction; Sinus tachycardia  
ENDOCRINE  DISORDERS  - Hyperthyroidism; H ypothyroidism  
EYE DISORDERS - Blurred vision; Eye disorders - Other (amaurosis fugax); Eye 
disorders - Other (visual acuity reduced); Eye disorders - Other (visual 
impairment); Eye disorders - Other (vitreous detachment); Floaters; Photophobia; 
Retinopathy  
GASTROINTESTINAL DIS ORDERS  - Colitis; Colonic perforation; Dry mouth; 
Dyspepsia; Gastritis; Stomach pain  
GENERAL DISORDERS AN D ADMINISTRATION SIT E CONDITIONS  - 
Localized edema; Non- cardiac chest pain; Pain  
HEPATOBILIARY DISORDERS - Cholecystitis; Hepatic pain 
INJURY, POISONING AN D PROCEDURAL COMPLIC ATIONS  - Bruising  
INVESTIGATIONS  - Alanine aminotransferase increased; Alkaline phosphatase 
increased; Aspartate aminotransferase increased; Blood bilirubin increased; CD4 lymphocytes decreased; Ejection fraction decreased; Electrocardiogram QT corrected interval prolonged; GGT increased; Lipase increased; Lymphocyte 
count decreased; Weight loss  
METABOLISM AND NUTRI TION DISORDERS  - Dehydration; Hypercalcemia; 
Hypernatremia; Hypocalcemia; Hypoglycemia; Hypomagnesemia  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DI SORDERS  - Arthritis; 
Generalized muscle weakness; Musculoskeletal and connective tissue disorder - 
Other (muscle spasms); Neck pain  
NEOPLASMS BENIGN, MA LIGNANT AND UNSPECIFIED (INCL CYSTS AND 
POLYPS)  - Leukemia secondary to oncology chemotherapy; Myelodysplastic 
syndrome; Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other (mycosis fungoides)  
NERVOUS SYSTEM DISOR DERS - Ataxia; Cognitive disturbance; Dysgeusia; 
Intracranial hemorrhage; Lethargy; Nervous system disorders - Other 
(intracranial pressure increased); Paresthesia; Seizure; Somnolence  
PSYCHIATRIC DISORDERS  - Anxiety; Confusion; Depression  
RENAL AND URINARY DI SORDERS - Hematuria; Renal calculi; Urinary 
frequency  
REPRODUCTIVE SYSTEM AND BREA ST DISORDERS  - Menorrhagia; 
Reproductive system and breast disorders - Other (hematospermia)  
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DI SORDERS  - Nasal 
congestion; Respi[INVESTIGATOR_696], thoracic and mediastinal disorders - Other 
(oropharyngeal pain); Sore throat; Stridor; Voice alteration  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - Photosensitivity; Purpura; 
Skin and subcutaneous tissue disorders - Other (palmoplantar keratoderma)  
VASCULAR DISORDERS  - Flushing; Hot flashes; Hypertension; Hypotension  
 
Note: Dabrafenib mesylate ([COMPANY_004]2118436B) in combination with other agents 
could cause an exacerbation of any adverse event currently known to be caused 
by [CONTACT_6767], or the combination may result in events never previously 
associated with either agent.  
  S1221  
 Page 18  
Version Date 8/21/17  
 
  
 
c. PHARMACOLOGY  
 
How Supplied: Dabrafenib mesylate ( [COMPANY_004]2118436B) capsules are supplied by 
[CONTACT_800841], NCI as 50 mg and 75 mg capsules (equivalent to the free- base) for oral administration.  
 1. Each investigationally -labeled bottle is white, opaque, high density 
polyethylene (HDPE) with child- resistant closure and contains 28 
capsules.  
 
• 50 mg capsule is Swedish orange, size 2 with markings of four black 
bars.  
 
• 75 mg capsule is pi[INVESTIGATOR_8745], size 1 with markings of four black bars.  
 
Capsule excipi[INVESTIGATOR_414549], magnesium stearate (vegetable source), colloidal silicon dioxide. Shell composition 
consists of an opaque hypromellose capsule, composed of red iron oxide 
(E172), titanium dioxide (E171), and hypromellose (E464). Four black bars are printed on the hypromellose capsules using black ink. The black 
ink contains black iron oxide (E172), shellac, propylene glycol, and 
ammonium hydroxide.  
 
2. E ach commercially -labeled bottle contains 120 capsules and a silica gel 
desiccant.  
 
• 50 mg capsule is dark red and imprinted with ‘GS TEW’ and ‘50 mg.’  
 
• 75 mg capsule is dark pi[INVESTIGATOR_800805] ‘GS LHF’ and ‘75 mg.’  
 
Capsule excipi[INVESTIGATOR_800806], magnesium 
stearate (vegetable source), and colloidal silicon dioxide. Capsule shells 
contain hypromellose, red iron oxide (E172), and titanium dioxide (E171).  
 
Storage:  Store between 15°C to 30°C (59°F to 86°F).  
 
Stability : Shelf -life studies of dabrafenib mesylate ([COMPANY_004]2118436B) are ongoing.  
 
Route of Administration: Oral administration. Patients should take dabrafenib at 
least one  hour prior to or two hours after a meal due to a potential food effect on 
dabrafenib absorption. A food effect study showed that food may decrease the dabrafenib C
max and AUC (0-∞) by 60% and 33%  respectively . If a dose is missed, 
it should not be taken if it is less than 6 hours until the next dose.  
 
Potential Drug Interactions : Dabrafenib mesylate ( [COMPANY_004]2118436B)  induces 
CYP3A4, 2C9 and possibly 2B6, 2C8, and 2C19 enzymes. Use caution in patients 
who are taking substrates that are metabolized in these enzyme pathways, such as 
warfarin.  
 
Dabrafenib mesylate ( [COMPANY_004]2118436B)  metabolism appears to be mediated by 
[CONTACT_097]3A4 and CYP2C8. Use caution if strong inducers or inhibitors of CYP2C8 or 3A4 are co- administered with dabrafenib.  
 
Dabrafenib solubility is pH -dependent and experiences decreased solubility at 
higher pH. Use caution in patients who are taking drugs that elevate gastric pH due to the theoretical risk of decreasing oral bioavailability of dabrafenib.  
  S1221  
 Page 19  
Version Date 8/21/17  
 
  
 Patient Care Implications: In the case of overdose, patients should be treated 
symptomatically since there is no specific antidote. Hemodialysis is likely to be 
ineffective since dabrafenib mesylate is highly bound to plasma proteins.  
 
d. SUPPLIER  
 
Dabrafenib is an investigational agent supplied to investigators by [CONTACT_33997] (DCTD), NCI. Dabrafenib is provided to the 
NCI under a Collaborative Agreement between [COMPANY_001]  and the DCTD, NCI.  
 
Drug Ordering: NCI supplied agents may be requested by [CONTACT_9532] (or their authorized designee) at each participating institution. 
Pharmaceutical Management Branch (PMB) policy requires that agent be shipped directly to the institution where the patient is to be treated. PMB does not 
permit the transfer of agents between institutions (unless prior approval from 
PMB is obtained). The CTEP assigned protocol number must be used for ordering all CTEP supplied investigational agents. The responsible investigator at 
each participating institution must be registered with CTEP, DCTD through an 
annual submission of FDA form 1572 (Statement of Investigator), Curriculum Vitae, Supplemental Investigator Data Form (IDF), and Financial Disclosure 
Form (FDF). If there are several participating investigators at one institution, 
CTEP supplied investigational agents for the study should be ordered under the name [CONTACT_170739].  Drug may be requested by 
[CONTACT_800842] 
(OAOP) application (https://eapps -ctep.nci.nih.gov/OAOP/pages/login.jspx). 
Access to OAOP requires the establishment of a CTEP Identity and Access 
Management (IAM) account (https://eapps -ctep.nci.nih.gov/iam/) and the 
maintenance of an "active"  account status and a "current" password.  
 
Drug Returns: All unused drug supplies should be returned to the PMB. When it 
is necessary to return study drug (e.g. sealed vials remaining when expi[INVESTIGATOR_800807]), investigators should retur n the study drug to the 
PMB using the NCI Return Agent Form available on the NCI home page (http://ctep.cancer.gov ). 
 
Drug Accountability : The investigator, or a responsible party designated by [CONTACT_1275], must maintain a careful record of the receipt, disposition and return of all drugs received from the PMB using the Drug Accountability Record Form 
available on the NCI home page ( http://ctep.cancer.gov ). 
 
Questions about drug orders, transfers, returns or accountability should be 
addressed to the PMB by [CONTACT_3379] 240/276-6575 Monday through Friday between 
8:30 a.m. and 4:30 p.m. Eastern time or by [CONTACT_110191] 
[EMAIL_087]  anytime.  
 
3.2 [COMPANY_004]2141795 ([COMPANY_004]2141795C) (NSC -767034) (CTEP IND #118705) 
 
a. DESCRIPTION  
 
Chemical Name:  N-[(1S) -2-amino-1- [(3,4 difluorophenyl)methyl]ethyl] -5-
chloro-4- (4-chloro-1- methyl -1H-pyrazol -5-yl)-2-
furancarboxamide 
 
Other Names : [COMPANY_004]2141795C  
  S1221  
 Page 20  
 Version Date 8/21/17  
 
  
Classification : pan-AKT inhibitor  
 
CAS Registry Number : 1047634- 65-0 
 
Molecular Formula:  C18H16Cl2F2N4O2 
 
Molecular Weight :  429.25 g/mol  
 
Approximate Solubility : Very slightly soluble in water at room temperature (0.18 
mg/mL). Solubility decreases as pH increases; for example solubility in gastr ic fluid 
at 37° C is >11 mg/mL.  
 
Mode of Action:  [COMPANY_004]2141795 is an ATP competitive pan- AKT inhibitor. AKT, a 
serine/threonine protein kinase with three isoforms, is active in several pathways 
that regulate survival, proliferation, tissue invasion and metabolism. Since AKT-
mediated pathways are important in tumor proliferation and survival, AKT kinases 
are promising targets for therapeutic intervention. Hyperactivation of the AKT 
pathway can also correlate with chemotherapy resistance and poorer prognosis.  
 
b. TOXICOLOGY  
 
Comprehensive Adverse Events and Potential Risks list (CAEPR) for 
[COMPANY_004]2141795 (NSC 767034)  
 
The Comprehensive Adverse Event and Potential Risks list (CAEPR) provides a 
single list of reported and/or potential adverse events (AE) associated with an agent using a uniform presentation of events by [CONTACT_6764]. In addition to the 
comprehensive list, a subset, the Specific Protocol Exceptions to Expedited 
Reporting (SPEER), appears in a separate column and is identified with bold and italicized text. This subset of AEs (SPEER) is a list of events that are protocol 
specific exceptions to expedited reporting to NCI via CTEP- AERS  (except as 
noted below).  Refer to the 'CTEP, NCI Guidelines: Adverse Event Reporting 
Requirements'  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/adverse_events.htm  for further clarification .  Frequency is provided based on 150 patients. 
Below is the CAEPR for [COMPANY_004]2141795.  
 
NOTE : Report AEs on the SPEER ONLY IF  they exceed the grade noted in 
parentheses next to the AE in the SPEER.  If this CAEPR is part of a 
combination protocol using multiple investigational agents and has an AE listed 
on different SPEERs, use the lower of the grades to determine if expedited reporting is required.  
Version 2.1, July 26, [ZIP_CODE] 
 
 Adverse Events with Possible  
 Relationship to [COMPANY_004]2141795 
 (CTCAE 4.0 Term)  
[n= 150]     
Specific Protocol 
Exceptions to 
Expedited 
Reporting 
(SPEER)  
Likely (>20%)  Less Likely (<=20%)  Rare but Serious 
(<3%)    
GASTROINTESTINAL DISORDERS    
Diarrhea     Diarrhea (Gr 2)  
 Esophagitis     
  Gastrointestinal 
mucositis2    
Nausea     Nausea (Gr 2)  
 Vomiting     Vomiting (Gr 2)  
 S1221  
 Page 21  
Version Date 8/21/17  
 
  
 
 Adverse Events with Possible  
 Relationship to [COMPANY_004]2141795 
 (CTCAE 4.0 Term)  
[n= 150]     
Specific Protocol 
Exceptions to 
Expedited 
Reporting 
(SPEER)  
Likely (>20%)  Less Likely (<=20%)  Rare but Serious 
(<3%)    
GENERAL DISORDERS AND ADMINISTRATION SITE 
CONDITIONS    
Fatigue     Fatigue (Gr 2)  
METABOLISM AND NUTRITION DISORDERS    
Anorexia     Anorexia (Gr 2)  
 Hyperglycemia    Hyperglycemia  
 (Gr 2)  
 Hypoglycemia     
RESPI[INVESTIGATOR_6709] , THORACIC AND MEDIAST INAL DISORDERS    
 Respi[INVESTIGATOR_800808]3    
SKIN AND SUBCUTANEOUS TISSUE DISORDERS    
 Rash maculo -papular     
1 This table will be updated as the toxicity profile of the agent is revised.  
Updates will be disbuted to all Principal Investigators at the time of revision.  
The current version can be obtained by [CONTACT_13172] [EMAIL_412].  
Your name, the name [CONTACT_6823], the protocol and the agent should be 
included in the e- mail.  
2 Gastrointestinal mucositis may include Anal mucositis,  Mucositis oral, Rectal 
mucositis, or Small intestinal mucosi tis under the GASTROINTESTINAL 
DISORDERS SOC.  
3 Respi[INVESTIGATOR_190738], Pharyngeal mucositis, 
or Tracheal mucositis under the R ESPI[INVESTIGATOR_6709] , THORACIC AND 
MEDIASTINAL DISORDER S SOC  
 Also reported on [COMPANY_004]2141795 trials but with the relationship to 
[COMPANY_004]2141795 still undetermined:  
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS  - Leukocytosis  
CARDIAC DISORDERS  - Cardiac arrest, Left ventricular systolic dysfunction, 
Ventricular tachycardia  
GENERAL DISORDERS AN D ADMINISTRATION SIT E CONDITIONS  - Non-
cardiac chest pain  
HEPATOBILIARY DISORDERS - Hepatic failure  
INFECTIONS AND INFESTATIONS  - Wound infection  
INVESTIGATIONS  - Alanine aminotransferase increased; Alkaline phosphatase 
increased; Aspartate aminotransferase increased; Ejection fraction decreased; GGT increased 
METABOLISM AND NUTRI TION DISORDERS  - Hypokalemia; Hyponatremia, 
Hypophosphatemia 
NERVOUS SYSTEM DISOR DER S - Dysgeusia; Dysphasia  
RENAL AND URINARY DISORDERS  - Acute kidney injury  
VASCULAR DISORDERS  - Thromboembolic event  
 
Note : [COMPANY_004]2141795 in combination with other agents could cause an 
exacerbation of any adverse event currently known to be caused by [CONTACT_800843], or the combination may result in events never previously associated with either agent.  
 S1221  
 Page 22  
Version Date 8/21/17  
 
  
 
c. PHARMACOLOGY 
 
How Supplied:  [COMPANY_004]2141795 capsules are supplied by [CONTACT_800844], NCI.  The 25 mg capsule is a size 2 Swedish orange 
opaque body and Swedish orange opaque cap with no markings.  The capsule 
contains active pharmaceutical ingredient, microcrystalline cellulose, and magnesium stearate.  The capsules are packaged in white high density 
polyethylene (HDPE) bottles with white plastic, induction- seal, child -resistant 
caps.  Each bottle contains 35 capsules.  
 
Storage:  Store bottles at 2- 8° C (36- 46° F). 
 
Stability : Shelf life studies of [COMPANY_004]2141795 are on- going.  
 
Route of Administration: Oral administration.   Capsules must be taken fasting one 
hour following a meal and two hours before the next meal.   These are the 
recommendations from the pharmaceutical collaborator.  
 
Potential Drug Interactions : In vitro  data suggest [COMPANY_004]2141795 is a substrate of 
CYP450 3A4. Potent inhibitors and inducers of 3A4 are prohibited. [COMPANY_004]2141795 
appears to be a moderate inhibitor of CYP 2C8 and 3A4 by [CONTACT_190779]. Drugs 
that are substrates of these isoenzymes should be used with caution and ones with 
a narrow therapeutic index should be avoided.  
 [COMPANY_004]2141795 is a substrate of p- glycoprotein (P -gp) and breast cancer resistant 
protein (BCRP). It is also an inhibitor of BCRP and OATP1B1. Administration of 
sensitive BCRP substrates should be prohibited, such as topotecan.  
 
d. SUPPLIER  
 
[COMPANY_004]2141795 is an investigational agent supplied to investigators by [CONTACT_110700] (DCTD), NCI. [COMPANY_004]2141795 is provided to 
the NCI under a Collaborative Agreement between GlaxoSmithKline, Inc. and the 
DCTD, NCI.  
 
Drug Ordering: NCI supplied agents may be requested by [CONTACT_9532] (or their authorized designee) at each participating institution. 
Pharmaceutical Management Branch (PMB) policy requires that agent be 
shipped directly to the institution where the patient is to be treated. PMB does not 
permit the transfer of agents between institutions (unless prior approval from PMB is obt ained). The CTEP assigned protocol number must be used for 
ordering all CTEP supplied investigational agents. The responsible investigator at each participating institution must be registered with CTEP, DCTD through an annual submission of FDA form 1572 (S tatement of Investigator), Curriculum 
Vitae, Supplemental Investigator Data Form (IDF), and Financial Disclosure Form (FDF). If there are several participating investigators at one institution, CTEP supplied investigational agents for the study should be ordered under the 
name [CONTACT_170739].  
 
Drug may be requested by [CONTACT_461481] (OAOP) application ( https://eapps -
ctep.nci.nih.gov/OAOP/pages/login.jspx).  Access to OAOP requires the 
establishment of a CTEP Identity and Access  Management (IAM) account 
(https://eapps -ctep.nci.nih.gov/iam/)  and the maintenance of an "active" account 
status and a "current" password.  
 S1221  
 Page 23  
Version Date 8/21/17  
 
  
 
Drug Returns: All unused drug supplies should be returned to the PMB. When it 
is necessary to return study drug (e.g. sealed vials remaining when expi[INVESTIGATOR_800807]), investigators should return the study drug to the 
PMB using the NCI Return Agent Form available on the NCI home page 
(http://ctep.cancer.gov ). 
 
Drug Accountability : The investigator, or a responsible party designated by [CONTACT_1275], must maintain a careful record of the receipt, disposition and return 
of all drugs received from the PMB using the Drug Accountability Record Form available on the NCI home page ( http://ctep.cancer.gov).  
 
Questions about drug orders, transfers, returns or accountability should be addressed to the PMB by [CONTACT_3379] 240/276-6575 Monday through Friday between 
8:30 a.m. and 4:30 p.m. Eastern time by [CONTACT_110191] [EMAIL_087]  
anytime.  
 3.3 Trametinib Dimethyl Sulfoxide  ([COMPANY_004]1120212B ) (NSC -763093)  (IND-119432)  
 a. PHARMACOLOGY  
 
Mechanism of Action: Trametinib is a reversible, highly selective allosteric 
inhibitor of mitogen- activated extracellular signal regulated kinase 1 (MEK1) and 
MEK2.  Tumor cells commonly have hyperactivated extracellular signal -related 
kinase (ERK) pathways in which MEK is a critical component.  Trametinib  
interferes with cellular signal -transduction and inhibits proliferation by [CONTACT_800845], with selective activity towards B-RAF serine/threonine protein 
kinase ( BRAF ) and v-ras oncogene homolog GTPase ( RAS) mutant cancer cell 
lines and hematopoietic cancer cells from acute myeloid leukemia ( AML) and 
chronic myeloid leukemia ( CML) origins.  
 
b. PHARMACOKINETICS  
 
Absorption : Peak plasma concentrations are observed at 1.5 hours following 
single dose oral administr ation of trametinib under fasted conditions in humans.  
Administration of trametinib with a high -fat, high- calorie meal resulted in a 70% 
decrease in the maximum concentration ( Cmax ) and 10% decrease in the area 
under the concentration curve ( AUC ) compared  to fasted conditions.   Therefore, 
it is recommended that trametinib be administered under fasting conditions.  The absolute oral bioavailability of a 2 mg tablet is moderate to high (72%) relative to 
a co- administered IV microdose (5 micrograms) .   
 
Distribution : Trametinib is highly b ound to plasma proteins (97.4%), and has a 
high volume of distribution (Vd) of 1060 L.    
 
Metabolism : Following single dose oral administration in humans, approximately 
50% of plasma radioactivity is present as the parent compound.  Trametinib is 
primarily metabolized via deacetylation mediated by [CONTACT_190759], such 
as carboxylesterases or amidases, with secondary oxidation or in combination 
with glucuronidation biotransformation pathways.   The high absolute 
bioavailability and low clearance relative to liver blood flow (3.21 L/hr) suggest 
low hepatic extraction of trametinib in addition to low first -pass metabolism.  
 
Elimination :  Trametinib has a long terminal half -life of 5.3 days and accumulates 
with repeat once daily dosing.   Fecal excretion is the major route of elimination 
accounting for >80% of excreted radioactivity recovered.  Urinary excretion 
accounted for <19% of excreted radioactivity recovered (<10% of the radioactive 
dose).  
 S1221  
 Page 24  
Version Date 8/21/[ADDRESS_1105374] (CAEPR) 
for Trametinib dimethyl sulfoxide ([COMPANY_004]1120212B, NSC 763093)  
 
The Comprehensive Adverse Event and Potential Risks list (CAEPR) 
provides a single list of reported and/or potential adverse events (AE) associated with an agent using a uniform presentation of events by [CONTACT_110377]. In addition to the comprehensive list, a subset, the Specific 
Protocol Exceptions to Expedited Reporting (SPEER), appears in a separate column and is identified with bold and italicized text. This  
subset of AEs (SPEER) is a list of events that are protocol specific exceptions to expedited reporting to NCI via CTEP -AERS (except  as 
noted below).  Refer to the ”CTEP, NCI Guidelines: Adverse Event 
Reporting  Requirements ”  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf  for further clarification.  Frequency is provided based on 
1,111 patients. Below is the CAEPR for trametinib dimethy l sulfoxide 
([COMPANY_004]1120212B).  
 
NOTE : Report AEs on the SPEER ONLY IF  they exceed the grade noted 
in parentheses next to the AE in the SPEER.  If this CAEPR is part of a combination protocol using multiple investigational agents and has an AE listed on different SPEERs, use the lower of the grades to determine if 
expedited reporting is required.  
 Version 2.4, October 7, [ZIP_CODE] 
 
 
 Adverse Events with Possible  
 Relationship to Trametinib dimethyl sulfoxide 
([COMPANY_004]1120212B)  
 (CTCAE 4.0 Term)  
[n= 1111]   
 Specific Protocol 
Exceptions to 
Expedited 
Reporting (SPEER)  
 Likely (>20%)  Less Likely 
(<=20%)  Rare but Serious 
(<3%)  
BLOOD AND LYMPHATIC SYSTEM DISORDERS   
 Anemia   Anemia (Gr 2)  
CARDIAC DISORDERS   
  Heart failure   
  Left ventricular 
systolic dysfunction   
 Sinus bradycardia    
EYE DISORDERS   
 Blurred vision    
 Dry eye    
  Eye disorders - 
Other 
(chorioretinopathy 
also known as retinal 
pi[INVESTIGATOR_23553])   
  Eye disorders - 
Other (retinal vein 
occlusion)   
 S1221  
 Page 25  
Version Date 8/21/17  
 
  
 
 
 Adverse Events with Possible  
 Relationship to Trametinib dimethyl sulfoxide 
([COMPANY_004]1120212B)  
 (CTCAE 4.0 Term)  
[n= 1111]   
 Specific Protocol 
Exceptions to 
Expedited 
Reporting (SPEER)  
 Likely (>20%)  Less Likely 
(<=20%)  Rare but Serious 
(<3%)  
EYE DISORDERS  (contd.)   
 Eye disorders - 
Other (visual 
disorders)2    
GASTROINTESTINAL DISORDERS   
 Abdominal pain   Abdominal pain 
(Gr 2)  
   Colitis   
   Colonic perforation   
 Constipation   Constipation (Gr 2)  
Diarrhea    Diarrhea (Gr 3)  
 Dry mouth   Dry mouth (Gr 2)  
 Dyspepsia   Dyspepsia (Gr 2)  
 Mucositis oral   Mucositis oral (Gr 
2) 
Nausea    Nausea  (Gr 3)  
 Vomiting   Vomiting (Gr 3)  
GENERAL DISORDERS AND ADMINISTRATION SITE 
CONDITIONS   
 Chills   Chills (Gr 2)  
 Edema face    
Fatigue    Fatigue (Gr 3)  
 Fever   Fever (Gr 2)  
IMMUNE SYSTEM DISORDERS   
 Allergic reaction3   
INFECTIONS AND INFESTATIONS   
 Lung infection    
 Paronychia   Paronychia (Gr 2)  
 Skin infection   Skin infection (Gr 
2) 
INVESTIGATIONS   
 Alanine 
aminotransferase 
increased   Alanine 
aminotransferase 
increased (Gr 2)  
 Alkaline 
phosphatase 
increased   Alkaline 
phosphatase 
increased (Gr 2)  
 Aspartate 
aminotransferase 
increased   Aspartate 
aminotransferase 
increased (Gr 2)  
 CPK increased    
 Ejection fraction 
decreased    
 S1221  
 Page 26  
Version Date 8/21/17  
 
  
 
 
 Adverse Events with Possible  
 Relationship to Trametinib dimethyl sulfoxide 
([COMPANY_004]1120212B)  
 (CTCAE 4.0 Term)  
[n= 1111]   
 Specific Protocol 
Exceptions to 
Expedited 
Reporting (SPEER)  
 Likely (>20%)  Less Likely 
(<=20%)  Rare but Serious 
(<3%)  
METABOLISM AND NUTRITION DISORDERS   
 Anorexia   Anorexia (Gr 2)  
 Dehydration   Dehydration (Gr 3)  
 Hypoalbuminemia    
 Hypomagnesemia   Hypomagnesemia 
(Gr 2)  
 Hyponatremia   Hyponatremia (Gr 
3) 
MUSCULOSKELETAL AND CONNECTIVE TISSUE 
DISORDERS   
 Arthralgia    
 Back pain   Back pain (Gr 2)  
  Musculoskeletal and 
connective tissue 
disorder - Other 
(rhabdomyolysis)   
 Pain in extremity   Pain in extremity 
(Gr 2)  
NERVOUS SYSTEM DISORDERS   
 Dizziness   Dizziness (Gr 2)  
 Headache   Headache (Gr 2)  
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL 
DISORDERS   
 Cough   Cough (Gr 2)  
 Dyspnea   Dyspnea (Gr 2)  
  Pneumonitis   
SKIN AND SUBCUTANEOUS TISSUE DISORDERS   
 Alopecia   Alopecia (Gr 2)  
 Dry skin   Dry skin (Gr 2)  
  Palmar -plantar 
erythrodysesthesia 
syndrome   
  Periorbital edema    
 Pruritus   Pruritus (Gr 2)  
 Skin and 
subcutaneous 
tissue disorders - 
Other (folliculitis)   Skin and 
subcutaneous 
tissue disorders - 
Other (folliculitis) 
(Gr 2)  
Skin and 
subcutaneous 
tissue disorders - 
Other (rash)[ADDRESS_1105375] ers - 
Other (rash)4 (Gr 3)  
 
   
 S1221  
 Page 27  
Version Date 8/21/17  
 
  
 
 Adverse Events with Possible  
 Relationship to Trametinib dimethyl sulfoxide 
([COMPANY_004]1120212B)  
 (CTCAE 4.0 Term)  
[n= 1111]   
 Specific Protocol 
Exceptions to 
Expedited 
Reporting (SPEER)  
 Likely (>20%)  Less Likely 
(<=20%)  Rare but Serious 
(<3%)  
VASCULAR DISORDERS   
 Hypertension   Hypertension (Gr 
2) 
Vascular disorders 
- Other (edema)5   Vascular disorders 
- Other (edema)5 
(Gr 2)  
 Vascular disorders - 
Other 
(hemorrhage)6   
 
1 This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all Principal Investigators at the time of revision.  The current version can be obtained by [CONTACT_13172] 
[EMAIL_412].
  Your name, the name [CONTACT_6823], 
the protocol and the agent should be included in the e- mail.  
2 Visual disorders include visual disturbance that can be associated with conjunctival hemorrhage, corneal graft rejection, cyclitis, eye nevus, 
halo vision, iritis, macular edema, retinal hemorrhage, visual acuity reduced, visual impairment, and vitreous detachment.  
3 Hypersensitivity (allergic reactions) may present with symptoms such as fever, rash, increased liver function tests,  and visual disturbances.  
4 Skin and subcutaneous tissue disorders - Other (rash) may include 
rash, rash acneiform, rosacea, erythematous rash, genital rash, rash macular, exfoliative rash, rash generalized, erythema, rash papular, seborrhoeic dermatitis, dermatitis psoriasiform, rash follicular, and skin 
fissures.  
5 Edema includes edema, lymphedema, and edema limbs.  
6 The majority of hemorrhage events were mild.  Major events, defined as symptomatic bleeding in a critical area or organ (e.g., eye, GI 
hemor rhage, GU hemorrhage, respi[INVESTIGATOR_36393]), and fatal 
intracranial hemorrhages have been reported.  
 Adverse events reported on Trametinib dimethyl sulfoxide ([COMPANY_004]1120212B) trials, but for which there is insufficient evidence to 
suggest that there was a reasonable possibility that Trametinib 
dimethyl sulfoxide ([COMPANY_004]1120212B) caused the adverse event : 
 
BLOOD  AND LYMPHATIC SYSTEM DISORDERS  - Disseminated 
intravascular coagulation; Febrile neutropenia; Leukocytosis  
CARDIAC DISORDERS  - Atrial fibrillation; Cardiac arrest; Myocardial 
infarction; Restrictive cardiomyopathy; Sinus tachycardia  
EYE DISORDERS - Corneal ulcer; Eyelid function disorder; Flashing 
lights; Floaters; Glaucoma; Papi[INVESTIGATOR_044]; Photophobia; Retinal detachment  
GASTROINTESTINAL DISORDERS  - Anal hemorrhage; Ascites; 
Duodenal ulcer; Enterocolitis; Esophageal necrosis; Esophageal ulcer; Esophagitis; Gastric hemorrhage; Gastric ulcer; Gastritis; 
Gastrointestinal disorders - Other (intestinal obstruction); Gastrointestinal 
disorders - Other (oropharyngeal pain); Gastrointestinal disorders - Other  
 S1221  
 Page 28  
Version Date 8/21/17  
 
  
(pneumatosis intestinalis); Gastrointestinal fis tula; Gingival pain; 
Hemorrhoidal hemorrhage; Ileus; Lower gastrointestinal hemorrhage; Obstruction gastric; Pancreatitis; Rectal hemorrhage; Small intestinal 
obstruction; Upper gastrointestinal hemorrhage  
GENERAL DISORDERS AN D ADMINISTRATION SIT E CONDITIO NS - 
Flu like symptoms; General disorders and administration site conditions - 
Other (axillary pain); Localized edema; Malaise; Non- cardiac chest pain; 
Pain 
HEPATOBILIARY DISORDERS - Cholecystitis; Hepatic failure; Hepatic 
pain; Hepatobiliary disorders - Other (hepatic encephalopathy)  
INFECTIONS AND INFES TATIONS  - Biliary tract infection; Catheter 
related infection; Device related infection; Endocarditis infective; Enterocolitis infectious; Hepatitis viral; Infections and infestations - Other 
(abscess limb); Infections and infestations - Other (necrotizing fasciitis); 
Infections and infestations - Other (oral infection); Pharyngitis; Rash 
pustular; Sepsis; Upper respi[INVESTIGATOR_4416]; Urinary tract infection  
INJURY, POISONING AND PROCEDURAL COMPLIC ATIONS  - 
Bruising  
INVESTIGATIONS  - Blood bilirubin increased; Creatinine increased; 
Electrocardiogram QT corrected interval prolonged; GGT increased; 
Investigations - Other (blood lactate dehydrogenase increased); Lipase 
increased; Lymphocyte count decreased; Platelet count decreased; Serum amylase increased; White blood cell decreased  
METABOLISM AND NUTRITION DISORDERS  - Hyperglycemia; 
Hyperkalemia; Hyperuricemia; Hypocalcemia; Hypoglycemia; Hypokalemia; Metabolism and nutrition disorders - Other 
(hyperphosphatemia)  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DI SORDERS - 
Generalized muscle weakness; Musculoskeletal and connective tissue disorder - Other (compression fracture); Musculoskeletal and connective 
tissue disorder - Other (muscle spasm); Myalgia; Neck pain  
NEOPLASMS BENIGN, MALIGNANT  AND UNSPECIFIED (INCL 
CYSTS AND POLYPS)  - Neoplasms benign, malignant and unspecified 
(incl cysts and polyps) - Other (tumor hemorrhage); Tumor pain  
NERVOUS SYSTEM DISOR DERS  - Dysgeusia; Encephalopathy; 
Intracranial hemorrhage; Lethargy; Nervous system disorders - Other 
(diplopia); Seizure; Somnolence; Stroke; Syncope; Transient ischemic attacks  
PSYCHIATRIC DISORDERS  - Anxiety; Confusion; Delirium; Depression; 
Hallucinations; Insomnia; Personality change  
RENAL AND URINARY DI SORDERS  - Acute kidney injury; Cystitis 
noninfective; Hematuria; Proteinuria; Renal and urinary disorders - Other 
(dysuria); Urinary incontinence REPRODUCTIVE SYSTEM AND BREAST DISORDERS  - Vaginal 
fistula; Vaginal hemorrhage  
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DI SOR DERS  - 
Bronchopulmonary hemorrhage; Epi[INVESTIGATOR_3940]; Hypoxia; Laryngeal edema; Pleural effusion; Pneumothorax; Productive cough; Pulmonary 
hypertension; Respi[INVESTIGATOR_1399]; Sinus disorder  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - Bullous 
dermatitis; Photosensitivity; Purpura; Skin and subcutaneous tissue disorders - Other (erythema nodosum); Skin and subcutaneous tissue 
disorders - Other (nail disorder); Skin and subcutaneous tissue disorders 
- Other (skin fissures); Skin ulceration; Urticaria  
VASCULAR DISORDERS  - Hematoma; Hot flashes; Hypotension; 
Thromboembolic event (venous)  
 S1221  
 Page 29  
Version Date 8/21/17  
 
  
 
2. Pregnancy and Lactation: There are no adequate and well -controlled 
studies of trametinib  in pregnant women.  Animal studies have shown 
reproductive toxicity, decreased maternal and fetal weight, fetal malformations, and early termination of pregnancy .  Therefore, trametinib 
should not be administered to pregnant women. Women of childbearing 
potential should use effective methods of contraception during therapy 
and for [ADDRESS_1105376] to the f etus.  
 
It is not known whether trametinib  is excreted in human milk.   Because of 
the potential for drugs  to be excreted in human milk, the risk to the 
nursing infant cannot be  excluded and therefore trametinib should not be 
administered to nursing mothers . 
 
3. Drug Interactions : In vitro  studies suggest that trametinib may be a 
substrate for  CYP3A4 metabolism and consideration should be used 
when trametinib is given in combination with a strong CYP3A4 inducer or inhibitor. Trametinib is a weak CYP2C8 inhibitor and may affect medications that are substrates of  CYP2C8.  Trametinib is not a 
substrate for human P-glycoprotein ( Pgp), breast cancer resistance 
protein ( BCRP ), OAT P1B1, or OATP1B2 transporters.  
 
Patients who are taking concomitant medications that have the potential 
to interact with trameti nib may continue taking them, but should be 
monitored for additional toxicities.  
 
d. DOSING & ADMINISTRATION  
 
1. Dosing – See Section 7.0 Treatment Plan  
 
2. Administration Instructions:  Administer orally, on an empty stomach, either 
1 hour before or 2 hours after food. 
 
e. PREPARATION, STORAGE & STABILITY 
 
Store tablets at 2°C – 8°C in the original bottle. Do not package tablets or remove 
desiccant. Bottles should be stored in the manufacturer’s package carton for light 
protection. Protect from moisture. Shelf life surveillance of the intact bottles is ongoing.  
 
Patient Storage Instructions:  
 
- Study drug can be transported home in the bottle(s) that were dispensed to 
the patient at room temperature.   Avoid exposing the bottle(s) to prolonged 
temperature extremes (i.e.  do not leave bottle(s) in a hot car while doing 
errands)  
- At home, store the study drug in the refrigerator, 2°C – 8°C (36°F - 46°F).  Do 
not freeze the bottles.  
- Keep the tablets in the original bottle(s).   Do not remove tablets from the 
bottle(s) and put them in a pi[INVESTIGATOR_800809].  
- Keep desiccant cylinder in the bottles in order to keep tablets dry.  
 
f. HOW SUPPLIED  
 1. [COMPANY_001] supplies and CTEP, NCI, DCTD distributes  0.5 mg and 2 mg (as 
free base) tablets.  
  S1221  
Page 30  
Version Date 8/21/17  
 
  
 
a. Investigationally labeled bottles each contain 32 tablets packaged in high density polyethylene bottles with child- resistant closures 
including an induction seal liner.  
 The tablet core contains mannitol, microcrystalline cellulose, 
hypromellose, croscarmellose sodium, magnesium stearate (non- animal), colloidal silicon dioxide and sodium lauryl sulfate.  
 
• 0.5 mg tablets are yellow, modified oval, biconvex and film -
coated. Aqueous film coating consists of Opadry Yellow 
03B120006 (hypromellose, titanium dioxide, polyethylene 
glycol, iron oxide yellow).  
 
• 2 mg tablets are pi[INVESTIGATOR_8745], round, biconvex and film -coated. 
Aqueous film coating consists of  Opadry Pi[INVESTIGATOR_800810] -1-[ZIP_CODE]- A 
(hypromellose, titanium dioxide, polyethylene glycol, polysorbate 80, iron oxide red).  
 
b. Each commercially -labeled bottle contains 30 tablets with a 
desiccant.  
 
The tablet core contains mannitol, microcrystalline cellulose, 
hypromellose, croscarmellose sodium, magnesium stearate 
(non- animal), colloidal silicon dioxide and sodium lauryl sulfate.  
 
• 0.5 mg tablets are yellow, modified oval, biconvex and film -
coated with ‘GS’ debossed on one face and ‘TFC’ on the 
opposing face. Aqueous film coating consists of hypromellose, 
titanium dioxide, polyethylene glycol, iron oxide yellow.  
 
• 2 mg tablets are pi[INVESTIGATOR_8745], round, biconvex and film -coated with ‘GS’ 
debossed on one face and ‘HMJ’ on the opposing face. 
Aqueous film coating consists of  hypromellose, titanium 
dioxide, polyethylene glycol, polysorbate 80, iron oxide red.  
 
2. Supplied by:  [CONTACT_800846] 
(DCTD), NCI. Dabrafenib is provided to the NCI under a Collaborative 
Agreement between [COMPANY_001] and the DCTD, NCI.  
 
3. Drug Ordering: NCI supplied agents may be requested by [CONTACT_9532] (or their authorized designee) at each participating institution. Pharmaceutical Management Branch (PMB) policy requires that agent be shipped directly to the institution where the patient is to be 
treated. PMB does not permit the transfer of agents between institutions 
(unless prior approval from PMB is obtained). The CTEP assigned protocol number must be used for ordering all CTEP supplied 
investigational agents. The responsible investigator at each participating 
institution must be registered with CTEP, DCTD through an annual submission of FDA form 1572 (Statement of Investigator), Curriculum 
Vitae, Supplemental Investigator Data Form (IDF), and Financial 
Disclosure Form (FDF). If there are several par ticipating investigators at 
one institution, CTEP supplied investigational agents for the study should 
be ordered under the name [CONTACT_170739].  
  S1221  
Page 31  
Version Date 8/21/17  
 
  
 
Drug may be requested by [CONTACT_800847] (OAOP) application (https://eapps -
ctep.nci.nih.gov/OAOP/pages/login.jspx). Access to OAOP requires the establishment of a CTEP Identity and Access Management (IAM) account (https://eapps -ctep.nci.nih.gov/iam/) and the maintenance of an 
"active" account status and a "current" password.  
 
4. Drug Returns: All unused drug supplies should be returned to the PMB. 
When it is necessary to return study drug (e.g. sealed vials remaining when expi[INVESTIGATOR_800811]), investigators should 
return the study drug to the PMB using the NCI Return Agent Form 
available on the NCI home page ( http://ctep.cancer.gov ). 
 
5. Drug Accountability: The investigator, or a responsible party des ignated 
by [CONTACT_093], must maintain a careful record of the receipt, 
disposition and return of all drugs received from the PMB using the Drug Accountability Record Form available on the NCI home page 
(http://ctep.cancer.gov ). 
 
6. Contact [CONTACT_7171]:  Questions about drug orders, transfers, returns or 
accountability should be addressed to the PMB by [CONTACT_3379] 240/276- 6575  
Monday through Friday between 8:30 a.m. and 4:30 p.m. Eastern time or 
by [CONTACT_110191] [EMAIL_087]  anytime.  
 
4.0 STAGING CRITERIA  (AJCC 7th Edition, 2010)  
 
Stage IIIC  Colon  
T4a N2a M0 
T3-T4a N2b M0 
T4b N1-N2 M0 
 
 
Stage IIIC  Ovarian  
T3c N0 M0 
Any T  N1 M0 
 
STAGE IIIC    Melanoma 
T1-4b N1b M0 
T1-4b N2b M0 
T1-4b N2c M0 
Any T  N3 M0 
 Stage IV   Melanoma 
Any T    Any N   M1 
 Distant Metastasis (M)  
 
M1 Distant metastasis  
M1a Metastases to skin, subcutaneous or distant lymph nodes  
M1b Metastases to lung  
M1c Metastases to all other visceral sites or distant metastases to any site combined with an 
elevated serum LDH  
 
NOTE:  for all other disease sites Stage IV is defined as any distant metastasis for this 
study.  
 
 
 S1221  
 Page 32  
 Version Date 8/21/[ADDRESS_1105377] be met in order for a patient to be considered eligible for 
registration.  Use the spaces provided to confirm a patient's eligibility.  For each criterion requiring test 
results and dates, please record this information on the Onstudy Form and submit via Medidata Rave ® 
(see Section 14.0
).  Any potential eligibility issues should be addressed to the Data Operations Center in 
Seattle at 206/652- [ADDRESS_1105378] is done on a Monday, the Monday 2 weeks later would be considered Day 14.  This 
allows for efficient patient scheduling without exceeding the guidelines.  If Day 14, 28 or 42 falls on a 
weekend or holiday, the limit may be extended to the next working day.  
 
SWOG Patient No.     
 
Patient's Initials (L, F, M)    
 5.[ADDRESS_1105379] be assessed (by [CONTACT_5292], CT, or 
MRI scan) within [ADDRESS_1105380] 
be assessed and documented on the Baseline Tumor Assessment Form (RECIST 1.1).  
 
e. All patients must undergo a CT or MRI of the brain within 42 days prior to registration.  Patients with asymptomatic brain metastases or previously treated 
brain metastases that are stable  (i.e. not requiring corticosteroids)  at the time of 
registration will be eligible.  
 
f. Patients may have received prior systemic therapy (chemotherapy, 
immunotherapy, biologic therapy, or combination regimens).  All adverse events 
associated with prior treatment must have resolved to < Grade 1 prior to 
registration.  
 
 S1221  
 Page 33  
 Version Date 8/21/17  
 
  
SWOG Patient No.     
 
Patient's Initials (L, F, M)    
 g. Patients progressing on a prior BRAF inhibitor -based therapy will be eligible, as 
are patients naïve to BRAF inhibitor therapy. Resistance to BRAF inhibitor -based 
therapy will be defined as progressive disease by [CONTACT_393] 1.1 criteria while receiving therapy with a BRAF inhibitor (vemurafenib or dabrafenib, alone or in combination with a MEK inhibitor).  This may be innate resistance (patients who 
never achieved a tumor response while on BRAF inhibitor therapy) or acquired 
resistance (progression after having a tumor response to BRAF inhibitor 
therapy).  There will not be a period of break between progression on the prior 
BRAF inhibitor -based therapy and the start of dabrafenib, trametinib  and 
[COMPANY_004]2141795.  
 
h. Patients may have received prior surgery (for both the primary and Stage  IV 
disease).  All adverse events associated with prior surgery must have resolved to 
≤ Grade [ADDRESS_1105381] resolved to ≤ Grade [ADDRESS_1105382] be willing to submit blood for pharmacokinetics (see Section 15.3
).  
Sites must order S1221 PK k it immediately after registration (see Section 18.6 ).  
The SWOG patient ID number must be provided on the S1221 PK Kit Request 
Form.   
  
k. Patients must have available and be willing to submit baseline tissue taken at the time of disease progression to prior BRAF inhibitor -based therapy (either fresh 
frozen [preferred], or paraffin- embedded tumor blocks) OR must have a site of 
disease that can be biopsied within this study for translational medicine studies outlined in Section 15.[ADDRESS_1105383] Zubrod Performance Status ≤ 1 (see Section 10.4
). 
 
m. Patients must have adequate bone marrow function as evidenced by [CONTACT_3959]:  ANC ≥ 1,2 00/ul; platelets ≥ 100,000/ ul; and hemoglobin ≥ 9 g/dL.  
These results must be obtained within [ADDRESS_1105384] adequate liver function as evidenced by [CONTACT_716]: total 
bilirubin ≤ 1.5 x institution al upper limit of normal (IULN)  ( o r  ≤  2 . 5  x  U L N  for 
patients with Gilbert’s syndrome ), and AST and ALT ≤ 2.[ADDRESS_1105385] (or < [ADDRESS_1105386] 
for patients with known liver metastases). Patients must have a serum albumin ≥  
2.5 g/dL.   These results must be obtained within 28 days prior to registration.   
 S1221  
 Page 34  
 Version Date 8/21/17  
 
  
SWOG Patient No.     
 
Patient's Initials (L, F, M)    
 
o. Patient must have adequate renal function as evidenced by [CONTACT_209695]: 
serum creatinine ≤ 1.5 mg/dL OR measured or calculated creatinine clearance ≥ 
50 mL/min.  This result must have been obtained within 28 days prior to 
registration.  
 
Estimated creatinine clearance = (140 - age) x wt (kg) x 0.85 (if female)  
72 x creatinine (mg/dl)  
 
p. Patient must have a left ventricular ejection fraction ≥ institutional lower limit of normal (LLN) by [CONTACT_710002] [ADDRESS_1105387] a corrected QT (QTc) interval ≥  [ADDRESS_1105388] a history of acute coronary syndromes (including 
unstable angina), myocardial infarction within  [ADDRESS_1105389] 24 weeks; Class II, III, or IV heart failure as defined by [CONTACT_89792] (NYHA) functional classification system  (see 
Appendix 18.6) ; or history of known cardiac arrhythmias  (such as atrial 
fibrillation)  unless it has been stably controlled for > 30 days prior to registration . 
Abnormal cardiac valve morphology (≥ Grade 2) documented by [CONTACT_6751] 
(subjects with Grade 1 abnormalities [i.e., mild regurgitation/stenosis]) can be entered on study.  Subjects with moderate valvular thickening are not eligible.  
 
s. Patients with melanoma must have a serum lactate dehydrogenase (LDH) test 
performed within [ADDRESS_1105390]  
adequate CD4 counts (≥ 500 mm
3). 
 
u. P atients  receiving anticoagulation treatment are allowed to participate with INR 
established within the therapeutic range. (See Section 7.2b ).  
 
v. At the time of registration, patients must not be receiving any medications or substances that are strong inhibitors or inducers of CYP3A or CYP2C8.  Patients 
must not be planning to use herbal remedies ( e.g., St. John’s wort), or strong 
inhibitors or inducers of P -glycoprotein (Pgp) or breast  cancer resistance protein 
1 (Bcrp1) .  See Appendix 18.[ADDRESS_1105391] within 14 
days of registration.  
 S1221  
 Page 35  
 Version Date 8/21/17  
 
  
SWOG Patient  No.    
 
Patient's Initials (L, F, M)    
 
x. Patients must not be pregnant or nursing due to unknown teratogenic side effects.  Women/men of reproductive potential must have agreed to use an 
effective contraceptive method.  A woman is considered to be of "reproductive 
potential" if she has had menses at any time in the preceding 12 consecutive months.  In addition to routine contraceptive methods, "effective contraception" 
also includes heterosexual celibacy and surgery intended to prevent pregnancy 
(or with a side- effect of pregnancy prevention) defined as a hysterectomy, 
bilateral oophorectomy or bilateral tubal ligation.  Hormonal contraception is not 
allowed due to drug interactions which can render hormonal contraceptives  
ineffective.   However, if at any point a previously celibate patient chooses to 
become heterosexually active during the time period for use of contraceptive 
measures outlined in the protocol, he/she is responsible for beginning 
contraceptive measures.  
 
y. Patient must not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, previously diagnosed Type 1 diabetes 
mellitus /Type 2 diabetes, psychiatric illness/social situations, symptomatic 
congestive heart failure, unstable angina pectoris, cardiac arrhythmia, that would limit compliance with study requirements.   Patients must not have any evidence 
of mucosal or internal bleeding. Patients must not have a history of pneumonitis  
or interstitial lung disease.  Patients must not have received any major surgery 
within four weeks prior to registration. 
 
z. Patients must not have an active Hepatitis B Virus (HBV) or Hepatitis C Virus 
(HCV) infection.  
 
aa. Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or other agents  used in 
this study  including dimethyl sulfoxide (DMSO) . 
 
bb. Patients must be able to retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as 
malabsorption syndrome or major resection of the stomach or bowels.  Patients  
who have feeding tubes can enroll in the study provided that the capsules do not 
need to be modified.  
 
cc. P atients or their legally authorized representative must be informed of the 
investigational nature of this study and must sign and give written informed 
consent in accordance with institutional and federal guidelines.  
 
dd. As a part of the OPEN registration process (see Section 13.3
 for OPEN access 
instructi ons) the treating institution's identity is provided in order to ensure that 
the current  (within 365 days) date of institutional review board approval  for this 
study has been entered in the system.  
 ee. Patie nts must be ≥ [ADDRESS_1105392] a serum albumin ≥  2.5 g/dL  within 28 days prior to 
registration.   
 S1221  
 Page 36  
 Version Date 8/21/17  
 
  
SWOG Patient No.     
 
Patient's Initials (L, F, M)    
 
gg. Patients with known history or current evidence of retinal vein occlusion (RVO) are not eligible:  
 • History of RVO, or predisposing factors to RVO (e.g. uncontrolled glaucoma or ocular hypertension, uncontrolled systemic disease 
such as hypertension, diabetes mellitus, or history of hyperviscosity 
or hypercoagulability syndromes).  
• Visible retinal pathology as assessed by [CONTACT_800848] a risk factor for RVO such as:  
• Evidence of new optic disc c uppi[INVESTIGATOR_007]  
• Evidence of new visual field defects  
• Intraocular pressure > 21 mmHg  
 
• NOTE:  Ophthalmic exam is required for all patients.  Exam must be obtained within [ADDRESS_1105393] uncontrolled hypertension (defined as  systolic blood 
pressure > 140 mm Hg and/or diastolic blood pressure > 90 mm Hg which cannot be controlled by [CONTACT_14181] -hypertensive therapy) , 
 
5.[ADDRESS_1105394] ricted to the 
following:  
 
a. Patients must have histologically confirmed melanoma with BRAF
V600 mutation .  
Patients must have Stage IIIC or Stage IV disease as outlined in Section 4.[ADDRESS_1105395] received prior BRAF inhibitor therapy (e.g. dabrafenib, 
vemurafenib) within [ADDRESS_1105396] be assessed (by [CONTACT_5292], CT, or MRI 
scan) within [ADDRESS_1105397] demonstrate clearly progressive disease (in the opi[INVESTIGATOR_800812]) prior to registration.  All disease must be assessed and documented 
on the Baseline Tumor Assessment Form (RECIST 1.1).  
 
d. Patients must have Zubrod Performance status ≤ 2 (see Section 10.4 ). 
 
e. No other prior malignancy is allowed except for the following:  adequately treated 
basal cell or squamous cell skin cancer, in situ  cervical cancer, adequately 
treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for 
five years.  Patients with history of RAS mutation- positive tumors are not eligible 
regardless of interval from the current study.  Note: Prospective RAS testing is 
not required.  However, if the results of previous RAS testing are known, they must be used in assessing eligibility.  
 
 
 S1221  
 Page 37  
 Version Date 8/21/[ADDRESS_1105398]. Ribas at 310/206- [ADDRESS_1105399]. 
Algazi at 415/353- 7552.  For dosing principles or questions, please consult SWOG Policy #38 
"Dosing Principles for Patients on Clinical Trials" at http://swog.org (then click on "Policies and Manuals" under the "Visitors" menu and choose Policy 38).  
 
NOTE:  [COMPANY_004]2141795 will not be available after September 30, 2018.  At that time, patients 
remaining on protocol treatment may continue with dabrafenib and trametinib alone.   
 
7.1 Treatment Overview  
 
The study will be conducted in two sequential parts.  A patient may be enrolled to 
either the Phase I Portion or the Phase II Portion, but not both.  
Phase I Dabrafenib plus [COMPANY_004]2141795   (D+G)  Details are in Section 7.3
 and 
Dabrafenib and Trametinib plus [COMPANY_004]2141795 (D+T+G)  Portion – Details are in 
Section 7. 4. 
 Phase II Portion – Details are in Section 7. [ADDRESS_1105400] selected CYP450 isoenzymes 
(see Section  18.4).  Appendix 18.6  contains  a patient information sheet that can 
be used for this specific protocol and presented to the patient.  
 
 S1221  
 Page 38  
 Version Date 8/21/17  
 
  
 Dabrafenib is metabolized primarily by [CONTACT_13439] P450 (CYP) 2C8 and CYP3A4.  Co- administration of dabrafenib with ketoconazole, a CYP3A4 
inhibition, or with gemfibrozil, a CYP2C8 inhibitor, resulted in increases in dabrafenib AUC of 71%  and 47%, respectively.  Drugs that are strong inhibitors 
or inducers of CYP3A and CYP2C8  (see list in Section  18.4
) may only be used 
under special circumstances (e.g. as a single use for a procedure) while treatment with study drug is interrupted as they may alter dabrafenib concentrations; consider therapeutic substitutions for these medications.  
 
b. Warfarin  exposure may be decreased due to enzyme induction when on 
treatment, thus warfarin dosing may need to be adjusted based u pon PT/INR.  
Consequently, when discontinuing dabrafenib, warfarin exposure may be increased and thus dose monitoring via PT/INR and warfarin dose adjustments must be made as clinically appropriate.  Prophylactic low dose warfarin may be 
given to maintain central catheter potency.  
 
c. Patients should  have a baseline fasting glucose level within the institutional 
upper limit of normal (IULN).   This result should be obtained within [ADDRESS_1105401] an HgA1c 
≤ 7% within [ADDRESS_1105402] two days prior to registration.  
 
7.3 Treatment - Phase I  Dabrafenib + [COMPANY_004]2141795 (D+G)    
 
a. Dose Escalation  Scheme for D + G  
 
Effective November 15, 2014, this trial will not proceed to the Phase II study of 
dabrafenib and [COMPANY_004]2141795, in favor of  evaluation of triple therapy.  (See 
Section 7.4
). 
 
This will be a dose- escalation clinical trial using a standard 3+[ADDRESS_1105403] 3 patients enrolled at the previous dose level. The maximum tolerated dose (MTD) is defined as the highest dose studied in which the incidence of dose- limiting toxicities (DLT) is < 33%. The cohort of the MTD (or proposed dose 
for Phase II P ortion if MTD not reached) will be at least 6 patients . 
 S1221  
 Page 39  
 Version Date 8/21/17  
 
  
 
Dose escalation scheme for D+G: 
 
Dose Level  Dabrafenib  
(twice a day ) [COMPANY_004]2141795  
(once a day ) 
1 150 mg 50 mg 
2 150 mg 75 mg 
2+ 12/1/15  12/1/15  
 
NOTE:  The drug regimen will be given on an outpatient basis. A cycle equals 28 days . 
 In the case that the PK sampling suggests that there is a drug- drug interaction 
between dabrafenib and [COMPANY_004]2141795 resulting in decreased exposure of one or 
both of the study drugs, a cohort 2+ will be open with dosing increased over 
cohort [ADDRESS_1105404] their doses of [COMPANY_004]2141795 
increased to the next cohort level if DLT is < 33% and at least [ADDRESS_1105405] 
gone through the full DLT assessment period of 2 months.   
 
b. Dose Determination Rules  
 
1. Dose Limiting Toxicity (D LT) is defined in Section 7.3c
. 
 
2. Only DLTs occurring during Cycles 1 and 2 will be used to gu ide dosing 
determination of [COMPANY_004]2141795. 
 
3. Patients will be considered evaluable for DLT if they fulfill one of the following criteria:  
 
• They experience a DLT or  
 
• They received [COMPANY_004]2141795 at the assigned dose for at least [ADDRESS_1105406] 28 days combined of dabrafenib over 
Cycles 1 and 2 or  
 
• They received [COMPANY_004]2141795 at the assigned dose for at least [ADDRESS_1105407] 50% of dabrafenib during Cycle 1. 
 
Patients who do not meet at least one of these criteria will be considered 
not evaluable for DLT and will be replaced.  
 S1221  
 Page 40  
 Version Date 8/21/17  
 
  
 
4. The following dosing scheme will be used for dose determination: 
 
a. Begin  at Dose Level 1 ( see Dose Escalation Scheme  above): 
 
1) Enroll [ADDRESS_1105408] been 
enrolled.  
 
2) If 0 of the initial 3 patients experience a DLT stop enrollment at this dose and continue to Dose Level 2.  
 
3) If only [ADDRESS_1105409] been enrolled or a second patient experiences  
a DLT.  
 
4) If 1 of 6 patients experiences  a DLT, continue to Dose Level 
2. 
 
5) If 2 or more patients experience a DLT, lower dose levels 
may be investigated to find the recommended dose for the Phase II P ortion or the study may be permanently closed.  
 
b. At Dose Level 2 ( see Dose Escalation Scheme above):  
 
1) Enroll [ADDRESS_1105410] been 
enrolled.  
 
2) If [ADDRESS_1105411] been enrolled or a second patient experiences a DLT.  
 
3) If 0 or 1 of 6 patients experiences a DLT, Dose Level 2 is the 
MTD.  
 
4) If 2 or more patients experience a DLT,  
 
a) If [ADDRESS_1105412] been enrolled in Dose Level 1, Dose Level 1 is the MTD.   
 
b) If [ADDRESS_1105413] been enrolled in Dose Level 1, expand enrollment to 6 evaluable patients.  
 
1. If 0 or 1 patients of 6 patients experience a DLT, Dose Level 1 is the MTD.  
 
2. If 2 or more patients experience a DLT, l ower 
dose levels may be investigated to find the 
recommended dose for the Phase II P ortion or 
the study may be permanently  closed.  
 S1221  
 Page 41  
 Version Date 8/21/17  
 
  
 c. Definition of Dose- Limiting Toxicity  
 
Toxicities will be graded according to the NCI Common Terminology Criteria for Adverse Events  Version 4.0.  
 
Dose- limiting toxicities (DLT) apply only during Cycle s 1 and 2 and should be 
drug- related (possible, probable or definite).  The following events are considered 
dose limiting:  
 
1. Febrile neutropenia, 
 2. Grade 4 neutrophil count decrease for more than 7 days  duration, 
 
3. Grade 4 platelet count decreas e, 
 4. Grade 3 or 4 skin rash, fevers and hyperglycemia that do not recover 
within 14 days with adequate medical management as described in 
Section 8.0, 
 
5. Grade 3 or 4 non- hematologic toxicity that does not recover within 7 days 
with adequate medical management.   
 
7.4 Treatment - Phase I  Dabrafenib + Trametinib + [COMPANY_004]2141795 (D + T + G)   
   
a. Dose Escalation Scheme of D + T + G:  
Phase I portion:  The primary objective is to assess the safety of dabrafenib, 
trametinib, and [COMPANY_004]2141795 in combination and to determine the dos ing of the 3 
drug combination for the Phase II portion. Dose escalation of dabrafenib, trametinib, and [COMPANY_004]2141795 will b e initiated after completion of the dabrafenib + 
[COMPANY_004]2141795 phase I dose escalation. This three drug dose escalation will follow 
a standard 3+[ADDRESS_1105414] 3 patients enrolled at the previous dose level. The maximum 
tolerated dose (MTD) is defined as the highest dose studied in which the incidence of dose- limiting toxicities (DLT) is < 33%. The MTD c ohort (or 
proposed dose for Phase II portion if MTD not reached) will include at least 6 patients.  
Dose escalation scheme for D+T+G  
 
Dose Level  Dabrafenib  
(mg PO BID)  Trametinib  
(mg PO daily)  [COMPANY_004]2141795  
(mg PO daily)  
1 150 1.5 25 
2 150 1.5 50 
3 150 1.5 75 
4 150 2 75 
 S1221  
 Page 42  
 Version Date 8/21/17  
 
  
 
b. Dose Determination Rules  
 
1. Dose Limiting Toxicity (D LT) is defined in Section 7.4c . 
 
2. Only DLTs occurring during Cycles 1 and 2 will be used to guide dosing 
determination of the study combinations . 
 
3. Patients will be considered evaluable for DLT if they fulfill one of the 
following criteria:  
 
• They experience a DLT or  
 
• They received [COMPANY_004]2141795 at the assigned dose for at least [ADDRESS_1105415] 28 days of dabrafenib over Cycles 1 and 2 or 
 
• They received [COMPANY_004]2141795 at the assigned dose for at least [ADDRESS_1105416] 50% of trametinib during Cycle [ADDRESS_1105417] 
50% of dabrafenib during Cycle 1. 
. 
Patients who do not meet at least one of these criteria will be considered not evaluable for DLT and will be replaced.  
 
4. The following dosing scheme will be used for dose determination: 
 
a. Begin at Dose Level 1 ( see Dose Escalation Scheme
 above): 
 
1) Enroll [ADDRESS_1105418] been 
enrolled.  
 
2) If [ADDRESS_1105419] been enrolled or  two patient s 
experience a DLT.  
 3) If 0-1 out of 6 patients experience a DLT on Dose Level 4, 
then Dos e Level 4 is the MTD.  
 4) If only [ADDRESS_1105420] been enrolled or a second patient experiences a DLT.  
 5) If [ADDRESS_1105421] level or if the current 
dose level is Dose Level 4 then the current dose level is the 
MTD.  
 6) If [ADDRESS_1105422] dose level then that dose level is the MTD. If the current dose level is Dose Level 1  lower dose levels may 
 S1221  
 Page 43  
 Version Date 8/21/17  
 
  
be investigated to find the recommended dose for the Phase II Portion or the study may be permanently closed.  
 
c. Definition of Dose- Limiting Toxicity  
 
Toxicities will be graded according to the NCI Common Terminology Criteria for 
Adverse Events Version 4.0.  
 
Dose- limiting toxicities (DLT) apply only during Cycles 1 and 2 and should be 
drug- related (possible, probable or definite).  The following events are considered 
dose limiting:  
 
1. Febrile neutropenia,  
 2. Grade 4 neutrophil count decrease for more than 7 days duration,  
 3. Grade 4 platelet count decrease,  
 
4. Grade 3 or 4 skin rash, fevers and hyperglycemia that do not recover 
within 14 days with adequate medical management as described in Section 8.0
, 
 5. Grade 3 or 4 non- hematologic toxicity that does not recover within 7 days 
with a dequate medical management.  
 
7.5 Treatment - Phase II Portion of the S tudy 
 
Agen t Dose  Route  Schedule*   
 
Dabrafenib  150 mg PO Twice a day  
 
Trametinib  determined in  PO Once a day  
 Phase I portion  
 [COMPANY_004]2141795  determined in  PO Once a day  
 Phase I portion  
 
*  Note:  One cycle = 28 days  
 
Patients will continue treatment until disease progression or other reason for 
discontinuation of protocol treatment (see Section 7. 9). 
 
7.[ADDRESS_1105423] should be instructed not to 
retake the dose and should take the next dose as originally scheduled.  Study drugs may 
be delivered to patients with feeding tube as long  the capsules and tablets are not 
modified.  
 
 S1221  
 Page 44  
 Version Date 8/21/[ADDRESS_1105424] 12 hours later.  
 
7.7 Drug Compliance Documentation  
 
Drug compliance will be recorded by [CONTACT_461482] (see Appendix 
18.3).  Institutional CRAs will review and ascertain patient adherence with protocol 
therapy at the end of treatment for each cycle.  Calendar should be kept in the patient's  
clinic chart.  Note that the Intake Calendar is provided only as a tool for tracking patient 
compliance.  Sites may utilize institutional pi[INVESTIGATOR_800813].  
 
7.8 Full CDUS Reporting Requirement s 
 
Because this study contains an investigational drug for which CTEP holds the IND, it falls 
under CTEP requirements for full reporting.  This involves required submission of cycle-
specific toxicity and dos e informat ion ( see Section 14. 4c
, the S1221 Treatment Form, 
and the S1221 Adverse Event Form).  A cycle is defined as 28 days.  
 7.9 Criteria for Removal from Protocol Treatment  
 
a. Progression of disease as defined in Section 10.2d
.  However, the patient may 
continue to stay on protocol treatment  as long as in the opi[INVESTIGATOR_800814].  This may 
be if there are lesions that continue to respond to the therapy despi[INVESTIGATOR_726201] s 
progressing, or if there is symptomatic relief of symptoms on therapy.  
 
b. Symptomatic deterioration (as defined in Section 10.2e ). 
 
c. Unacceptable toxicity.  
 d. Treatment delay of both protocol drugs for any reason > [ADDRESS_1105425].  
 
 S1221  
 Page 45  
 Version Date 8/21/17  
 
  
 8.0 TOXICITIES TO BE MONITORED AND DOSAGE MODIFICATIONS  
 
8.1 NCI Common Terminology  Criteria for Adverse Events  
 
This study will utilize the CTCAE  (NCI Common Terminology Criteria for Adverse Events)  
Version 4.0 for toxicity and Serious Adverse Event reporting.  A copy of the CTCAE 
Version 4.0 can be downloaded from the CTEP home page (http://ctep.cancer.gov).  All appropriate treatment areas should have access to a copy of the CTCAE Version 4.0.  
 
8.[ADDRESS_1105426] dose reductions.  
 
b. No dose escalation or re- escalation is allowed.
 
 
8.3 Dose Modifications for Dabrafenib, Trametinib, and [COMPANY_004]2141795  
 The table below outlines the dose levels to be used for any necessary dabrafenib, trametinib and [COMPANY_004]2141795 dose modifications:  
 
Dose Level  Dabrafenib  Dose/Schedule  
0 150 mg BID  
-1 100 mg BID  
-2 75 mg BID  
-3 50 mg BID 
 
 
Dose Level  Trametinib Dose/Schedule  
0 2 mg QD  
-1 1.5 mg QD  
-2 1.0 mg QD  
 
 
Dose Level  [COMPANY_004]2141795 Dose/Schedule  
0  75 mg QD  
-1 50 mg QD  
-2 25 mg QD  
 
Dabrafenib, Trametinib, and [COMPANY_004]2141795 Dose Modification Guidelines  
 
If an AE resolves to Grade 1 or baseline at the reduced dose level, and no additional 
toxicities are seen after 4 weeks of study treatment at the reduced dose, the dose may be 
increased to the previous dose level.  A dose reduction below 50 mg BID for dabrafenib is not allowed.   Dose reduction below 1 mg once daily for trametinib is not allowed.  Dose 
reduction below 25 mg once daily for [COMPANY_004]2141795 is not allowed.  However, if dabrafenib, trametinib, or [COMPANY_004]2141795 is permanently discontinued due to an agent specific toxicity (see below), the patient will be allowed to continue on the remaining 
agent(s).   
 Study Chair approval is required to restart study treatment after ≥  28 days of dose 
interruption.  
 S1221  
 Page 46  
 Version Date 8/21/17  
 
  
The dose modifications may involve one or both agents, and should be based on the nature, severity and attributions of the AEs.  General guidelines are provided in Tables below, with details stipulated in subsequent sections.  Study Chair should be consulted if 
there are questions about the attribution of AEs and how the doses should be modified.  
 
a. Dose Modification for Toxicities Not Specified  in Subsequent Sections  
 
CTCAE Grade  Action and Dose Modification  
Grade 1  
Grade 2 (tolerable)  • Continue study treatment at  same dose level (no 
dose modification).  
• Monitor closely.  
• Provide supportive care according to institutional 
standards.  
Grade 2 (intolerable) 
Grade 3  • Interrupt study treatment.  
• Monitor closely.  
• Provide supportive care according to institutional 
standards.  
• When toxicity resolves to grade 1 or baseline, restart study treatment reduced by [CONTACT_37387] . 
• If the grade 2 (intolerable) or grade 3 toxicity recurs, interrupt study treatment.  
• When toxicity resolves to grade 1 or baseline, restart study treatment reduced by [CONTACT_710004] . 
Grade 4  • Permanently discontinue, or interrupt, study 
treatment.  
• Monitor closely.  
• Provide supportive care according to institutional 
standards.  
• If study treatment was interrupted, restart  study 
treatment reduced by [CONTACT_800849] 1 or baseline.  
*If the AEs are thought to be due to one of the two agents, resumption of the 
other agents may be considered if the first agent is discontinued due to toxicities and treatment interruption is <28days.  CTEP monitor should be consulted for resumption of single agent.  
 
b. Dose Modification for Pyrexia  
 
• Pyrexia is defined as a body temperature equal to or above 38.5○ Celsius or 
101.3○ Fahrenheit  
• Pyrexia is an adverse event associated with dabrafenib and is increased in 
frequency and severity in subjects receiving dabrafenib in combination with trametinib.  In a minority of cases, pyrexia was accompanied by [CONTACT_800850]/rigors, dehydration, hypotension, dizziness or 
weakness and required hospi[INVESTIGATOR_059].  
 S1221  
 Page 47  
 Version Date 8/21/[ADDRESS_1105427] should be instructed to 
take anti -pyretics (e.g. ibuprofen or acetaminophen/paracetamol) as 
appropriate to control fever.  The use of oral corticosteroids should be 
considered in those instances in which anti -pyretics are insufficient. 
Monitor . 
• serum creatinine and other evidence of renal function during and following 
severe events of pyrexia  
Dose Modification and Management Guidelines for  Pyrexia
a 
Event  Management Guideline  Dose Modification  
Work up:  
• Clinical evaluation for infection and hypersensitivity, especially if pyrexia is complicated by [CONTACT_483021], 
severe chills, dehydration, etc.  
• Laboratory work -up (should include full-blood -count, electrolytes, creatinine, BUN, CRP, liver -
function tests, blood and urine culture).  
 
Management :  
• Anti-pyretic treatment should be started immediately at the first occurrence.  Anti -pyretic treatment 
may include acetaminophen (paracetamol), ibuprofen, or suitable anti -pyretic medication per 
institutional standards.  
• Oral hydration is encouraged in subjects without evidence of dehydration.  Intravenous hydration is recommended if pyrexia is complicated by [CONTACT_114475]/hypotension.  
• In subject experiencing pyrexia complicated by [CONTACT_483021], severe chills, etc., which cannot be controlled 
with anti -pyretic medication, oral corticosteroids should be started.  
• Prophylactic anti -pyretic treatment is recommended after the 2nd event, or after the 1st event if 
complicated by [CONTACT_800851]. Prophylactic anti-pyretics may be d iscontinued after three days 
in absence of pyrexia   
1st Eventb: • Cinical evaluation for 
infection and  
hypersensitivityc 
• Laboratory work -upc 
• Hydration as requiredd 
 
• Administer anti -pyretic 
treatment if clinically indicated and continue 
prophylactic treatmentf • Interrupt dabrafenib.  
• Continue trametinib and 
[COMPANY_004]2141795.  
• Upon recovery to baseline, restart dabrafenib at the same dose level.  If fever was associated with dehydration or hypotension, 
reduce dabrafenib by [CONTACT_37387] . 
 
2nd Event  • Clinical evaluation for 
infection and hypersensitivity
c 
• Laboratory work -upc 
• Hydration as requiredd 
• Within 3 days of onset of pyrexia:  
− Optimize anti- pyretic 
therapy.  
− Consider oral corticosteroids ( i.e., 
prednisone 10 mg) for at least 5 days or as 
clinically indicated.f • Interrupt dabrafenib.  
• Continue trametinib and [COMPANY_004]2141795  
• Upon recovery to baseline, restart 
dabrafenib at the same dose level.  
If fever was associated with dehydration or hypotension, reduce dabrafenib by [CONTACT_37387] . 
 S1221  
 Page 48  
 Version Date 8/21/17  
 
  
Dose Modification and Management Guidelines for  Pyrexiaa (contd)  
Event  Management Guideline  Dose Modification  
Subsequent Events :  
 • Clinical evaluation for 
infection and 
hypersensitivityc 
• Laboratory work -upc 
• Hydration as requiredd 
• Blood sample for cytokine analysis
e 
• Within 3 days of onset of pyrexia:  
− Optimize oral corticosteroid dose as clinically indicated for recalcitrant pyrexia.
g 
− If corticosteroids have been tapered and pyrexia recurs, restart 
steroids.  
− If corticos teroids cannot 
be tapered, consult 
medical monitor.  • Interrupt dabrafenib.  
• Continue trametinib and 
[COMPANY_004]2141795.  
• Once pyrexia resolves to baseline, restart dabrafenib reduced by [CONTACT_23615] .
h 
• If dabrafenib must be reduced to 
<[ADDRESS_1105428] supportive 
care and increasing doses of oral 
steroids.  Escalation of dabrafenib is allowed if no epi[INVESTIGATOR_482962] 4 weeks 
subsequent to dose reduction.  −   
 
c. Dose Modification for Rash  
 
Rash is a frequent AE observed in patients receiving trametinib, dabrafenib, and 
[COMPANY_004]2141795.  
 The institutional standards for the management of skin- related AEs can differ 
from these guidelines.  In this case, best clinical judgment should be applied and 
a consultation with the study chair or the CTEP Medical Monitor may be required.  
 
Supportive Care and Dose Modification for Rash  
CTCAE Grade  Adverse Event Management  Action and Dose 
Modification  
Supportive care:  
Prevention:   
• Avoid unnecessary exposure to sunlight  
• Apply broad- spectrum sunscreen (containing titanium dioxide or zinc oxide) with a skin 
protection factor (SPF) ≥[ADDRESS_1105429] twice daily.  
• Use thick, alcohol -free emollient cream (e.g., glycerine and cetomacrogol cream) on dry 
areas of the body at least twice daily.  
• Topi[INVESTIGATOR_800815] [ADDRESS_1105430], and upper back.   
Use mild -strength topi[INVESTIGATOR_27560]  (hydrocortisone 1% cream) or topi[INVESTIGATOR_11978] (e.g., 
clindamycin) or oral antibiotics (e.g., doxycycline 100 mg BID, minocycline 100 mg BID)  
 S1221  
 Page 49  
 Version Date 8/21/17  
 
  
Supportive Care and Dose Modification for Rash  
CTCAE Grade  Adverse Event Management  Action and Dose 
Modification  
Symptom management:  
• Pruritic lesions: cool compresses and oral antihistamine therapi[INVESTIGATOR_014]  
• Fissuring lesions: Monsel’s solution, silver nitrate, or zinc oxide cream  
• Desquamation: thick emollients and mild soap  
• Paronychia: antiseptic bath, local potent corticosteroids in addition to oral antibiotics; if no 
improvement, consult dermatologist or surgeon  
• Infected lesions: appropriate bacterial/fungal culture- driven systemic or topi[INVESTIGATOR_8163]  
*Rash prophylaxis is recommended for the first 6 weeks of study treatment  
a. * Subjects who develop rash/skin toxicities should be seen by a qualified physician and 
should receive evaluation for symptomatic/supportive care management  
Grade 1  
 • Initiate prophylactic and 
symptomatic treatment measures.
1 
• Use moderate strength topi[INVESTIGATOR_159811].2 
• Reassess after 2 weeks.  • Continue study treatment.  
• If rash does not recover to baseline within [ADDRESS_1105431] supportive care, reduce 
study treatment by [CONTACT_37387]  (all agents) .3 
Grade 2  
 • Initiate prophylactic and 
symptomatic treatment 
measures.1 
• Use moderate strength topi[INVESTIGATOR_159811].2 
• Reassess after 2 weeks.  • Reduce study treatment by 
[CONTACT_30560].  
• If rash recovers to ≤ grade 1 within 2 weeks, increase dose to 
previous dose level.  
• If no recovery  to ≤ grade 1 within 
2 weeks, interrupt study treatment until recovery to ≤ grade 1.  
• Restart study treatment at 
reduced dose level  (all 
agents) .3 
Grade ≥3  
 • Use moderate strength topi[INVESTIGATOR_190723] -
prednisolone dose pack.2 
• Consult dermatologist.  • Interrupt study treatment until 
rash recovers to ≤ grade 1.  
• Restart study treatment reduced by [CONTACT_30560]  (all 
agents) .
3,4 
• If no recovery to ≤ grade [ADDRESS_1105432] 6 weeks of study treatment.  
2.  Moderate- strength topi[INVESTIGATOR_8826]:  Hydrocortisone 2.5% cream or fluticasone 
priopi[INVESTIGATOR_16847] 0.5% cream.  
3.  Approval of Study Chair  is required to restart study treatment after >28 days of 
interruption.  
4.  Study treatment may be escalated to previous dose level if no rash is evident 4 weeks 
after restarting study treatment.  
 
d. Dose Modification for palmar -plantar erythrodysesthesia syndrome (PPES)  
 
• Lifestyle modification:  avoidance of hot water, traumatic activity, constrictive 
footwear, or excessive friction on the skin and the use of thick cotton socks and 
gloves, and shoes with padded insoles  
 S1221  
 Page 50  
 Version Date 8/21/17  
 
  
 
• Symptomatic treatments:  apply moisturizing creams frequently, topi[INVESTIGATOR_800816] (e.g. urea 20- 40 % cream, salicylic acid 6%, tazarotene 0.1% cream, 
fluorouracil 5% cream), clobetasol propi[INVESTIGATOR_16847] 0.05% ointment for erythematous areas, topi[INVESTIGATOR_24242] 2%, and / or systemic pain medication such as  
nonsteroidal anti -inflammatory drugs, codeine, and pregabalin for pain.  
• Dose modification may also be required. – Refer to table for dose modification for 
non-specific AEs  
e. Treatment Modification for New Primary/ Recurrent Malignancies:   
 
Cutaneous SCC  and New Primary Melanoma  
Dermatologic skin assessments for subjects on treatment should be performed 
before initiation of dabrafenib, then every 2 months through treatment.  (For 
protocols that start after June 2014, it is also recommended that skin exams  
should continue every 2 -3 months for 6 months after discontinuation of 
dabrafenib or initiation of another anti- neoplastic therapy. )  Report any new 
primary/recurrent malignancies as SAE through CTEP -AERS.     
 
• Cutaneous SCC  
Cases of cuSCC (which include those classified as keratoacanthoma or 
mixed keratoacanthoma subtype) have been observed in subjects 
treated with dabrafenib.  Approximately 70 % of events occurred within 
the first 12 weeks of treatment with a median time to onset of 8 weeks.  
 
These should be surgically removed according to institutional practices.  Dose modification or interruption of study treatment is not required for cuSCC or KA, however cuSCC should be reported as an SAE . In 
addition, a biopsy of the lesion should be taken, where possible, and a summary of the results submitted to CTEP through the SAE reporting.   
 
Patients should be instructed to immediately inform their physician if new lesions develop.  
 
• New Primary Melanoma  
New primary melanomas have been reported in patients treat ed with 
dabrafenib. These were identified primarily within the first [ADDRESS_1105433] been 
seen with BRAF inhibitors.   Patients should be monitored as clinically 
appropriate.  
 
Permanently discontinue dabrafenib in patients who develop RAS mutation-
positive non- cutaneous malignancies.  If used in combination with trametinib, 
trametinib may continue.   
 Following discontinuation of dabrafenib, monitoring for non- cutaneous 
secondary/recurrent malignancies should continue for up to 6 months or until 
initiation of another anti -neoplastic therapy.  
 S1221  
 Page 51  
 Version Date 8/21/17  
 
  
 New non -cutaneous malignancies should be reported as a SAE. A biopsy of the 
new malignancy should be taken, where possible, and submitted for further 
analyses with the results provided to CTEP via SAE reporting.  Testing of these 
biopsies should include RAS mutation analysis and may include analysis of genomic alterations, which include but not limited to DNA, RNA and protein 
analysis of these biopsy specimens, and would analyze the biological pathways 
known to be associated with, and relevant to, BRAF -mutant tumor activation.  
 
f. Dose Modification for Hemorrhages  
 
Grade 3  • Hold dabrafenib , trametinib  and [COMPANY_004]2141795  for up to 3 weeks  
• If improved, resume the drugs at one dose reduction  
• If no improvement, permanently discontinue dabrafenib or 
dabrafenib -trametinib  
Grade 4  • Permanently discontinue dabrafenib or dabrafenib -trametinib  
   
g. Dose Modification for Pancreatitis  
 
In the event of abdominal pain or suspected pancreatitis, amylase and lipase 
laboratory samples should be collected for confirmation of the diagnosis.  Patients should be closely monitored when re- starting dabrafenib after an 
epi[INVESTIGATOR_28547].  
 
h. Dabrafenib- Trametinib Dose Modification for Hyperglycemia  
 Hyperglycemia requiring an increase in the dose of, or initiation of insulin or oral therapy can occur with dabrafenib. Monitor serum glucose levels as clinically 
appropriate during treatment with dabrafenib in subjects with pre- existing 
diabetes or hyperglycemia. Advise patients to report symptoms of severe 
hyperglycemia such as excessive thirst or any increase in the volume or 
frequency of urination.   See Section 8.4a for [COMPANY_004]2141795 dose m odificat ion 
instructions . 
 S1221  
 Page 52  
 Version Date 8/21/17  
 
  
i. Dose Modification for Renal Insufficiency  
 
Prior to start of study treatment, concomitant medications should be reviewed for 
the potential risk of inducing nephrotoxicity and modified if clinically possible.  
 
Dose Modification for  Renal Insufficiency  
Serum Creatinine Level  Management Guideline  Action and Dose 
Modification  
Serum creatinine 
increase  
>0.2 mg/dL (18 mcmol/L)  
BUT 
≤0.5 mg/dL (44 mcmol/L) 
above baseline  • Recheck serum creatinine within 1 
week.  
• Serum creatinine increase >1 week:  
contact [CONTACT_800852]. If 
elevation persists beyond 4 weeks, 
recommend evaluation (consider renal biopsy) for etiology; consider nephrology consultation.  
• If pyrexia is present, treat pyrexia as 
per guidelines.a Continue study 
treatment at the same dose level.  
Serum creatinine 
increase  
>0.5 mg/dL (44 mcmol/L)  
OR 
>2 mg/dL (>177 mcmol/L)  • Monitor serum creatinine ≥2 -times 
per week.  
• Hospi[INVESTIGATOR_800817].  
• If pyrexia is present, treat pyrexia per guidelines.  
• Consult nephrologist if clinically 
indicated.  
• Perform renal biopsy if clinically indicated, for example:  
− Renal insufficiency persists 
despi[INVESTIGATOR_800818].  
− Patient has  new rash or signs of 
hypersensitivity (such as 
elevated eosinophil count).  • Interrupt study 
treatment until serum creatinine recovers to baseline.  
• Restart study 
treatment.b 
  
a  NSAIDs can induce renal insufficiency, especially in patients with dehydration; 
;encourage oral fluids or consider IV fluids as clinically indicated. See guidelines for 
pyrexia Section 6.1.2.  
b  Investigator may restart at either the same or a reduced dose level.  Escalation of 
study treatment to previous dose level is allowed if another epi[INVESTIGATOR_800819] 4 weeks of dose reduction.  Consultation with the Study Chair  is 
required before restarting study treatment if there is evidence of thrombotic 
microangiopathy.  
 
j. Dose Modification for Reduced Left Ventricular Ejection Fraction  
 
Decreases of the left ventricular ejection fraction (LVEF) have been observed in 
patients receiving trametinib.  Therefore, ECHO/MUGA must be performed in 
regular intervals outlined in the Study Calendar.  The same procedure (either 
ECHO or MUGA, although ECHO is preferred) should be performed at baseline and at follow -up visit(s).   
 S1221  
 Page 53  
 Version Date 8/21/17  
 
  
 
Treatment Modification and Management Guidelines for LVEF Decrease  
Clinic  LVEF -drop (%) or  
CTCAE grade  Dose Modification 
Asymptomatic  
 Absolute decrease of >10% 
in LVEF compared to 
baseline and ejection 
fraction below the institution’s LLN.  • Interrupt trametinib.  Dabrafenib may continue  
• repeat ECHO within 2 weeks.a 
• If the LVEF recovers  within 4 weeks (defined 
as LVEF ≥LLN and absolute decrease ≤10% compared to baseline):  
− Consult with the Study Chair  and request 
approval for restart.  
− Restart trametinib at reduced doses by [CONTACT_30560].  
− Repeat ECHO 2, 4, 8, and 12 weeks after re-start; continue in intervals of 12 weeks thereafter.  
• If LVEF does not  recover  within 4 weeks:  
− Consult with cardiologist.  
− Permanently discontinue trametinib . 
Report as SAE  
− Continuation of dabrafenib and [COMPANY_004]214175 
may be considered after consultation with Study Chair . 
− Repeat ECHO after 2, 4, 8, 12, and 16 
weeks or until resolution.  
Symptomaticb 
 • Grade 3:  resting LVEF 39 -
20% or >20% absolute 
reduction from baseline  
• Grade 4:  Resting LVEF 
≤20%.  • Permanently discontinue trametinib.  Report 
as SAE  
• Hold dabrafenib and [COMPANY_004]2141795 until 
LVEF improves.  Consult Study Chair  for 
resumption of  dabrafenib and [COMPANY_004]2141795  
• Consult with cardiologist.  
• Repeat ECHO after 2, 4, 8, 12, and 16 weeks 
or until resolution.  
a If ECHO does not show LVEF recovery after 2 weeks, repeat ECHO 2 weeks later.  
b Symptoms may include:  dyspnea, orthopenea, and other signs and symptoms of pulmonary 
congestion and edema.  
 
k. Dose Modification for Hypertension  
 
Increases in blood pressure (BP) have been observed in patients receiving 
dabrafenib plus trametinib.  Recommendations for BP monitoring and 
management are provided below.  
 
Monitoring:   All BP assessments should be performed under the following optimal 
conditions:  
 
• The subject has been seated with back support, ensuring that legs are 
uncrossed and flat on the floor.  
• The subject is relaxed comfortably for at least 5 minutes.  
• Restrictive clothing has been removed from the cuff area, and the right cuff has been selected.  
• The subject’s arm is supported so that the middle of the cuff is at heart level.  
• The subject remains quiet during the measurement.  
 S1221  
 Page 54  
 Version Date 8/21/17  
 
  
• In subjects with an initial BP reading within the hypertensive range, a second 
reading should be taken at least 1 minute later, with the two readings averaged to obtain a final BP measurement.  The averaged value should be 
recorded in the eCRF.  
• Visits to monitor increased blood pressure can be scheduled independently 
from the per-protocol visits outlined in the study calendar.  Ideally, 
subsequent blood pressure assessments should be performed within 1 week.  
• Persistent hypertension is defined as an increase of systolic BP (SBP) >140 
mmHg and/or diastolic BP (DBP) >90 mmHg in three consecutive visits with 
blood pressure assessments from two readings.  
• Asympomatic hypertension  is defined as an increase of SBP >140 mmHg 
and/or diastolic BP (DBP) >90 mmHg in the absence of headache, light -
headedness, vertigo, tinnitus, epi[INVESTIGATOR_31901], or other symptoms 
indicative of hypertension.  
 
Treatment Modification for Hypertension  
Event Management Guideline  Dose Modification 
(Scenario A)  
• Asymptomatic and 
persistenta SBP of ≥140 
and <  160 mmHg, or DBP 
≥ 90 and <  100 mmHg  
OR 
• Clinically significant increase in DBP of 20 
mmHg (but DBP still below 100 mmHg)
 • Adjust current or initiate new 
antihypertensive medication(s).  
• Titrate antihypertensive 
medication(s) during the next 2 
weeks to achieve well -
controlledb BP.   
• If BP is not well -controlled within 
[ADDRESS_1105434] and go to scenario (B).
 • Continue study 
treatment . 
 
(Scenario B)  
• Asymptomatic SBP ≥160 
mmHg, or DBP 
≥100 mmHg,  
OR 
• Failure to achieve well -
controlled BP within 2 
weeks in Scenario A.  • Adjust current or initiate new 
antihypertensive medication(s).  
• Titrate antihypertensive 
medication(s) during the next 2 
weeks to achieve well -controlled 
BP. • Interrupt study 
treatment if clinically indicated.  
• Once BP is well -
controlledb, restart 
study treatment reduced  by [CONTACT_30560]
c  
 
(Scenario C)  
• Symptomaticd 
hypertension  
OR 
• Persistent SBP ≥160 
mmHg, or DBP 
≥100 mmHg, despi[INVESTIGATOR_800820]  • Adjust current or initiate new 
antihypertensive medication(s).  
• Titrate antihypertensive 
medication(s) during the next 2 
weeks to achieve well -controlled 
BP. 
• Referral to a specialist for further 
evaluation and follow -up is 
recommended.  • Interrupt study 
treatment  
• Once BP is well controlled, restart 
study treatment  
reduced by [CONTACT_800853]. 
 
 S1221  
 Page 55  
 Version Date 8/21/17  
 
  
Treatment Modification for  Hypertension  
Event  Management Guideline  Dose Modification 
(Scenario D)  
Refractory hypertension 
unresponsive to above interventions or 
hypertensive crisis.  Continue follow -up per protocol.  • Permanently 
discontinue study 
treatment.  
 
a. Hypertension detected in two separate readings during up to three consecutive visits  
b. Well- controlled blood pressure defined as SBP ≤140 mm Hg and DBP ≤90 mm Hg in 
two separate readings during up to three consecutive visits.  
c. Escalation of trametinib to previous dose level can be considered if BPs remain well-
controlled for 4 weeks after restarting of trametinib.  Approval from Study Chair  is 
required.  
d. Symptomatic hypertension defined as hypertension aggravated by [CONTACT_23805] (e.g., 
headache, light -headedness, vertigo, tinnitus, epi[INVESTIGATOR_31901]) that resolve after 
the blood pressure is controlled within the normal range  
 
l. Dose Modification for QTc Prolongation  and Valvular Changes  
 
Dose M odification  for QTc Prolongation  
QTc Prolongationa Action and Dose Modification 
• QTcB ≥501 msec  
 • Interrupt study treatment  until QTcB prolongation resolves to 
grade 1 or baseline.  
• Test serum potassium, calcium, phosphorus and magnesium. 
If abnormal, correct per routine clinical practice to within normal limits.   
• Review concomitant medication usage for agents that prolong 
QTc.  
• If the event resolves, restart study treatment at current dose 
level
b. 
• If the event does not resolve, permanently discontinue study treatment. Consider evaluation with cardiologist.  
• If the event recurs, permanently discontinue study 
treatment. Consider evaluation with cardiologist.  
Abbreviations:  msec = milliseconds; QTcB = QT interval on electrocardiogram corrected 
using the Bazett’s formula 
a) Based on average QTc value of triplicate ECGs.  For example, if an ECG 
demonstrates a prolonged QT interval, obtain two or more ECGs over a brief period, and then use the averaged QTc values of the three ECGs to determine if study treatments should be interrupted or discontinued.  
b) If the QTc prolongation resolves to grade [ADDRESS_1105435] 
will benefit from further treatment.  
 
 S1221  
 Page 56  
 Version Date 8/21/17  
 
  
 
Dose modifications for valvular  changes  
Asymptomatic, moderate 
regurgitation or stenosis by 
[CONTACT_18585] (Grade 2 mitral/tricuspid/aortic valvular toxicity per CTC AE v4.0)  • Hold study therapy.   Repeat ECHO within 1 week, and 
every 1- 2 weeks for 4 weeks.  
• If abnormality recovers within 4 weeks, resume study 
therapy with one dose level reduction.   For such 
subjects, continue ECHO monitoring 2 and 4 weeks 
after rechallenge, then every 4 weeks for 12 weeks and then per protocol.  
• If no recovery by 4 weeks, discontinue the study drug.   
Follow up with echocardiogram as above  
Grade 3 or 4 (symptomatic, 
severe regurgitation/stenosis by [CONTACT_9661], with symptoms controlled by [CONTACT_800854])  • Permanently discontinue [COMPANY_004]2118436 . 
• Continue echocardiogram every [ADDRESS_1105436] recovered from the valvular toxicities, but would require approval by [CONTACT_30292] (CTEP) and study chair)  
 
m. Dabrafenib or Dabrafenib- Trametinib Dose Modification for Diarrhea  
 
Epi[INVESTIGATOR_800821], 
trametinib, or both therapi[INVESTIGATOR_730408].  Other, frequent causes for diarrhea including concomitant medications ( e.g., stool softeners, laxatives, antacids, 
etc.), infections caused by C. difficile or other pathogens, partial bowel 
obstruction, etc., should be clinically excluded.  
 
 
Dabrafenib or Dabrafenib -Trametinib Treatment Modification and Management 
Guidelines for Diarrhea  
CTCAE Grade  Management Guideline  tion and Dose Modification  
Uncomplicated 
Diarrhea,1 
Grade 1  
or 2 • Diet:  Stop all lactose containing 
products; eat small meals, BRAT -diet 
(banana, rice, apples, toast) 
recommended.  
• Hydration:  8-10 large glasses of clear 
liquids per day ( e.g., Gatorade or broth).  
• Loperamide3:  Initially 4 mg, followed by 
2 mg every 4 hours or after every unformed stool; maximum 16 mg/day.  
Continue until diarrhea- free for 12 hours.  
• Diarrhea >24 hours :  Loperamide 2 mg 
every 2 hours; maximum 16 mg/day.  Consider adding oral antibiotics.  
• Diarrhea >48 hous:  Loperamide 2 mg 
every 2 hours; maximum 16 mg/day.  
Add budesonide or other second- line 
therapi[INVESTIGATOR_014] (octreotide, or tincture of 
opi[INVESTIGATOR_1890]) and oral antibiotics.  • Continue study treatment.  
• If diarrhea is grade 2 for > 
48 hours, interrupt study 
treatment until diarrhea resolves to grade ≤1.  
• Restart study treatment at 
the same dose level.  
 
 S1221  
 Page 57  
 Version Date 8/21/17  
 
  
Dabrafenib or Dabrafenib -Trametinib Treatment Modification and Management 
Guidelines for Diarrhea  
CTCAE Grade  Management Guideline  tion and Dose Modification  
Uncomplicated 
Diarrhea,1 
Grade 3 or 4  
 
Any Complicated Diarrhea
2 
 • Clinical evaluation mandatory.  
• Loperamide3:  Initially 4 mg, followed by 2 
mg every 4 hours or after every unformed stool; maximum 16 mg/day.  Continue until diarrhea- free for 12 hours.  
• Oral antibiotics and second- line therapi[INVESTIGATOR_485164]  
• Hydration:  Intravenous fluids if clinically 
indicated.  
• Antibiotics  (oral or intravenous) if clinically 
indicated.  
• Intervention should be continued until the 
subject is diarrhea- free for ≥24 hours.  
• Intervention may require hospi[INVESTIGATOR_800822] -threatening 
complications.  • Interrupt study treatment 
until diarrhea resolves to ≤ 
grade 1.  
• Restart study treatment  
reduced by [CONTACT_37387].4 
• If 3 dose reductions of study treatment are clinically indicated, permanently discontinue study treatment. 
1. Uncomplicated diarrhea  defined by [CONTACT_800855] a s crampi[INVESTIGATOR_007], 
nausea/vomiting, ≥ G rade 2, decreased performance status, pyrexia, sepsis, neutropenia ≥ 
Grade 3, frank bleeding, and/or dehydration requiring intravenous fluid substitution.  
2. Complicated diarrhea defined by [CONTACT_190772][INVESTIGATOR_007], 
nausea/vomiting, ≥ G rade 2, decreased performance status, pyrexia, sepsis, neutropenia ≥ 
Grade 3, frank bleeding, and/or dehydration requiring intravenous fluid substitution.  
3. Loperamide should be made available prior to start of study treatment so loperamide administration can begin at the first signs of diarrhea.  
4. Escalation of study treatment  to previous dose level is allowed after consultation with the medical monitor and in the absence of another epi[INVESTIGATOR_800823] [ADDRESS_1105437] should be consulted 
if changes in vision develop.  However, if the visual changes are clearly unrelated to 
study treatment (e.g., allergic conjunctivitis), then monitor closely as it may be reasonable to defer ophthalmic examination.  
 Uveitis and iritis have been associated with dabrafenib, while RPED and RVO have been associated with trametinib therapy.  Monitor patients for visual signs and symptoms (such 
as change in vision, photophobia, and eye pain) during therapy. Special attention should 
be given to retinal findings ( e.g., retinal pi[INVESTIGATOR_6678] (RPED) or 
retinovascular abnormalities ( i.e., branch or central retinal vein occlusions [RVO]).  For 
events of visual changes regardless of severity but for which an ophthalmic examination is conducted, a blood sample for PK analysis is encouraged when feasible, and the blood sample should be drawn as close as possible to the time of the event.  
 The ophthalmology exam will include best corrected visual acuity, visual field examination, tonometry, slit lamp biomicroscopic examination of the anterior segment 
(with special attention to inflammation) and the posterior segment, and dilated indirect 
fundoscopy with special attention to retinal abnormalities.  Optical coherence tomography is strongly recommended at scheduled visits and if retinal abnormalities are suspected.  
Other types of ancillary testing including color fundus photography, and fluorescein 
angiography may also be indicated as determined by [CONTACT_461].  
 S1221  
 Page 58  
 Version Date 8/21/17  
 
  
 Guidelines regarding event management and dose reduction for visual changes considered to be related to study treatment are provided in the table below.  
 
Treatment Modification for Visual Changes   
CTCAE Grade  Management Guideline  Action and Dose Modification 
Grade 1*  
 
 • Consult ophthalmologist 
within 7 days of onset.  
 • If dilated fundus examination cannot 
be performed within [ADDRESS_1105438]/ 
ophthalmologist. Dabrafenib may be continued.  
• If RPED and RVO excluded, 
continue (or restart) trametinib at 
same dose level  
•  
• If Uveitis/Iritis, refer to table below 
for Iritis/Uveitis  
• If RPED suspec ted or diagnosed, 
refer to RPED dose modification table below; report as SAE if 
diagnosed .
 
• If RVO diagnosed:  Permanently 
discontinue trametinib and report 
as SAE . 
Grade 2 and 
Grade 3  
 • Consult ophthalmologist 
immediately.  
 • Hold trametinib.  Dabrafenib and 
[COMPANY_004]2141795 may be continued.  
• If RPED and RVO excluded, restart 
trametinib at same dose level  
• If Uveitis/Iritis, refer to table below 
for Uveitis/Iritis  
• If RPED diagnosed, see RPED dose 
modification table below; report as 
SAE. 
• If RVO diagnosed:  Permanently 
discontinue trametinib and report 
as SAE . 
Grade 4  
 • Consult ophthalmologist 
immediately.  
 • Interrupt trametinib.  Dabrafenib and 
[COMPANY_004]2141795 may be continued.  
• If RPED and RVO excluded, may 
consider restarting trametinib at 
same or reduced dose after 
discussion with study medical 
monitor.  
• If Uveitis/Iritis, refer to table below  
• If RVO or RPED diagnosed, 
permanently discontinue 
trametinib  and report as SAE.  
Abbreviations: RPED = retinal pi[INVESTIGATOR_70341] ; RVO = retinal vein 
occlusion; SAE = serious adverse event  
*If visual changes are clearly unrelated to study treatment (e.g., allergic conjunctivitis), 
monitor closely but ophthalmic examination is not required.  
 S1221  
 Page 59  
 Version Date 8/21/17  
 
  
 
 
Dose Modification for RPED  
Event  
CTCAE Grade  Action and Dose Modification 
Grade 1 RPED  (Asymptomatic; 
clinical or diagnostic observations only)  • Continue trametinib with retinal evaluation monthly 
until resolution.  If RPED worsens, follow instructions below.  
• Dabrafenib and [COMPANY_004]2141795 treatment is not 
affected  
Grade 2 -3 RPED  (Symptomatic 
with mild to moderate decrease in visual acuity; limiting instrumental ADL)  • Interrupt trametinib.  Continue dabrafenib  and 
[COMPANY_004]2141795  
• Retinal evaluation monthly.  
• If improved to ≤ Grade 1, restart trametinib with one dose level reduction (reduced by 0.5 mg) or 
discontinue in patients taking trametinib 1 mg 
daily.  
• If no recovery within 4 weeks permanently 
discontinue trametinib  
 
 
Dabrafenib or Dabrafenib -Trametinib Dose Modification for Uveitis and Iritis  
CTCAE Grade  Action and Dose Modification 
Uveitis and Iritis  • Continue study treatment  
• Control ocular inflammation with local therapi[INVESTIGATOR_014]  
• If not improved to grade ≤1 within 1 week , interrupt 
dabrafenib until resolution of ocular inflammation and then restart dabrafenib reduced by [CONTACT_30560] 
• If no recovery within 4 weeks, permanently 
discontinue dabrafenib.  Trametinib may continue.  
 
o. Dose Modification for Pneumonitis  
 
Pneumonitis has been observed in patients receiving trametinib in combination 
with dabrafenib.  To reduce the risk of pneumonitis, patients will be monitored closely for symptoms, evaluated with imaging and functional tests when 
appropriate.  
 
 
 S1221  
 Page 60  
 Version Date 8/21/17  
 
  
 
     
CTCAE Grade         
Grade 1          
         
       
             
Grade 2          
         
   
               
       
                
         
                  
               
Grade 3               
                
 
               
Grade 4             
 
 S1221  
 Page 61  
 Version Date 8/21/17  
 
  
p. Dose Modification for Liver Chemistry Changes  
 
Dabrafenib or Dabrafenib- Trametinib Dose Modification for Liver Chemistry Changes  
Event  Treatment modifications and 
assessment/monitoring  
• ALT ≥3x ULN but <5x ULN and 
TB <2x ULN, without 
symptoms considered related to 
liver injury or hypersensitivity and who can be monitored 
weekly for 4 weeks  
 • May continue study treatment . 
• Report as SAE if CTEP -AERS reporting criteria is 
met. 
• If liver chemistry stoppi[INVESTIGATOR_800824], proceed as described below.  
 MONITORING:  
Repeat LFT (ALT, AST, ALK, bilirubin) until they return to normal/baseline or stabilise (LFT may be every 2 weeks after 4 weeks if ALT <3x ULN and TB 
<[ADDRESS_1105439]).  
Criteria for discontinuing study  
drug :  When any of the liver 
stoppi[INVESTIGATOR_800825], discontinue trametinib and 
dabrafenib.  
 
1. ALT ≥3xULN and bilirubin ≥2x 
ULN  or >35% direct bilirubin1, 2 
2. ALT ≥ 3xULN and INR >1.5, if 
INR measured2  (INR threshold 
does not apply if subject is on anticoagulant)  
3. ALT ≥5x ULN  
4. ALT ≥3x ULN persists for ≥4 
weeks  
5. ALT ≥3x ULN and cannot be 
monitored weekly for 4 weeks  
6. ALT  ≥3x ULN associated with 
symptoms3  (new or worsening) 
believed to be related to  liver injury or hypersensitivity  
 • Immediately discontinue study treatment.  
• Do not restart/rechallenge  unless approved by 
[CONTACT_33984] .   
• Report as SAE if:  1) CTEP -AERS reporting 
criteria are met, or 2) patients meet criteria 1- 2. 
• Perform liver event ASSESSMENT AND 
WORKUP (see below) . 
• Monitor the subject until liver chemistries  resolve, 
stabilize, or return to baseline (see MONITORING  
below).  
If applicable, provide details on required follow up assessments ( e.g., follow up for overall survival or 
disease recurrence or progression).  
 
MONITORING:  
In patients stoppi[INVESTIGATOR_485168] 1- 2 (with abnormal TB 
and INR, indicating potentially more significant liver 
toxicities):  
• Repeat liver chemistries (ALT, AST, ALK, 
bilirubin) and perform liver event follow -up 
assessments within 24 hours . 
• Monitor subjects twice weekly until LFT return to 
normal/baseline or stabilize.  
• A specialist or hepatology  consultation is 
recommended. 
In patients stoppi[INVESTIGATOR_485168] 2- 6: 
• Repeat LFT and perform liver event follow up 
assessments within  24-72 hours   
• Monitor subjects weekly until LFTs return to normal/baseline or stabilize.  
ASSESSMENT and WORKUP:  
• Viral hepatitis serology.
4 
• If possible, obtain blood sample for PK analysis.5 
• Serum CPK and LDH.  
• Fractionate bilirubin, if total bilirubin ≥2x ULN.  
•  
 S1221  
 Page 62  
 Version Date 8/21/17  
 
  
Event  Treatment modifications and 
assessment/monitoring  
(Contd.)  
  
• CBC with differential to assess eosinophilia.  
• Record clinical symptoms of liver injury, or 
hypersensitivity on AE CRF.  
• Record concomitant medications (including 
acetaminophen, herbal remedies, other over the 
counter medications) . 
• Record alcohol use.  
 
Additional work up for patient stoppi[INVESTIGATOR_485168] 1-2  
(with abnormal TB and INR, indicating potentially 
more significant liver toxicities) : 
• Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti -liver kidney microsomal 
antibodies, and quantitative total immunoglobulin G (IgG or gamma globulins).  
• Serum acetaminophen adduct HPLC assay (in 
subjects with likely acetaminophen use in the 
preceding).  
• If there is underlying chronic hepatitis B (e.g. 
positive hepatitis B surface antigen):  quantitative 
hepatitis B DNA and hepatitis delta antibody.
6 
• Liver imaging (ultrasound, MRI, CT) and /or liver 
biopsy.  
Footnotes:  
1.  Serum bilirubin fractionation should be performed if testing is available. If serum 
bilirubin fractionation testing is unavailable, record presence of detectable urinary bilirubin on dipstick, which indicates direct bilirubin elevations and suggesting liver 
injury.  
2.  All events of ALT ≥3xULN and bilirubin ≥2xULN (>35% direct bilirubin) or ALT ≥3x 
ULN and INR >1.5 (if INR measured) may indicate severe liver injury (possible “Hy’s Law”).  INR measurement is not required, and the threshold value stated w ill not 
apply to subjects receiving anticoagulants.  
3.  New or worsening symptoms believed to be related to liver injury (such as fatigue, 
nausea, vomiting, right upper quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity  (such as fever, rash or eosinophilia)  
4.  Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core 
Antibody (IgM); Hepatitis C RNA; Cytomegalovirus IgM antibody;  Epstein- Barr viral 
capsid antigen IgM antibody (or if unavailable, obtain heterophile antibody or monospot testing);  Hepatitis E IgM antibody  
5.  PK sample is desired if feasible.  Record the date/time of the PK blood sample draw 
and the date/time of the last dose of study treatment prior to blood sample draw on 
the CRF. If the date or time of the last dose is unclear,  provide the subject’s best 
approximation. If the date/time of the last dose cannot be approximated OR a PK 
sample cannot be collected in the time period indicated above, do not obtain a PK sample.  Not required for single- dose studies.  
6.  If hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR 
of hepatitis D RNA virus (where needed) (Le Gal et al. , 2005).  
 S1221  
 Page 63  
 Version Date 8/21/17  
 
  
 
q. Dose Modification for Venous Thromembolism (VTE) 
 
Event  Dabrafenib  Trametinib  
(When Used in Combination)  
Uncomplicated 
DVT or PE  Do not modify the 
dose.  
 Withhold trametinib for up to 3 
weeks.  
• If improved to Grade 0- 1, resume 
at a lower dose level.  
• If not improved, permanently 
discontinue.  
Life Threatening 
PE Permanently 
discontinue 
dabrafenib  Permanently discontinue trametinib.  
 
8.4 Dose Modifications for [COMPANY_004]2141795  
 
a. [COMPANY_004]2141795 Dose Modification for Hypo - or Hyperglycemia  
 
Management and Dose Modification Guidelines for Hypo - or Hyperglycemia  
Criteria  Management Guidelines  Study Drug 
Modification  
(For management purposes, refer to mild, moderate and severe intensity criteria; 
however for eCRF reporting use NCI -CTCAE version 4.0 Grades 1 -5) 
Mild 
Fasting blood glucose 
> 150mg/dL  Monitor fasting and 
preprandial glucose.  Continue study drug  
Moderate to Severe  
Fasting blood glucose 
<70 mg/dL OR any 
blood glucose > 
250mg/dL  
 • If a blood glucose >250 
mg/dL, monitor for 
ketoacidosis as clinically 
indicated.  
• When managing 
hyperglycemia associated 
with [COMPANY_004]2141795, be aware that the action of 
insulin or other 
antihyperglycemic agents (e.g., sulfonylureas, 
biguanides, etc.) may be 
substantially blocked by [CONTACT_4526].   However the 
action of antihyperglycemic agents would be restored as [COMPANY_004]2141795 is 
cleared.   The patient 
should be observed closely for rebound hypoglycaemia 
as [COMPANY_004]2141795 is held/or 
discontinued.    
• Intravenous insulin 
treatment is recommended.  Hold [COMPANY_004]2141795  and 
notifyinvestigator 
immediately.   
 
Continue dabrafenib 
and trametinib.  
 
The investigator 
should discuss 
intervention and possible resumption of 
[COMPANY_004]2141795  with the  
Study Chair.  
 S1221  
 Page 64  
 Version Date 8/21/[ADDRESS_1105440]. Ribas at 310/206- [ADDRESS_1105441]. Algazi at 415/353- 7552. 
 
8.6 Adverse Event Reporting  
 
Toxicities (including suspected reactions) that meet the expedited reporting criteria as outlined in Section 16.[ADDRESS_1105442] be reported to the Operations Office, Study 
Chair  and NCI via CTEP- AERS , and to the IRB per local IRB requirements.  
 9.0 STUDY CALENDAR  
 
 
 
 S1221  
 Page 65  
 Version Date 8/21/17  
 
  
9.1 Study Calendar – Phase I D+G Portion  
 
 Cycle 1  Cycle 2  Cycle 3 + β Follow -Up 
Prior to 
Progression  At Time of 
Progression Post-
Progression 
Follow -Up Ψ 
REQUIRED 
STUDIES  PRE- 
STUDY  Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk    
1 2 3 4 5 6 7 8 9 10 11 12 
PHYSICAL                                  
H & P  X X   X  X   X   X      X X X 
Wt & PS X X   X    X   X    X          X 
Baseline  
Abnormality  
Assessment  X                            
Tox Notation    X    X   X   X    X      X≠ X≠ X≠ 
Eye Exam√√  X                
Derm Exam**  X             X** X** X** 
Disease  
Assessment ¥  X                X      X X   
Review  Intake  
Calendar            X       X            
LAB ∏                              
CBC/  
Diff/PLT /Hg  X X   X   X   X    X          X 
Serum Bili rubin  X X   X   X   X    X          X 
AST & ALT  X X   X    X   X   X          X 
Serum  
Creat or CrCl  X X   X    X   X    X          X 
Serum Glucose  X X  X  X  X  X       
Serum albumin  X X  X  X  X  X       
Amylase/Lipase+  X X  X  X  X  X       
PT/INR, PTT ∆  X                
LDH Ω X                               
Pregnancy  test 
(women of  child 
bearing  potential)  X                               
Section 9.1 Study Calendar continues on next page.  Click here for footnotes . 
  S1221  
  Page 66  
  Version Date 8/21/17  
 
  
9.1 Study Calendar – Phase I D+G Portion  (contd.)  
   
  Cycle 1  Cycle 2  Cycle 3 + β Follow -Up 
Prior to 
Progression At Time of 
Progression Post-
Progression 
Follow -Up 
Ψ 
REQUIRED 
STUDIES  PRE- 
STUDY  Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk    
1 2 3 4 5 6 7 8 9 10 11 12 
X-RAYS & 
SCANS                  
Brain CT or MRI  X               X 
CT or MRI  ¥ X         X    X£ X  
ECH O or MUGA  X         Xπ    Xπ   
ECG X                
SPECIMEN  
SUBMISSION                  
Blood for PK   ∝ X   X  X           
Paraffin-Embedded  
Tissue /Slide s (Fresh 
Frozen Tissue i f 
Available ) X   XΦ           X  
Plasma  and buffy 
Coat  ® X         X     X  
TREATMENT                  
Dabrafenib  ∑   X X X X X X X X X X X X    
[COMPANY_004]2141795  ⌐ 
  X X X X X X X X X X X X    
 
Click here for footnotes . 
 
   S1221  
  Page 67  
 Version Date 8/21/17  
 
  
NOTE:  Forms are found on the protocol abstract page of the SWOG website (www.swog.org).  Forms submission guidelines are found in Section 
14.0. 
 
Footnotes : 
 ¥ For the first two years after registration, disease assessments must be performed after every two cycles of treatment using the same method 
as baseline and must be documented on the Follow -Up Tumor Assessment Form (RECIST 1.1). A response must be confirmed by a second 
determination at least 4 weeks after a complete or partial response has been noted.  After two years (measured from time of registration), the 
frequency of disease assessment, CT, and MRI may be reduced to once every 12 weeks.  
√√ Ophthalmic exam must be performed at baseline.  Follow -up exams should be perf ormed as clinically indicated.  
** Dermatology exams are required every 2 months throughout treatment, and every 2 months through 6 months after discontinuation of 
dabrafenib or until the start of another anti -neoplastic therapy.  
π On treatment echocardiogram  (or MUGA)  should be obtained every 2 months for all patients in the Phase I portion.  
∏ Patients known to be HIV + must not be on antiviral agents and must have CD34 counts ≥ 500 mm
3 (see Section 5.1t ). 
Δ See Sections 5.1u  and 7.2b. 
Β Protocol treatment assessments will continue on this schedule until any one of the criteria in Section 7.8 is met.  
£ Once off protocol treatment, disease assessments must  be performed every 8 weeks until disease progression.  After two years (measured 
from time of registration), the frequency of disease assessments, CT and MRI may be reduced to once every 12 weeks.  
Ψ After disease progression (see Section 10.2 ), follow -up for survival status must be performed every [ADDRESS_1105443].  
≠ Assessments should continue until resolution of  all acute adverse events.  Patients with AEs at progression should be followed at frequencies 
appropriate for the nature and duration of the events, until the AE has resolved or is deemed irreversible.  
∑ To be taken twice daily.  
⌐ To be taken once a day.  
Ω For melanoma patients only.  
∝ Required at baseline and prior to dosing on Days 15 and 29.  Three patients treated within the second cohort of the Phase I Portion ( D+G) will 
have more extensive PK sampling at baseline, pre- dose and +1, +2, +4, and +8 hours  on Day 15, and pre- dose Day 29.  
Φ Optional biopsy between Day 15- 28. 
® Plasma  and buffy coat  must be submitted at baseline, before the start of Cycle 3 and at the time of progression.  
+ As clinically indicated to evaluate adverse events (i.e., abdominal pain, pancreatitis, etc).  
 
 
 
 S1221  
 Page 68  
 Version Date 8/21/17  
 
  
9.2 Study  Calendar – Phase I D+T +G Portion  
 
 Cycle 1  Cycle 2  Cycle 3 + β Follow -Up 
Prior to 
Progression  At Time  
of 
Progression  Post- 
Progression 
Follow -Up Ψ 
REQUIRED 
STUDIES  PRE- 
STUDY  Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk    
1 2 3 4 5 6 7 8 9 10 11 12    
PHYSICAL                                
H & P  X X   X  X   X   X      X X X 
Wt & PS  X X   X    X   X    X        X X 
Baseline  
Abnormality  
Assessment  X                            
Tox Notation    X    X   X   X    X      X≠ X≠ X≠ 
Eye Exam√√  X                 
Derm Exam**  X             X** X** X** 
Disease  
Assessment ¥  X                X      X X   
Review  
Intake  
Calendar            X       X           
LAB ∏                             
CBC/  
Diff/PLT /Hg  X X   X   X   X    X         X 
Serum Bilirubin  X X   X   X   X    X         X 
AST & ALT  X X   X    X   X   X         X 
Serum  
Creat or CrCl  X X   X    X   X    X         X 
Serum Glucose  X X  X  X  X  X        
Serum albumin  X X  X  X  X  X        
Amylase/  
Lipase +  X X  X  X  X  X       
PT/INR, PTT ∆  X                
LDH Ω X                               
Pregnancy  test 
(women of  child 
bearing  
potential)  X                              
Section 9. 2 Study Calendar continues on next page.  Click here for footnotes . 
 S1221  
 Page 69  
 Version Date 8/21/17  
 
  
9.2 Study Calendar – Phase I D+T +G Portion  (contd.)  
  
 
 
 Cycle 1  Cycle 2  Cycle 3 + β Follow -Up 
Prior to 
Progression At Time  
of 
Progression  Post- 
Progression 
Follow -Up Ψ 
REQUIRED 
STUDIES   
 
PRE- 
STUDY  Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk    
1 2 3 4 5 6 7 8 9 10 11 12 
X-RAYS & 
SCANS                  
Brain CT or MRI  X               X 
CT or MRI  ¥ X         X    X£ X  
ECHO or 
MUGA  X          Xπ    X π   
ECG  X                
SPECIMEN  
SUBMISSION                   
Blood for PK  ∝ X   X  X            
Paraffin -
Embedded 
Tissue /Slides  
(Fresh Frozen 
Tissue if 
Available ) X   XΦ   
         X  
Plasma  and 
Buffy Coat  ® X         X     X  
TREATMENT                  
Dabrafenib  ∑   X X X X X X X X X X X X    
Trametinib ⌐  X X X X X X X X X X X X    
[COMPANY_004]2141795  ⌐  X X X X X X X X X X X X    
 
Click here for footnotes . 
 
 S1221 
 Page 70  
 Version Date 8/21/17  
 
  
NOTE:  Forms are found on the protocol abstract page of the SWOG website (www.swog.org).  Forms submission guidelines are found in Section 
14.0. 
 Footnotes : 
 ¥ For the first two years after registration, disease assessments must be performed after every two cycles of treatment using the same method 
as baseline and must be documented on the Follow -Up Tumor Assessment Form (RECIST 1.1). A response must be confirmed by a second 
determination at least 4 weeks after a complete or partial response has been noted.  After two years (measured from time of registration), the 
frequency of disease assessments, CT and MRI may be reduced to once every 12 weeks.  
√√ Ophthalmic exam must be performed at baseline.  Follow -up exams as clinically indicated.  
** Dermatology exams are required every 2 months throughout treatment, and every 2 months through 6 months after discontinuation of 
dabrafenib or until the start of another anti -neoplastic therapy.  
π On treatment echocardiogram should be obtained every 2 months for all patients in the Phase I portion.  
∏ Patients known to be HIV + must not be on antiviral agents and must have CD34 counts ≥ 500 mm
3 (see Section 5.1t ). 
Δ See Sections 5.1u  and 7.2b. 
Β Protocol treatment assessments will continue on this schedule until any one of the criteria in Section 7.8  is met.  
£ Once off protocol treatment, disease assessments must be performed every 8 weeks  until disease progression.  After two years (measured 
from time of registration), the frequency of disease assessments, CT and MRI may be reduced to once every 12 weeks.  
Ψ After disease progression (see Section 10.2 ), follow -up for survival status must be performed every [ADDRESS_1105444].  
≠ Assessments should continue until resolution of all acute adverse events.  Patients with AEs at progression should be followed at frequencies appropriate for the nature and duration of the events, until the AE has resolved or is deemed irreversible.  
∑ To be taken twice daily.  
⌐ To be taken once a day.  
Ω For melanoma patients only . 
∝ Required at baseline and prior to dosing on Days 15 and 29.  Three patients treated within the second cohort of the Phase I Portion ( D+G) will 
have more extensive PK sampling at baseline, pre- dose and +1, +2, +4, and +8 hours on Day 15, and pre- dose Day  29.
 
Φ Optional biopsy between Day 15- 28. 
® Plasma  and buffy coat  be submitted at baseline, before the start of Cycle 3 and at the time of progression.  
+ As clinically indicated to evaluate adverse events (i.e., abdominal pain, pancreatitis, etc).  
 
 
 
  
 S1221  
 Page 71  
 Version Date 8/21/17  
 
  
9.3 Study Calendar – Phase II D+T+G  
 
 Cycle 1  Cycle 2  Cycle 3 + β Follow -Up 
Prior to 
Progression  At Time of 
Progression  Post-
Progression 
Follow  Up Ψ   
REQUIRED 
STUDIES   
 
PRE- 
STUDY  Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk    
1 2 3 4 5 6 7 8 9 10 11 12 
PHYSICAL                                  
H & P  X X      X      X       X X X 
Wt & PS X X       X       X          X 
Baselin e 
Abnormality  
Assessment  X                            
Tox Notati on   X       X       X      X≠ X≠ X≠ 
Disease  
Assessment ¥  X                X      X£ X   
Eye Exam √√ X                
Dermato logy 
Exam ** X             X** X** X** 
Review  Intake Cal  
           X       X            
LAB ∏                              
CBC/Dif f/PLT /Hg X X       X       X          X 
Serum  Bili X X       X       X          X 
AST & ALT  X X       X      X           X 
Serum  Cr or CrCl  
 X X    X    X      X 
Serum Glucose  X     X    X       
Serum Albumin  X X    X    X       
Amylase /Lipase + X     X    X       
PT/INR , PTT   ∆ X     X    X       
LDH  X                               
Pregnancy  
test (women of  
child bearing  
potential)  X                               
Section 9. 3 Study Calendar continues on next page.  Click here for footnotes . 
  S1221  
  Page 72  
  Version Date 8/21/17  
 
  
9.3 Study Calendar – Phase II D+T+G (contd.)  
 
 
 Cycle 1  Cycle 2  Cycle 3 + β Follow -Up 
Prior to 
Progression  At Time of 
Progression  Post-
Progression 
Follow  Up 
Ψ 
REQUIRED 
STUDIES  
   
 
PRE- 
STUDY  Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk    
1 2 3 4 5 6 7 8 9 10 11 12 
X-RAYS & 
SCANS                                  
CT or MRI Scan of  
the brain  X                              
CT or MRI  ¥ X                X        X£ X   
ECHO  or MUGA  X         X𝜋𝜋       
ECG X                
SPECIMEN  
SUBMISSION                                 
Paraffin -Embedded  
Tissue /Slides  
(Fresh Frozen Tissue  
If Available ) X     XΦ                     X   
Plasma  and Buffy 
Coat  ® X              X        X   
                                  
TREATMENT                                  
Dabrafenib  ∑    X X X X X X X X X X X X       
Trametinib  ⌐  X X X X X X X X X X X X    
[COMPANY_004]2141795  ⌐   X X X X X X X X X X X X       
Click here for footnotes . 
  S1221  
  Page 73  
  Version Date 8/21/17  
 
  
 
 
NOTE:  Forms are found on the protocol abstract page of the SWOG website (www.swog.org).  Forms submission guidelines are found in Section 
14.0. 
 Footnotes:  
 ¥ Disease assessments must be performed after every two cycles of treatment using the same method as baseline and must be documented on the Follow -Up Tumor Assessment Form (RECIST 1.1). A response must be confirmed by a second determination at least 4 weeks after a 
complete or partial response has been noted.  
√√ Ophthalm ic exam must be performed at baseline.  Follow -up exams are to be performed as clinically indicated.  
** Dermatology exams are required every 2 months throughout treatment, and every 2 months through 6 months after discontinuation of 
dabrafenib or until the start of another anti -neoplastic therapy.  
π On treatment echocardiogram should be obtained every 2 months for all patients.  
∏ Patients known to be HIV + must not be on antiviral agents and must have CD34 counts ≥ 500 mm
3 (see Section 5.1t ). 
Δ See Sections 5.1u  and 7.2b. 
Β Protocol treatment assessments will continue on this schedule until any one of the criteria in Section 7.8  is met.  
£ Once off protocol treatment, disease assessments must be performed every 8 weeks until disease progression.  
Ψ After disease progression (see Section 10.2 ), follow -up for survival status must be performed every [ADDRESS_1105445].  
≠ Assessments should continue until resolution of all acute adverse events.  Patients with AEs at progression should be followed at frequencies appropriate for the nature and duration of the events, until the AE has resolved or is deemed irreversible.  
∑ To be taken twice daily.  
⌐ To be taken once a day.  
Ω For melanoma patients only.  
∝ Required at baseline and prior to dosing on Days 15 and 29.  Three patients  treated within the second cohort of the Phase I Portion (D+T+G) 
will have more extensive PK sampling at baseline, pre -dose and +1, +2, +4, and +8 hours on Day 15, and pre- dose Day 29.  
Φ Optional biopsy between Day 15- 28. 
® Plasma and buffy coat must be submitted at baseline, before the start of Cycle 3 and at the time of progression.  
+ As clinically indicated to evaluate adverse events (i.e., abdominal pain, pancreatitis, etc).  
 
 
  
 S1221  
Page 74  
Version Date 8/21/17  
 
  
10.0 CRITERIA FOR EVALUATION AND ENDPOINT DEFINITIONS  
 
10.1 Measurability of Lesions  
 
a. Measurable disease: Measurable disease is defined differently for lymph nodes 
compared with other disease and will be addressed in a separate section below.  
 
1. Lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 2.[ADDRESS_1105446] x -ray, by ≥ 1.[ADDRESS_1105447] or MRI scans, or ≥ 1.[ADDRESS_1105448] be recorded in decimal fractions of 
centimeters (or millimeters).  
 
The defined measurability of lesions on CT scan is based on the 
assumption that CT slice thickness is 0.[ADDRESS_1105449] slice thickness greater than 0.5 cm, the minimum size for a measurable 
lesion should  be twice the slice thickness.  
 
2. Malignant lymph nodes  are to be considered pathologically enlarged and 
measurable if it measures ≥ 1.5 cm in SHORT AXIS (greatest diameter 
perpendicular to the long axis of the lymph node) when assessed by 
[CONTACT_39710] (CT scan slice recommended being no greater than 0.5 cm).  
 
b. Non-measurable disease:  All other lesions (or sites of disease), including small 
lesions (longest diameter < 1.0 cm or pathologic lymph nodes with ≥ 1.0 cm to <  
1.5 cm short axis), are considered non- measurable disease.  Bone lesions, 
leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not 
followed by [CONTACT_462]), are considered non- measurable as are previously 
radiated lesions that have not progressed.  
 
c. Notes on measurability  
 
1. For CT and MRIs, the same type of scanner should be used and the image acquisition protocol should be followed as closely as possible to 
prior scans.  Body scans should by [CONTACT_39711]- hold sc anning 
techniques, if possible.  
 2. PET-CT:  At present, the low dose or attenuation correction CT portion of 
a PET -CT is not always of optimal diagnostic CT quality for use with 
RECIST measurements.  However, if the site can document that the C T 
performed as part of a PET -CT is of identical diagnostic quality to a 
diagnostic CT, then the CT portion of the PET -CT can be used for 
RECIST measurements and can be used interchangeably with conventional CT.  
 
3. Ultrasound: Ultrasound is not useful in assessment of lesion size and 
should not be used as a method of measurement.  
 
4. Cystic lesions that meet the criteria for radiographically defined simple 
cysts should not be considered as malignant lesions (neither measurable nor non- measurable) since they are, by [CONTACT_39712].  
 5. If a target lesion becomes very small some radiologists indicate that it is too small to measure.  If the lesion is actually still present, a default 
measurement of 0.[ADDRESS_1105450] believes the 
lesion has gone, a default measurement of 0.0cm should be recorded.  
 S1221  
Page 75  
Version Date 8/21/17  
 
  
 
10.2 Objective Status at Each Disease Evaluation  
 
Objective Status is to be recorded at each evaluation.  All measurable lesions up to a 
maximum of 2 lesions per organ 5 lesions in total, representative of all involved organs, should be identified as target  lesions at baseline.  All other lesions (or sites of disease) 
including any measurable lesions over and above the [ADDRESS_1105451] be noted for non- target measurable and non-
measurable disease.  
 For studies that use disease progression as an endpoint, whole body scanning at specific 
intervals is necessary to determine that progression is NOT present outside of the “target” areas.  Therefore, in these studies it is not acceptable to image only the “target” 
areas of the body in follow -up scans.  For study -specific imaging requirements, see the 
Study Calendar in Section 9.0
. 
 
a. Complete Response (CR):  Complete disappearance of all target and non-
target lesions (with the exception of lymph nodes mentioned below).  No new lesions.  No disease related symptoms.  Any lymph nodes (whether target or 
non-target) must have reduction in short axis to < 1.[ADDRESS_1105452] be 
assessed using the same technique as baseline.  
 
b. Partial Response (PR):  Applies only to patients with at least one measurable 
lesion.   Greater than or equal to 30% decrease under baseline of the sum of 
appropriate diameters of all target measurable lesions.  No unequivocal progression of non- measurable disease.  No new lesions.  All target measurable 
lesions must be assessed using the same techniques as baseline.  
 
c. Stable:   Does not qualify for CR, PR, Progression or Symptomatic D eterioration.  
All target measurable lesions must be assessed using the same techniques as baseline.  
 
d. Progression :  One or more of the following must occur:  20% increase in the 
sum of appropriate diameters of target measurable lesions over smallest sum  
observed (over baseline if no decrease during therapy) using the same 
techniques as baseline, as well as an absolute increase of at least 0.5 cm.  
Unequivocal progression of non- measurable disease in the opi[INVESTIGATOR_33398] (an explanation m ust be provided).  Appearance of any new lesion/site.  
Death due to disease without prior documentation of progression and without symptomatic deterioration (see 
Section 10.2e ). 
 
 Notes regarding new lesions:  FDG -PET imaging can complement regular scans 
in identifying new lesions according to the following algorithm.  
 
1. Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is 
a sign of progression based on a new lesion.  
 2. No FDG -PET at baseline and a positive FDG -PET at follow -up 
corresponding to a potential new site of disease must have a 
confirmation by [CONTACT_39713] (e.g. , CT, MRI, x -ray) as new 
site of disease to be considered progressive disease.  In such a case, the date of progressive disease will be the date of the initial abnormal 
FDG -PET.  
 
e. Symptomatic deterioration :  Global deterioration of health status requiring 
discontinuation of treatment without objective evidence of progression.  Efforts 
should be made to obtain objective evidence of progression after discontinuation.  
 S1221  
Page 76  
Version Date 8/21/[ADDRESS_1105453] not been assessed or inconsistent assessment 
methods were used.  
 
g. Objective status notes:  
 
1. Non- measurable and non -target measurable disease do not affect 
Objective Status  in determination of CR (must be absent --a patient who 
otherwise has a CR, but who has non- measurable or non- target 
measurable disease present or not assessed, will be classified as having 
a PR).  However, non- measurable and non- target lesions are included in 
determination of progression (if new sites of disease develop or if unequivocal progression occurs in the opi[INVESTIGATOR_021]).  
 
2. An objective status of PR or stable cannot follow one of CR.  Stable can 
follow PR only in the rare case that tumor increases too little to qualify as progression, but enough that a previously documented 30% decrease no 
longer holds.  
 
3. In cases for which initial flare reaction is possible (hypercalcemia, 
increased bone pain, erythema of skin lesions), objective status is not 
progression unless either symptoms persist beyond [ADDRESS_1105454] Response  
 
This is calculated from the sequence of objective statuses.  
 
a. CR:  Two or more objective statuses of CR a minimum of four weeks apart 
documented before progression or symptomatic deterioration.  
 
b. PR:  Two or more objective statuses of PR or better a minimum of four weeks 
apart documented before progression or symptomatic deterioration, but not 
qualifying as CR.  
 c. Unconfirmed CR:  One objective status of CR documented before progression or symptomatic deterioration but not qualifying as CR or PR.  
 
 S1221  
Page 77  
Version Date 8/21/17  
 
  
d. Unconfirmed PR:  One objective status of PR documented before progression or symptomatic deterioration but not qualifying as CR, PR or unconfirmed CR.  
 
e. Stable/no response:  At least one objective status of stable/no response documented at least 6 weeks after registration and before progression or symptomatic deterioration, but not qualifying as anything else above.  
 f. Increasing disease:  Objective status of progression within 12 weeks of registration, not qualifying as anything else above.  
 g. Symptomatic deterioration:  Objective status of symptomatic deterioration within 
12 weeks of registration, not qualifying as anything else above.  
 Inadequate assessment,  response unknown:  Progression or symptomatic deterioration 
greater than 12 weeks after registration and no other response category applies.  
 
10.4 Performance Status  
 
Patients will be graded according to the Zubrod Performance Status Scale.  
 
POINT  DESCRIPTION  
 
0 Fully active, able to carry on all pre- disease performance without 
restriction.  
 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g.,  light 
housework, office work.  
 
2 Ambulatory and capable of self -care but unable to carry out any 
work activities; up and about more than 50% of waking hours.  
 
3 Capable of limited self -care, confined to bed or chair more than 
50% of waking hour s. 
 
4 Completely disabled; cannot carry on any  self-care; tot ally 
confined to bed or chair.  
 
10.[ADDRESS_1105455] documentation of  progression or symptomatic 
deterioration ( see Section 10.2e
), or death due to any  cause.   Patients last known to be 
alive without report of progression are censored at date of last contact.  
 
10.[ADDRESS_1105456].  
 
 
11.0 STATISTICAL CONSIDERATIONS  
 
11.1 Accrual Goals  
 
This study will initially be open to limited institutions, with an expected accrual of 3-12 
patients in the D+G Phase I P ortion and 6- 18 patients in the D+T+G Phase I Portion.   
The Phase II Portion of the trial will be open Group- wide and will require 10-33 eligible 
patients . Assuming that 10% of patients  enrolled will be ineligible or not evaluable,  
 S1221  
 Page 78  
 Version Date 8/21/17  
 
  
approximately 70 patients will be required. Based on data from previous studies in similar 
patient populations the estimated accrual rate is 2-3 patients  per month.  
 
11.2 Evaluation of Dabrafenib + [COMPANY_004]2141795 (D+G)  
 
a. Analysis of Phase I Portion  
 Section 7. 3
 provides the details of the study design for the Phase I Portion of the 
study. The Phase I Portion will be a limited dose- escalation.  
 The primary objective of the Phase I Portion will be  to determine the maximum 
tolerated dose (MTD) of [COMPANY_004]2141795 and dabrafenib in patients with BRAF 
mutant locally advanced or metastatic cancer .  The regimen will be considered 
safe and the MTD determined if the dose- limiting toxicity rate is ≤ 33%.  
 
Prior to implementation of the Phase II Portion, a temporary closure wi ll occur in 
order to assess dose and to evaluate the safety profile more fully. 
 b. Analysis of Phase II Portion  
 
Note:  Effective  November 15, 2014, this trial wi ll not proceed to the P hase II 
study of dabrafenib and [COMPANY_004]2141795, but will be moving to an evaluation of 
triple therapy.  
 
The study will be conducted in two sequential parts.   Patient s enrolled to the 
Phase I P ortion  will not be included in the analysis of the Phase II P ortion.  
 The primary objective of the Phase II Portion of this study is to evaluate the 
objective response rate (confirmed and unconfirmed, complete and partial 
responses) of [COMPANY_004]2141795 used in combination with dabrafenib in patients with 
Stage IV or unresectable Stage III melanoma who have acquired resistance t o 
BRAF inhibitor -based therapy.  Resistance to BRAF inhibitor -based therapy will 
be defined as progressive disease by [CONTACT_393] 1.1 criteria while receiving therapy 
with a BRAF inhibitor (vemurafenib or dabrafenib, alone or in combination with a 
MEK inhibitor). This may be innate resistance (patients who never achieved a tumor response while on BRAF inhibitor therapy) or acquired resistance 
(progression after having a tumor response to BRAF inhibitor therapy).  
 
It is assumed that this regimen will not be of further interest if t he true response 
rate is less than 5% (null) and that a true response rate of 25% or more would be 
of considerable interest for further investigation ( alternative).  
 
Parallel patient enrollment will be implemented for two strata (prior therapy with 
BRAF -inhibitor only versus prior therapy with both a BRAF -inhibitor and a MEK -
inhibitor), and a two- stage design will proceed separately for each stratum as 
follows:   In the first step, [ADDRESS_1105457] one response is observed, an additional 15 
eligible patients will be accrued.  Three or more responses out of 24 will be 
considered evidence that this regimen warrants  further study, provided other 
factors such as overall survival and adverse events also appear favorable.  This 
design has 90% power with a one- sided alpha of 10%.  
 
 
 S1221  
Page 79  
Version Date 8/21/17  
 
  
11.3 Evaluation of Dabrafenib + Trametinib + [COMPANY_004]2141795 (D+T+G) 
 
a Analysis of Phase I Portion  
 
Section 7. 4 provides the details of the study design for the Phase I Portion of the 
study. The Phase I Portion will be a limited dose- escalation.  
 
The primary objective of the Phase I Portion will be to determine the maximum tolerated dose (MTD) of [COMPANY_004]2141795, dabrafenib and trametinib  in patients with 
BRAF mutant locally advanced or metastatic cancer.  The regimen will be considered safe and the MTD determined if the dose- limiting toxicity rate is ≤ 
33%.  
 Prior to implementation of the Phase II Portion, a temporary closure will occur in order to assess dose and to evaluate the safety profile more fully.  
 
 b Analysis of Phase II Portion  
 
The study will be conducted in two sequential parts.  Patients enrolled to the Phase I Portion will not be included in the analysis of the Phase II Portion.  
 
 
The primary objective of this p ortion  study is to evaluate the objective response 
rate (confirmed and unconfirmed, complete and partial responses) of 
[COMPANY_004]2141795 used in combination with dabrafenib and trametinib in patients with 
Stage IV or unresectable Stage III melanoma who have acquired resistance to 
BRAF inhibitor -based therapy. Resistance to BRAF inhibitor -based therapy will 
be defined as progressive disease by [CONTACT_393] 1.1 criteria while receiving therapy with a BRAF inhibitor (vemurafenib or dabrafenib, alone or in combination with a 
MEK inhibitor). This may be innate resistance (patients who never achieved a 
tumor response while on BRAF inhibitor therapy) or acquired resistance 
(progression after having a tumor response to BRAF inhibitor therapy).   
 
It is assumed that this regimen will not be of further interest  if the true response 
rate is less than 15% (null) and that a true response rate of 35% or more would 
be of considerable interest for further investigation (alternative).   
 
A two -stage design will be used for patient accrual.  In the first step, [ADDRESS_1105458] 2 responses are observed, an additional 23 eligible patients will be accrued. Eight or more responses out of 33 will be considered 
evidence that this regimen warrants further study, provided other factors such as overall survival and adverse events also appear favorable. This design has 87% 
power with a one- sided alpha of 0.9%.  
 
 S1221  
 Page 80  
Version Date 8/21/17  
 
  
 
11.4 Analysis of Secondary Endpoints  
 
The Phase II Portion will  include estimating overall survival, progression- free survival , 
and toxicity  rates .  Assuming 33 eligible patients are enrolled, this will be sufficient to 
estimate overall survival, progression- free survival, and toxicity rates to within ± 17% 
(95% confidence int erval).  Assuming [ADDRESS_1105459] 
a 5% chance of occurring has a 82% chance of being observed at least once.  In 
addition, to assess safety and feasibility in both the Phase I and Phase II  Portions of the 
trial, descriptive statistics will be presented for the number of patients requiring dose reduction, interruption or discontinuation and the percentage of dose delivery.  
 
11.5 Analysis of Translational Medicine Component  
 
This analysi s will include those patients enrolled to the Phase I or II Portion of the study  
with adequate specimens .  Every attempt will be made for pre- study collection of blood 
and tissue specimens.  Blood and tissue specimens from accessible metastatic lesions 
will be requested from two other time points:  1) after start  on therapy (approximately Day 
15-30), and 2) at the time of progression on this study.  
 
For the pre- study time point, for each of the  categorical markers listed in Section  18.[ADDRESS_1105460] binomial confidence interval will be 
calculated.  The association between these categorical markers and clinical outcomes 
will be explored in a preliminary manner, using Fisher’s exact test to compare response 
and a logrank test to compare Kaplan- Meier estimates of OS and PFS between marker 
posit ive and marker negative groups.  
 For the quantitative markers in the previous section, we will estimate median and range values in this patient population.  The association between quantitative markers and 
clinical outcomes will be explored in a preliminary manner, using the Wilcoxon- rank sum  
 S1221  
 Page 81  
Version Date 8/21/[ADDRESS_1105461] to assess response and Cox regression to assess PFS and OS.  In addition, we may 
explore dichotomizing the patients into two groups by [CONTACT_800856] (or other cutpoints may be explored) and applying the methods specified above for the categorical 
markers.  
 
For patients with samples at more than one time we will examine changes in marker 
status over time.  This analysis will be very exploratory.  
 
For patients enrolled on the Phase I Portion, PK sampling steady state should be taken at 
baseline , pre- dose Day 15 and pre- dose D ay 29.  In addition, three patients treated within 
the second cohort of each of the Phase I Portions ( D+G and D+T+G) will have more 
extensive PK sampling at baseline, pre- dose and +1, +2, +4 , and +[ADDRESS_1105462] be registered prior to initiation of treatment (no more than eight  working 
days prior to planned start of treatment).   If enrolling a patient onto the Phase I portion, 
sites must order S1221  PK kit immediately after registration (see Section 18.6
).  The 
SWOG patient ID number must be provided on the S1221 PK Kit Request Form.  Allow up 
to five working days for the PK kit to arrive.  
 
13.[ADDRESS_1105463].   All site staff will use OPEN to 
create a slot reservation. OPEN is a web- based application and can be accessed at 
https://open.ctsu.org, or from the OPEN tab on the CTSU members’ side of the website at https://www.ctsu.org, or from the OPEN Patient Registration link on the SWOG CRA 
Workbench. Please refer to the ‘Slot Reservation Quick Reference Site User Guide’ within the OPEN tab on the CTSU members’ website under ‘Training and Demonstration Materials’ for detailed instructions.  
 
 S1221  
 Page 82  
 Version Date 8/21/[ADDRESS_1105464] be prepared to provide answers to the following ques tions:  
 
a.   Institution CTEP ID  
 
b.   Protocol Number  
 c.   Registration Step  
 
d.   Patient Initials  
 
e.    Patient’s Date of Birth  
 f.   ZIP Code  
 
g.   Gender (select one):  
• Female Gender  
• Male Gender  
 
Slot reservations expi[INVESTIGATOR_520629] [ADDRESS_1105465] be 
created for the patient before they can be enrolled to this trial. Reservations may also be 
withdrawn at any time.  If you withdraw a reservation, please notify the Statistical Center 
at [EMAIL_15238].  
 13.[ADDRESS_1105466] be prepared to provide answers to the following questions:  
 
a. Institution CTEP ID  
 
b. Protocol Number  
 c. Registration Step  
 
d. Treating Investigator  
 
e. Credit Investigator  
 
f. Patient Initials  
 g. Patient’s Date of Birth  
 
h. Patient SSN (SSN is desired, but optional.  Do not enter invalid numbers.)  
 
i. Country of Residence  
 
j. ZIP Code  
 
k. Gender (select one):  
• Female Gender  
• Male Gender  
 S1221  
 Page 83  
 Version Date 8/21/17  
 
  
 
l. Ethnicity (select one):  
• Hispanic or Latino  
• Not Hispanic or Latino  
• Unknown  
 
m. Method of Payment (select one):  
• Private Insurance  
• Medicare  
• Medicare and Private Insurance  
• Medicaid  
• Medicaid and Medicare  
• Military or Veterans Sponsored NOS  
• Military Sponsored (Including Champus & Tricare)  
• Veterans Sponsored  
• Self Pay (No Insurance)  
• No Means of Payment (No Insurance)  
• Other  
• Unknown  
 
n. Race (select all that apply):  
• American Indian or Alaska Native  
• Asian  
• Black or African American  
• Native Hawaiian or other Pacific Islander  
• White  
• Unknown  
 13.4 Registration P rocedures  
 
a. All site staff will use OPEN to  enroll patients to this study.  OPEN is a web -based 
application and can be accessed at https://open.ctsu.org, or from the OPEN tab 
on the CTSU members’ side of the website at https://www.ctsu.org,  or from the 
OPEN Patient Registration link on the SWOG CRA Workbench.  
b. Prior to accessing OPEN site staff should verify the following:  
 
• All eligibility criteria have been met  within the protocol stated timeframes  and 
the affirmation of eligibility on the Registration Worksheet has been signed by [CONTACT_461485].  Site staff 
should refer to Section 5.0
 to verify eligibility.  
 • All patients have signed an appropriate consent form and HIPAA 
authorization form (if applicable).  
 
c. Access requirements for OPEN:  
 
• Site staff will need to be registered with CTEP and have a valid and active 
CTEP- IAM account.   This is the same account (user ID and password) used 
for the CTSU members' web site.  
 • To perform registrations on SWOG protocols you must have an equivalent 
'Regi strar' role on the SWOG roster.  Role assignments are handled through 
SWOG.  
 
Note:  The OPEN system will provide the site with a printable confirmation of 
registrati on and treatment information.  Please print this confirmation for your 
records.  
 S1221  
Page 84  
Version Date 8/21/17  
 
  
 
d. Furth er instructional information is provided on the OPEN tab on the CTSU 
members’ side of the website at https://www.ctsu.org or at https://open.ctsu.org .  
For any additional questions contact [CONTACT_25518] 1- [PHONE_103] or 
[EMAIL_013] . 
 
13.[ADDRESS_1105467] be identified as approved for registration.  
 c. Registrations may not be cancelled.  
 
d. Late registrations (after initiation of treatment) will not be accepted.  
 
14.[ADDRESS_1105468] page on the SWOG website 
(www.swog.org)  and (with the exception of the sample consent form and the Registration 
Worksheet) must  be submitted on -line via the Web; see Section 14.3a
 for det ails. 
 
14.[ADDRESS_1105469] is granted through the iMedidata application to all persons with the appropriate roles assigned in 
Regulatory Su pport System (RSS).  To access Rave via iMedidata, the site user 
must have an active CTEP -IAM account (check at < https://eapps -
ctep.nci.nih.gov/iam/index.jsp >) and the appropriate Rave role (Rave CRA, 
Read- Only, Site Investigator) on either the LPO or participating organization 
roster at the enrolling site.  
 Upon initial site registration approval for the study in RSS, all persons with Rave 
roles assigned on the appropriate roster will be sent a study invitation e- mail from 
iMedidata.   To accept the invitation, site users must log into the Select Login 
(https://login.imedidata.com/selectlogin) using their CTEP -IAM user name [CONTACT_25558], and click on the “accept” link in the upper right -corner of the iMedidata 
page.   Please note, site users will not be able to access the study in Rave until all 
required Medidata and study specific trainings are completed.   Trainings will be 
in the  form of electronic learnings (eLearnings), and can be accessed by [CONTACT_654448].  
 Users that have not previously activated their iMedidata/Rave account at the time of initial site registration approval for the study in RSS will also receive a  
 S1221  
Page 85  
Version Date 8/21/[ADDRESS_1105470] resource materials (Medidata Account Activation and Study Invitation Acceptance).  
Additional informati on on iMedidata/Rave is available on the CTSU members’ 
website under the Rave tab at www.ctsu.org/RAVE/  or by [CONTACT_800857] 1- [PHONE_103] or by e- mail at [EMAIL_013] .  
 
b. You may also access Rave ® via the SWOG CRA Workbench.   Go to the SWOG 
web site ( http://swog.org) and logon to the Members Area using your SWOG 
Roster ID Number and password. After you have logged on, click on 
Workbenches , then  CRA Workbench to access the home page for the CRA 
Workbench and follow the link to Rave ® provided in the left -hand navigation 
panel.  
 
To access the CRA Workbench the following must be done (in order):  
 
1. You are entered into the SWOG Roster and issued a SWOG Roster ID Number,  
2. You are associated as an investigator or CRA/RN at the institution where  
the patient is being treated or followed,  
 
3. Your Web User Administrator has added you as a web user and has given you the appropriate system permissions to view data for that institution.  
 
For assistance with points 1 and 2 call the Operations Office at 210/614- 8808.  
For point 3, contact [CONTACT_99976] (refer to the "Who is my Web User Administrator?" function on the swog.org Members logon page).  
 
For difficulties with the CRA Workbench, please email  
[EMAIL_1193]. 
 
14.4 Data Submission Overview and Timepoints  
 
a. WITHIN 7 DAYS OF REGISTRATION  FOR ALL PATIENTS SUBMIT:  
 
S1221 On study Form  
 Baseline Tumor Assessment Form (RECIST 1.1)  
 
S1221 Baseline Abnormalities Form  
 
Radiology reports from all scans performed to assess disease at baseline  
 
Pathology report from a CLIA certified lab documenting BRAF mutation status  
 
ALSO  SUBMIT WITHIN 7 DAYS OF REGISTRATION FOR PATIENTS 
ENROLLED ON T HE PHASE II PORTION : 
 Pathology report documenting histologic confirmation of malignant melanoma. 
 S1221  
Page 86  
Version Date 8/21/17  
 
  
 
b. SUBMIT WITHIN 14 DAYS AFTER REGISTRATION : 
 
Pre-study specimens as outlined in Section 15.4. 
 
c. WITHIN 7 DAYS AFTER COMPLETION OF EVERY CYCLE (1 CYCLE = 28 
DAYS), SUBMIT:  
 
S1221 Treatment Form   
 
S1221 Adverse Event Form  (Submit every 14 days  during Cycle s 1 and 2 of 
Phase I Portion , see Section 15.1  for Rapid Reporting requirements ): 
 
d. WITHIN 7 DAYS AFTER EVERY TUMOR ASSESSMENT (INCLUDING BOTH 
ON TREATMENT AND OFF TREATMENT PRIOR TO DISEASE 
PROGRESSION ) (see Section 9.0  for Disease Assessment Schedule)  SUBMIT : 
 Follow -Up Tumor Assessment Form  
 Radiology reports  from all scans performed to assess disease.  Physician must 
note tumor measurement in patient records.  
 
e. WITHIN 14 DAYS OF PROGRESSION  SUBMIT : 
 
NOTE:  IF PATIENT REMAINS ON TREATMENT FOLLOWING 
PROGRESSION (SEE SECTION 7.9a, CONTINUE TO SUBMIT THE S1221  
ADVERSE EVENT FORM AND S1221 TREATMENT FORM AFTER EVERY 
CYCLE OF TREATMENT AS OUTLINED IN SECTION 14.4c ). 
 Follow -Up Tumor Assessment Form (RECIST 1.1)  
 Radiology reports from all scans performed to assess disease. Physician must 
note tumor measurement in patient records.  
 
S1221 Treatment  Form  and S1221  Adverse Event  Form  (if the patient was still 
on protocol treatment) or  
 Follow -Up Form (if patient was off treatment) documenting date, site and method 
for determining progression.  
 
f. WITHIN 14 DAYS OF DISCONTINUATION OF TREATMENT  SUBMIT : 
 
Off Treatment Notice  
 
S1221 Treatment Form  
 
S1221 Adverse Event Form . 
 
g. AFTER OFF TREATMENT, SUBMIT EVERY 3 MONTHS FOR 1 YEAR  AND 6 
MONTHS UP TO 3 YEARS FROM DATE OF REGISTRATION : 
 
Follow -Up Form  
 
Late Effects Form (if prior to treatment for progression or relapse or a second primary, and prior to non- protocol treatment, the patient experiences any severe 
[Grade ≥ 3] long term toxicity that has not been previously reported).  
 S1221  
 Page 87  
 Version Date 8/21/17  
 
  
 
h. WITHIN 4 WEEKS OF KNOWLEDGE OF DEATH  SUBMIT :  
 
Notice of Death and all of the items listed in Section 14. 4f (if the  patient was 
still on protocol treatment) or Follow -Up Form (if the patient was off protocol 
treatment) documenting death information.  
 
 
15.0 SPECIAL INSTRUCTIONS  
 
15.1 Phase I Portion:  Rapid Reporting  
 
RAPID REPORTING OF TREATMENT -RELATED DOSE- LIMITING TOXICITIES FOR 
PHASE I PORTION OF TRIAL  
 
Participation in the Phase I Portion of the trial requires that Adverse Events be reported 
every [ADDRESS_1105471] notify the study Data 
Coordinator (Jennie Barrett; [EMAIL_15239] ; 206/652 -2267) of any changes.  
 
The contact [CONTACT_800858] -up CRA will receive weekly e- mails including a list of the 
Adverse Event and Treatment forms that are overdue, currently due, or due in the next week.   These e- mails will include a reply -to address and phone number to contact [CONTACT_800859].  
 
15.2 Phase I Portion:   Mandatory Confer ence Calls  
 
A mandatory conference call for study teams with active patients will take place twice a month.  The call will update participants on the current status of the trial and will include 
representatives from the study team, investigators from all participating institutions and representatives from [COMPANY_004].   At this time any serious toxicities encountered will be discussed 
and appropriate action taken.   In between these regularly scheduled conference calls, 
investigators will be informed of important study decisions via e- mail. 
 
15.3 Phase I Portion:   Mandator y Pharmacokinetic (PK) Sampling  
 
a Pharmacokinetic (PK) kits will not be provided for this submission; sites will use 
institutional supplies.   NOTE: Kits are no longer being supplied by [CONTACT_800860].  
 b. In all Phase I Portion patients PK sampling will be obtained at baseline, pre- dose 
Day 15, and pre- dose Day 29. 
 
At each time point, collect [ADDRESS_1105472] the date and time each sample is 
collected.  
 
Immediately after collection, gently invert (DO NOT SHAKE) the evacuated blood 
collection tube 8- 10 times to mix the K2EDTA anticoagulant with the whole blood, 
 blood samples should remain at room temperature prior to centrifugation and 
should be processed within 30 minutes of collection. Centrifuge the sample at 2500 to 3000 rpm for 10 to 15 minutes at room temperature to achieve a clear plasma layer over the red cells. The speed and time may be varied according to the make 
and model of centrifuge used.   Immediately transfer plasma into two (2)  
  S1221  
 Page 88  
 Version Date 8/21/17  
 
  
corresponding pre- labeled 1.8 mL NUNC tubes (each containing approximately 
0.75 mL of plasma) and store at - 20°C until shipped.   The Covance Bioanalytical 
study number for S1221 is 8290125.  The [COMPANY_004] study number is BRA117182.  
Please include either the [COMPANY_004] or Covance study number along with the SWOG 
protocol number in all correspondenc e. 
 
PK samples will be shipped to:  
 
Lab #207:  Covance BioanalyticalLaborator y Services Inc.  
Sample Management -bioanalytical (Rm 131D 1S)  
[ADDRESS_1105473]  
Madison, WI [ZIP_CODE] -2523  
Attn: Principal Investigator: [INVESTIGATOR_800826] 608/310- 2939  
E-mail: [EMAIL_15240]  
 
Covance require an electronic manifest to be sent with each PK shipment. By 
[CONTACT_800861], an electronic 
manifest will be automatically emailed to Covance for you.  
 
c.   During each of the Phase I portions (D+G and D+T+G) a more intense PK 
sampling schedule will be followed for three patients of cohort 2, or as an 
extension to cohort 1 if it is identified as the MTD, (and additional ones if needed to further define potential drug- drug int eractions).   These patients will 
have PK sampling at baseline, pre- dose and +1, +2, + 4, +8 hours on Day 15, 
and pre- dose Day 29.  
 
15.4 Phase I & II Portions :  Mandatory Specimen Submission for Translational Medicine  
 
Specimens for Translational Medicine Studies and Banking submitted to the SWOG 
Specimen Repository – Solid Tissue, Myeloma and Lymphoma Division, Lab #201 
(required for patients) : 
 
a. Specimens must be submitted at the following times ( see Section  9.0
): 
 
1. Submit entire block of paraffin- embedded tissue (and if available entire 
fresh- frozen tumor)  or 20 unstained slides (if site cannot send tissue 
block)  at baseline, at anytime during Days 15- 28 of Cycle  1 (optional) , 
and at time of progression.  
 
2. Submit four separate purple- top EDTA tubes each containing four  ml of 
whole blood at baseline, prior to the start of Cycle 3 and at time of 
progression.   Follow guidelines on the SWOG Specimen Webpage for 
collecting, processing and shippi[INVESTIGATOR_800827].  
Batch ship frozen plasma and buffy coat specimens to the SWOG 
Specimen Repository.  
 
b. Specimen collection and submission instructions can be accessed on the SWOG Specimen Submission webpage  
 (http://swog.org/Members/ClinicalTrials/Specimens/STSpecimens.asp),  
or via the link on the S1221 protocol abstract page on the SWOG website 
(www.swog.org).  
 
c. Avoid refrigerated storage overnight before liquid nitrogen immersions; instead  
the tissue must be completely immersed in RNALater and then liquid nitrogen 
immediately after biopsy and must be maintained cryopreserved.  The specimens 
must be shipped in dry ice.  
 
d. Specimen collection kits are not being provided for this submission; sites will 
use institutional supplies.  
 S1221  
 Page 89  
 Version Date 8/21/[ADDRESS_1105474] and monitoring of clinical investigations; they also represent sound research practice:  
 
Informed Consent  
 
The principles of informed consent are described by [CONTACT_60836] (Federal Register Vol. 46, No. 17, January 27, 1981, part 50) and the Office for Protection from Research Risks Reports:  Protection of Human Subjects (Code of Federal Regulations 45 CFR 46).  They 
must be followed to comply with FDA regulations for the conduct and monitoring of clinical 
investigations.  
 
Institutional Review  
 
This study must be approved by [CONTACT_800862] (Ref. Federal Register Vol. 46, No. 17, January 27, 1981, part 56) 
and the Office for Protection from Research Risks Reports:  Protection of Human Subjects  (Code 
of Federal Regulations 45 CFR 46).  
 
Drug Accountability  
 
An investigator is required to maintain adequate records of the disposition of investigational drugs 
according to procedures and requirements governing the use of investigational new drugs as 
described in the Code of Federal Regulations [ADDRESS_1105475]  
 
The agent s supplied by [CONTACT_472], DCTD, NCI used in this protocol are provided to the NCI under a 
Collaborative Agreement (CRADA, CTA, CSA) between the Pharmaceutical Company 
(hereinafter  referred to as “Collaborator ”) and the NCI Division of Cancer Treatment and 
Diagnosis.  Therefore, the following obligations/guidelines, in addition to the provisions in the 
“Intellectual Property Option to Collaborator”  
(http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm ) contained within the 
terms of award, apply to the use of the Agent in this study:  
 
1. Agent may not be used for any purpose outside the scope of this protocol, nor can Agent 
be transferred or licensed to any party not participating in the clinical study.  Collaborator 
data for Agent are confidential and proprietary to the Collaborator and shall be 
maintained as such by [CONTACT_473].  The protocol documents for studies utilizing 
Agents contain confidential information and should not be shared or distributed without  
the permission of the NCI.  If a copy of this protocol is requested by a patient or patient’s family member participating on the study, the individual should sign a confidentiality agreement. A suitable model agreement can be downloaded from: http://ctep.cancer.gov . 
 
2. For a clinical protocol where there is an investigational Agent used in combination with 
another i nvestigational Agent, each the subject of different Collaborative Agreements , 
the access to and use of data by [CONTACT_474] (data pertaining 
to such combination use shall hereinafter be referred to as “Multi- Party Data” ): 
 
a. NCI will provide all Collaborators with prior written notice regarding the existence 
and nature of any agreements governing their collaboration with NCI, the design 
of the proposed combination protocol, and the existence of any obligations that 
would tend to r estrict NCI’ s participation in the proposed combination protocol.  
 S1221  
 Page 90  
 Version Date 8/21/[ADDRESS_1105476] agree in writing prior to the commencement of the trials that it will use the 
Multi -Party Data solely for development, regulatory approval, and 
commercialization of its own Agent.  
 
3. Clinical Trial Data and Results and Raw Data developed under a Collaborative Agreement will be made available to Collaborator(s), the NCI, and the FDA, as 
appropriate and unless additional disclosure is  required by [CONTACT_52381]  
(http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm ). 
 
Additionally, all Clinical Data and Results and Raw Data will be collected, used and 
disclosed consistent with all applicable federal statutes and regulations for the protection of human subjects, including, if applicable, the Standards for Privacy of Indi vidually 
Identifiable Health Information set forth in [ADDRESS_1105477] be sent to the NCI, who will then notify the appropriate investigators (Group Chair for Cooperative 
Group studies, or PI [INVESTIGATOR_349]) of Collaborator's wish to contact [CONTACT_476].  
 
5. Any data provided to the Collaborator (s) for Phase [ADDRESS_1105478] be in accordance with 
the guidelines and policies of the responsible Data Monitoring Committee (DMC), if there is a DMC for this clinical trial.  
 
6. Any manuscripts reporting the results of this clinical trial must be provided to CTEP by 
[CONTACT_477] [INVESTIGATOR_350]-Cooperative Group studies for immediate delivery to the Collaborator (s) for advisory 
review and comment prior to submission for publication.  Collaborator (s) will have [ADDRESS_1105479] that publication be delayed for up to an additional 30 days in or der to ensure that 
Collaborator( s) confidential and proprietary data, in addition to the Collaborator( s) 
intellectual property rights, are protected.  Copi[INVESTIGATOR_800828] (s) for courtesy review as soon as possible and 
preferably at least three (3) days prior to submission, but in any case, prior to 
presentation at the meeting or publication in the proceedings.  Press releases and other 
media presentation must also be forwarded to CTEP prior to release.  Copi[INVESTIGATOR_25490], abstract and/or press release/media presentation should be sent to:  
 
E-mail:  [EMAIL_001]   
 
The Regulatory Affairs Branch will then distribute them to Collaborator (s).  No publication, 
manuscript or other form of public disclosure shall contain any of the Collaborator's 
confidential/proprietary information.  
 
Monitoring  
 
This study will be monitored by [CONTACT_470] (CDUS) Version 3.0.  Cumulative CDUS data will be submitted quarterly to CTEP by [CONTACT_10075].  Reports are 
due January 31, April 30, July 31 and October 31.  
 S1221  
 Page 91  
Version Date 8/21/17  
 
  
 
Confidentiality  
 
Please note that the information contained in this protocol is considered confidential and should 
not be used or shared beyond the purposes of completing protocol requirements until or unless additional permission is obtained.  
 
16.1 Adverse Event Reporting Requirements  
 
a. Purpose  
 
Adverse event data collection and reporting, which are required as part of every 
clinical trial, are done to ensure the safety of patients enrolled in the studies as 
well as those who will enroll in future studies using similar agents. Adverse events are reported in a routine manner at scheduled times during a trial. 
(Directions for routine reporting are provided in Section 14.0
.) Additionally, 
certain adverse events must be reported in an expedited manner to allow for 
more timely monitoring of patient safety and care. The following guidelines 
prescribe expedited adverse event reporting for this protocol. See also Appendix 
18.1 for general and background information about expedited reporting.  
 b. Reporting method 
 
This study requires that expedited adverse event s be reported using the Cancer 
Therapy Evaluation Program (CTEP) Adverse Event Reporting System ( CTEP-
AERS). CTEP’s  guidelines for CTEP- AERS  can be found at  
http://ctep.cancer.gov .  A CTEP-A ERS report must be submitted to the SWOG 
Operations office electronically via the CTEP- AERS web -based application 
located at:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/adverse_events.
htm 
 
c. When to report an event in an expedited manner  
 
Some adverse events require 24- hour notification (refer to Table 16.1 ) via CTEP-
AERS.   
 
When the adverse event requires expedited reporting, submit the report within the number of calendar days of learning of the event specified in Table 16.[ADDRESS_1105480] be reported according to local policy 
and procedures.  
 S1221  
 Page 92  
Version Date 8/21/[ADDRESS_1105481] one dose of the investigational agent(s) as part of the trial. Reporting requirements are provided in 
Table 16.1
.  The investigational agent(s) used in Phase I and Phase II of this study 
are dabrafenib and [COMPANY_004]2141795 If there is any question about the reportability of an adverse event or if on- line CTEP- AERS cannot be used, please telephone or 
email the SAE Specialist at the Operations Office, 210/614- 8808 or [EMAIL_1196], 
before preparing the report.  
 S1221  
 Page 93  
 Version Date 8/21/17  
 
  
Table 16.1 Phase 1 and Early Phase 2 Studies:  Expedited Reporting Requirements for Adverse 
Events that Occur on Studies under a CTEP IND within [ADDRESS_1105482] Administration of the Investigational Agent/Intervention
1  Dabrafenib , Trametinib,  and [COMPANY_004]2141795 (Phase I and Phase II)  
FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312)  
NOTE:   Investigators MUST  immediately report to the sponsor (NCI) ANY Serious Adverse Events, 
whether or not they are considered related to the investigational agent(s)/intervention (21 CFR 
312.64)  
An adverse event is considered serious if it results in ANY  of the following outcomes:   
1) Death  
2) A life -threatening adverse event  
3) An adverse event that results in inpatient hospi[INVESTIGATOR_15163] ≥ 24 hours  
4) A persistent or significant incapacity or substantial disruption of the  ability to conduct normal life 
functions  
5) A congenital anomaly/birth defect.  
6) Important Medical Events (IME) that may not result in death, be life threatening, or require 
hospi[INVESTIGATOR_708], based upon medical judgment, they ma y 
jeopardize the patient or subject and may require medical or surgical intervention to prevent one of 
the outcomes listed in this definition. (FDA, 21 CFR 312.32; ICH E2A and ICH E6).  
ALL SERIOUS  adverse events that meet the above criteria MUST be immediately reported to the NCI via 
CTEP -AERS within the timeframes detailed in the table below.  
Hospi[INVESTIGATOR_317] 1 and Grade 2 Timeframes  Grade 3 -5 
Timeframes  
Resulting in 
Hospi[INVESTIGATOR_059]       
≥ 24 hrs  10 Calendar Days  
24-Hour 5 Calendar 
Days  Not resulting in 
Hospi[INVESTIGATOR_059]       
≥ 24 hrs  Not required  
NOTE:   Protocol specific exceptions to expedited reporting of serious adverse events are found in the 
Specific Protocol Exceptions to Expedited Reporting ( SPEER) portion of the CAEPR or Section 
16.1f . 
 
Expedited AE reporting timelines  are defined as:  
o “24-Hour; 5 Calendar Days” - The AE must initially be reported via CTEP -AERS within 24 hours of 
learning of the AE, followed by a complete expedited report within 5 calendar days of the initial 24-hour report.  
 
o “10 Calendar Days” - A complete expedited report on the AE must be submitted within [ADDRESS_1105483] administration of investigational 
agent/intervention and have an attribution of possible, probable, or definite require reporting as follows:  
 Expedited 24 -hour notification followed by [CONTACT_432] 5 calendar days for:  
• All Grade 3, 4, and Grade 5 AEs  
Expedited 10 calendar day reports for:  
• Grade 2 AEs resulting in hospi[INVESTIGATOR_800829] 5, 2011  
 S1221  
 Page 94    
Version Date 8/21/17  
 
  
f. Additional Instructions or Exceptions to CTEP- AERS Expedited Reporting 
Requirements for Phase I and Early Phase II Studies Utilizing an Agent  under 
a CTEP IND:  
 
Group -specific instructions:  Submission of the on- line CTEP- AERS report 
plus any necessary amendments generally completes the reporting 
requirements In addition, you may be asked to submit supporting clinical data 
to the SWOG Operations Offices in order to complete the evaluation of the event.  If requested, the supporting data should be sent within 5 calendar 
days  by [CONTACT_12100] 210 -614-0006.  Supporting clinical data submitted should 
include:  
 
• Printed copy of the first page of the CTEP- AERS Report.  
• Copi[INVESTIGATOR_99925].  
• If applicable, and they have not yet been submitted to the SWOG Data Operations Center copi[INVESTIGATOR_231560]/or Notice of Death.  
g. Reporting Secondary Malignancy, including AML/ALL/MDS  
 
1. A secondary malignancy is a cancer caused by [CONTACT_437] a 
previous malignancy (e.g., treatment with investigational agent/intervention, radiation or chemotherapy).  A secondary 
malignancy is not considered a metastasis of the initial neoplasm.  
 
 CTEP requires all secondary malignancies that occur following 
treatment with an agent under an NCI IND to be reported via CTEP-
AERS.  Three options are available to describe the event.  
 
• Leukemia secondary to oncology chemotherapy (e.g., Acute 
Myelocytic Leukemia [AML])  
• Myelodysplastic syndrome (MDS)  
• Treatment -related secondary malignancy  
  Any malignancy possibly related to cancer treatment (including 
AML/MDS) should also be reported via the routine reporting 
mechanisms outlined in each protocol.  
 
For more information see:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf.  
 
2. Supporting documentation should be submitted to CTEP in accordance with instructions provided by [CONTACT_16656]- AERS  system.  A 
copy of the report and the following supporting documentation must also be submitted to SWOG Operations Office within 30 days:  
 
• a copy of the pathology report confirming the AML/ALL /MDS 
diagnosis  
• (if available) a copy of the cytogenetics report   
 SWOG  
ATTN: SAE Program  
[ADDRESS_1105484]  
San Antonio, [LOCATION_007] [ZIP_CODE]  
 
NOTE: If a patient has been enrolled in more than one NCI -
sponsored study, the report must be submitted for the most recent 
trial.
 S1221  
 Page 95    
Version Date 8/21/17                                                                          
 
  
 
 
h.  Reporting Pregnancy, Fetal Death, and Death Neonatal  
 
1. Pregnancy Study participants who become pregnant while on study; that 
pregnancy should be reported in an expedited manner via CTEP -AERS 
as Grade 3 “Pregnancy, puerperium and perinatal conditions – 
Other (pregnancy)”  under the Pregnancy,  puerperium and perinatal 
conditions  SOC.   
 
Additionally, the pregnancy outcome for patients on study should be reported via CTEP -AERS at the time the outcome becomes known, 
accompanied by [CONTACT_90324].  
 
2. Fetal  Death Fetal Death defined in CTCAE as “A disorder characterized 
by [CONTACT_260765]; failure of the product of conception to show evidence of respi[INVESTIGATOR_1516], heartbeat, or definite movement of a voluntary muscle 
after expulsion from the uterus, without possibility of resuscitation”  
should be reported expeditiously as Grade 4 “pregnancy, puerperium 
and perinatal conditions – Other (pregnancy loss)” under the 
Pregnancy, puerperium and perinatal conditions  SOC.   
 
3. Death Neonatal  Neonatal death, defined in CTCAE as “A disorder 
characterized by [CONTACT_52372] 28 days of life” 
that is felt by [CONTACT_454514]/intervention should be reported expeditiously.   
 
A neonatal death should be reported expeditiously as Grade 4 “General 
disorders and administration – Other (neonatal loss)” under the 
General disorders and administration  SOC.  
 
Fetal death and neonatal death should NOT  be reported as a Grade [ADDRESS_1105485] EP-AERS interprets this as a death of the patient being 
treated.  
 
NOTE:   When submitting CTEP -AERS reports for “Pregnancy, “Pregnancy loss”, 
or “Neonatal loss”, the Pregnancy Information Form should also be completed 
and faxed with any additional medical information to 301- 230-0159.  The 
potential risk of exposure of the fetus to the investigational agent(s) or chemotherapy agent(s) should be documented in the “Description of Event” section of the CTEP -AERS report.  
 The Pregnancy Information Form is available at:  
http://ctep.cancer.gov/protocolDevelopment/adverse_effects.htm    
 
  
 S1221  
 Page 96    
Version Date 8/21/17  
 
  
17.0 BIBLIO GRAPHY  
 1. Flaherty, K. T. et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. 
Med.  363, 809– 819, 2010. 
 2. Sosman, J. A. et al.  Survival in BRAF V600- mutant advanced melanoma treated with 
vemurafenib. N. Engl. J. Med.  366, 707–714, 2012. 
 3. Chapman, P. B. et al.  Improved survival with vemurafenib in melanoma with BRAF V600E 
mutation. N. Engl. J. Med.  364, 2507– 2516, 2011. 
 4. Hauschild, A. et al.  Dabrafenib in BRAF -mutated metastatic melanoma: a multicentre, open- label, 
phase 3 randomised controlled trial. Lancet  380, 358–365, 2012. 
 5. Falchook, G. S. et al.  Dabrafenib in patients with melanoma, untreated brain metastases, and 
other solid tumours: a phase 1 dose- escalation trial. Lancet  379, 1893 –1901, 2012 . 
 6. Long, G. V. et al.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF -mutant melanoma 
metastatic to the brain (BREAK -MB): a multicentre, open- label, phase 2 trial. Lancet Oncol.  13, 
1087 –1095,2012. 
 
7. Bollag, G. et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant 
melanoma. Nature 467,  596–599, 2010 . 
 8. Gorre, M. E. et al.  Clinical resistance to STI -571 cancer therapy caused by [CONTACT_431938] -ABL gene 
mutation or amplification. Science 293, 876–880, 2001 . 
 9. Pao, W. et al.  Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated 
with a second mutation in the EGFR kinase domain. PLoS Med.  2, e73, 2005. 
 10. Shi, H. et al.  Melanoma whole- exome sequencing identifies (V600E)B- RAF amplification -
mediated acquired B- RAF inhibitor resistance. Nat. Commun.  3, 724, 2012. 
 11. Poulikakos, P. I. et al.  RAF inhibitor resistance is mediated by [CONTACT_800863](V600E) . Nature  480, 387–390, 2011. 
 12. Nazarian, R. et al.  Melanomas acquire resistance to B- RAF(V600E) inhibition by [CONTACT_540889] N -RAS 
upregulation. Nature 468, 973– 977, 2010. 
 
13. Wagle, N. et al.  Dissecting therapeutic resistance to RAF inhibition in melanoma by [CONTACT_800864]. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29, 3085 –3096, 2011. 
 
14. Shi, H. et al.  Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer 
resista nce to BRAF inhibitors. Cancer Discov.  2, 414– 424, 2012. 
 15. Johannessen, C. M. et al.  COT drives resistance to RAF inhibition through MAP kinase pathway 
reactivation. Nature 468,  968– 972, 2010. 
 16. Shi, H. et al.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor 
therapy. Cancer Discov.  4, 80–93, 2014 . 
 17. Flaherty, K. T. et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 
mutations. N. Engl. J. Med.  367, 1694– 1703, 2012 . 
 S1221  
 Page 97    
Version Date 8/21/17  
 
  
 18. Long, G. V. et al.  COMBI -d: A randomized, double- blinded, Phase III study comparing the 
combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first -line 
therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation- positive 
cutane ous melanoma. J. Clin. Oncol.  32:5s,  2014. 
 
19. Shi, H., Kong, X., Ribas, A. & Lo, R. S. Combinatorial treatments that overcome PDGFRβ -driven 
resistance of melanoma cells to V600EB -RAF inhibition. Cancer Res.  71, 5067 –5074, 2011. 
 20. Villanueva, J. et al.  Acquire d resistance to BRAF inhibitors mediated by a RAF kinase switch in 
melanoma can be overcome by [CONTACT_540892] -1R/PI3K. Cancer Cell  18, 683– 695, 
2010 . 
 
21. Wilson, Fridly, Yan et al. Widespread potential for growth- factor -driven resistance to anticancer kinase 
inhibitors.  Nature 26;487(7408):505- 9, 2012.  
 22. Straussman, Morikawa, Shee, et al. Tumor microenvironment contributes to RAF -inhibitor 
resistance through HGF secretion. Nature 26; 487(7408):500- 4, 2012.  
 23. Jiang, C. C. et al.  MEK -independent survival of B -RAFV600E melanoma cells selected for 
resistance to apoptosis induced by [CONTACT_800865]4720. Clin. Cancer Res. Off. J. Am. 
Assoc. Cancer Res.  17, 721– 730, 2011 . 
 
24. Atefi, M. et al. Reversing melanoma cross -resistance to BRAF and MEK inhibitors by [CONTACT_3252]- targeting 
the AKT/mTOR pathway. PloS One 6, e28973, 2011. 
 25. Paraiso, K. H. T. et al.  PTEN loss confers BRAF inhibitor resistance to melanoma cells through 
the suppression of BIM express ion. Cancer Res.  71, 2750– 2760, 2011. 
 26. Kurzrock, R. et al.  Phase I dose- escalation of the oral MEK1/2 inhibitor [COMPANY_004]1120212 ([COMPANY_004]212) 
dosed in combination with the oral AKT inhibitor [COMPANY_004]2141795 ([COMPANY_004]795). J. Clin. Oncol.  29: 2011 
(suppl; abstr 3085),  2011. 
 
27. Sosman, J. A. et al.  BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor 
(MEKi) trametinib in BRAFi -naive and BRAFi -resistant patients (pts) with BRAF mutation- positive 
metastatic melanoma (MM). J. Clin. Oncol.  31, 2013. 
 
28. Su, F. et al. RAS mutations in cutaneous squamous -cell carcinomas in patients treated with 
BRAF inhibitors. N. Engl. J. Med.  366, 207– 215, 2012. 
 29. Søndergaard, J. N. et al.  Differential sensitivity of melanoma cell lines with BRAFV600E mutation 
to the specific Raf inhibitor PLX4032. J. Transl. Med.  8, 39, 2010.  
 30. Lo, R. S. Combinatorial therapi[INVESTIGATOR_800830] B -RAF inhibitor resistance in melanomas. 
Pharmacogenomics  13, 125– 128, 2012 . 
 
  S1221  
 Page 98  
 Version Date 8/21/17  
 
  
18.0 APPENDIX  
 
18.1 Determination of Expedited Adverse Event Reporting Requirements   
 18.2 Translational Medicine  
 
18.3 Intake Calendar  
 
18.4 Strong  inducers/inhibi tors of CYP3A, CYP2C8, Pgp, Bcrp and possibly 2C8/9 and 2C19  
 18.5 [LOCATION_001] Heart Association Classifications  
 
18.6 Information on Possible Drug Interactions  
 
18.7 Patient Information – Wallet Card  
 18.8 Instructions for Patients for Storage of Trametinib Tablets  
 
 S1221  
  Page 99  
Version Date 8/21/17  
 
  
18.1 Determination of Expedited Adverse Event Reporting Requirements  
 
Adverse event data collection and reporting, which are required as part of every clinical 
trial, are done to ensure the safety of patients enrolled in the studies as well as those who 
will enroll in future studies using similar agents. Adverse events are reported in a routine manner at scheduled times during a trial. (Directions for routine reporting are provided in 
Section 14.0.
) Additionally, certain adverse events must be reported in an expedited 
manner to allow for more timely monitoring of patient safety and care. Expedited adverse 
event reporting principles and general guidelines follow; specific guidelines for expedited 
adverse event reporting on this protocol are found in Section 16.[ADDRESS_1105486] be reported according to local policy and procedures.  Documentation of this reporting should be maintained for possible inspection during quality assurance audits.  
 Steps to determine if an adverse event is to be reported in an expedited manner (This includes all events that occur while on treatment or within [ADDRESS_1105487] dose 
of protocol treatment. ) 
 
Step 1 : Determine whether the patient has received an investigational agent, commercial 
agent, or a combination of investigational and commercial agents.  
 An investigational agent is a protocol drug administered under an Investigational New 
Drug Submission (IND).  In some instances, the investigational agent may be available 
commercially, but is actually being tested for indications not included in the approved package label.  
 Commercial agents  are those agents not provided under an IND but obtained instead 
from a  commercial source. The NCI, rather than a commercial distributor, may on some 
occasions distribute commercial agents for a trial.  
 When a study includes both investigational and commercial agents, the following rules 
apply.   
 
• Concurrent administration : When an investigational agent(s) is used in 
combination with a commercial agent(s), the combination is considered to be 
investigational and expedited reporting of adverse events would follow the guidelines for investigational agents.  
• Sequential administrati on:   When a study includes an investigational agent(s) 
and a commercial agent(s) on the same study arm with sequential administration all expedited reporting of adverse events should follow the guidelines for the type 
of agent being given.  For example, if the patient begins the study on the 
investigational agent(s), then all expedited reporting of adverse events should follow guidelines for the investigational agent(s).  Once the patient begins 
receiving the commercial agent(s) then all expedited reporting of adverse events 
should follow the guidelines for commercial agent(s).   
 
Step 2 : Identify the type of event using the NCI Common Terminology Criteria for 
Adverse Events (CTCAE). The CTCAE provides descriptive terminology and a grading scale for each adverse event listed. A copy of the CTCAE can be downloaded from the 
CTEP home page (http://ctep.cancer.gov) . Additionally, if assistance is needed, the NCI 
has an Index to the CTCAE that provides help for classifying and locating terms.  
 
Step 3 :  Grade the event using the NCI CTCAE version specified in the protocol for 
reporting serious adverse events.  
 S1221  
  Page 100  
Version Date 8/21/17  
 
  
 
Step 4 : Determine if the adverse event is Expected or an Exception to Expedited 
Reporting.   Expected  events are those that have been previously identified as resulting 
from administration of the agent and are listed in one of the following:   
 
• The current NCI SPEER (Specific Protocol Exceptions to Expedited Reporting) 
for treatments using agents provided under an NCI -held IND, or an equivalent 
listing for treatments using agents provided under a Non- CTEP- held IND; located 
in Section 3.0  of the protocol.  
• For treatments using commercial agents, the current CAEPR (Comprehensive 
Adverse Event and Potential Risks), ASAEL (Agent Specific Adverse Event List), or other list of expected toxicities located in Section 3.0
 of the protocol, or the 
drug package insert.   
• Exception to Expedited reporting located in Section 16.1f  of the protocol.  
 
An adverse event is considered unexpected,  for expedited reporting purposes only, 
when either the type of event or the severity of the event is not listed in one of the areas 
outlined above.  
 
Step 5 :  Determine whether the adverse event involved hospi[INVESTIGATOR_26109] a prolongation 
of hospi[INVESTIGATOR_059] (≥ 24 hours).  
 
Step 6 :  Additionally, for commercial drugs, determine whether the adverse event is 
related to the protocol therapy.  Attribution categories are as follows: Unrelated, Unlikely, 
Possible, Probable, and Definite.  Consult the appropriate table for expedited reporti ng 
criteria for commercial agent(s).  
 
NOTE :   Any event that occurs more than [ADDRESS_1105488] dose of study agent and 
is attributed (possible, probable, or definite) to the study agent(s) must be reported according to the instructions above and as outlined in the appropriate table in 
Section 
16.1. 
 S1221  
  Page 101  
Version Date 8/21/17  
 
  
18.2 Translational Medicine  
 
Pre-study (after failing frontline BRAF inhibitor therapy) blood and tissue specimens will 
be required. Blood and tissue specimens will be requested from two other time points: 1) 
prior to starting first line BRAF inhibitor therapy (initial diagnosis) and 2) at the time of 
progression on this study.   
 Studies will be done in blood, formalin- fixed paraffin embedded (FFPE) tissues, and if 
availa ble in fresh cryopreserved tissues.  
 
From FFPE the following studies will be done:  
-       NRAS, MEK1/2, PI3K and AKT1 mutations by [CONTACT_174960]  
-       Mutant BRAF amplification by [CONTACT_800866] (gDNA) Q -PCR  
-       pERK and pAKT by [CONTACT_4658]  
-       PDGFRβ,  EGFR, cKIT, cMET by [CONTACT_4658]  
-       HGF by [CONTACT_800867], the following studies will be done:  
-       Growth factor (HGF) levels  
-       Extraction of gDNA for validation of somatic alterations in collected tumors  
 From fresh frozen tissue (when available),  the following studies will be done:  
-       NRAS, MEK1/2, PI3K and AKT1 mutations by [CONTACT_174960] (if available and if 
any assay above fails or the results of which is equivocal)  
-       Mutant BRAF amplification by [CONTACT_800866] (gDNA) Q -PCR (if available and if any 
assay above fails or the results of which is equivocal)  
-       Mutant BRAF truncation by [CONTACT_800868] Q -PCR  
-       RTK (PDGFRβ, EGFR, cKIT, cMET) by [CONTACT_800868] Q -PCR  
 Phosphorylation of receptor tyrosine kinases (RTKs) may be analyzed by a reverse phase protein array assay.  
 In cases a fresh tissue sample of sufficient size is available, whole- exome sequencing 
and RNA -Seq will be attempted, with parallel testing of peripheral blood cells.  Fresh 
tissues cryoperserved in RNALater are expected to provide more reliable cDNA Q -PCR 
assay performance.  Highly pi[INVESTIGATOR_800831]/cDNA during sample processing.  
 
 
  
 
 
 S1221  
  Page 102  
Version Date 8/21/17  
 
  
18.3 Intake Calendar  
 
 
  
 
     
 
     
 
    
 
Sunday  Monday  Tuesday  Wednesday  Thursday  Friday  Saturday  
       
       
       
       
       
Patient Signature:    [CONTACT_461488]________  Patient Initials (L, F, M) ________  SWOG Study #__________
   
Institution/Affiliate _______________________  Physician _____________________________  
 
Instructions for the participant:  
 
This is a monthly calendar on which you are to record the number of tablets/pi[INVESTIGATOR_3353]/capsules you take each day.  Be sure you have enough calendars to last until your next appointment.  If you develop any side effects from the tablets/pi[INVESTIGATOR_3353]/capsules, mark this on the calendar on the day you note the effect.  Bring your calendars with you each time you have an appointment.  
 
If you have questions contact: ____________________ Telephone: _____________________  
 
Your next appointment is: _______________________  
Special instructions:  
 
Month:  Year:  
 
 S1221  
  Page 103  
Version Date 8/21/17  
 
  
18.4 Strong  inducers/inhibi tors of CYP3A, CYP2C8, Pgp, Bcrp and possibly 2C8/9 and 2C19  
 Prohibited Medications  
 
PROHIBITED – strong inducers of CYP3A or CYP2C8, since concentrations of dabrafenib may be 
decreased  
Class/Therapeutic 
Area  Drugs/Agents  
Antibiotics  Rifamycin class agents (e.g.,  rifampin, rifabutin, rifapentine),  
Anticonvulsant  Carbamazepi[INVESTIGATOR_050],  oxcarbazepi[INVESTIGATOR_283567], phenytoin, s -mephenytoin  
Miscellaneous  bosentan, St. John’s wort  
PROHIBITED – Strong inhibitors of CYP3A, or CYP2C8 since concentrations of dabrafenib  may 
be increased  
Class/Therapeutic 
Area  Drugs/Agents  
Antibiotics  Clarithromycin, telithromycin, troleandomycin  
Antidepressant  Nefazodone  
Antifungals  Itraconazole, ketoconazole, posaconazole, voriconazole  
Hyperlipi[INVESTIGATOR_377461], saquinavir, atazanavir  
Miscellaneous  Conivaptan  
 
The following medications should be used with caution as their concentrations may be altered by [CONTACT_800869]:  
• Drugs that are moderate inhibitors or inducers of CYP3A and CYP2C8 as they may alter 
concentrations of dabrafenib.  
• Dabrafenib has been shown to induce CYP3A4 and CYP2C9 in vivo using midazolam  
(CYP3A4 substrate) and S -warfarin (CYP2C9 substrate).  Dabrafenib is an in vitro 
inducer of CYP2B6 and other enzymes such as CYP2C8, CYP2C19, UDP- glucuronyl 
transferases, and transporters may also be affected.  Co- administration of dabrafenib and 
medications which are affected by [CONTACT_483039] (including warfarin) and transporters may result in loss of efficacy.  If co- administration of these medications 
is necessary, investigators should monitor subjects for loss of efficacy or consider 
substitutions of these medications. A partial list of these medications is provided in Table 
1 and in the SPM.  
• Dabrafenib solubility is pH -dependent with decreased solubility at higher pH.  Drugs such 
as proton pump inhibitors that inhibit gastric acid secretion to elevate gastric pH may decrease the solubility of dabrafenib and reduce its bioavailability.  No clinical study has 
been conducted to evaluate the effect of pH on dabrafenib pharmacokinetics. In an ad-hoc analysis, no differences in C
max and AUC were noted between subjects who reported 
taking pH -elevating products relative to other subjects.  Due to the theoretical risk that 
pH-elevating agents may decrease oral bioavailability and exposure to dabrafenib, these 
medicinal products that increase gastric pH should be used with caution when administered with dabrafenib.  
 S1221  
  Page 104  
Version Date 8/21/17  
 
  
 
• A list of medications that should be used with caution are listed in the table below:  
 
 
                     
 
                             
 
 Table 1 Medications to be used with Caution  
USE WITH CAUTION:  Moderate  inhibitors of CYP3A, or CYP2C8 since concentrations of 
dabrafenib may be increased  
Class/Therapeutic Area  Moderate CYP3A and CYP2C8 Inhibitors  
Antiarrhythmics Diltiazem, verapamil  
Antibiotic  Erythromycin  
Antifungal  Fluconazole  
Miscellaneous  Aprepi[INVESTIGATOR_482972]: Co -administration of these drugs with study treatment may result in loss 
of efficacy.  Monitor subjects for loss of efficacy or substitute with another medication.  
Class/Therapeutic Area CYP3A4, CYP2B6, CYP2C8, CYP2C9, or CYP2C19 Substrates 
that May be Affected by [CONTACT_483041], buprenorphine, celecoxib, codeine, fentanyl, methadone, 
oxycodone  
Antiarrhythmics Disopyramide, dronedarone,  mexiletine, propafenone, quinidine  
Antibiotics  Chloramphenicol, doxycycline, erythromycin, moxifloxacin  
Anticoagulants/ Antiplatelets  Cilostazole, warfarin  
Anticonvulsants  Divalproex, lamotrigine, valproate, zonisamide  
Antidepressants and Antipsychotics  Aripi[INVESTIGATOR_4253], bupropi[INVESTIGATOR_2394], buspi[INVESTIGATOR_5331], desipramine,  haloperidol, 
mirtazapi[INVESTIGATOR_050], pi[INVESTIGATOR_3924], quetiapi[INVESTIGATOR_050], trazodone, amitriptyline, 
clomipramine, imipramine  
Antidiabetics  Glyburide,  saxagliptin, tolbutamide, nateglinide, pi[INVESTIGATOR_051],  
repaglinide,  rosiglitazone  
Antifungals  Caspofungin, fluconazole, terbinafine  
Antihistamines  Astemizole, chlorpheniramine, ebastine  
Antihypertensives  Amlodipi[INVESTIGATOR_050], diltiazem, felodipi[INVESTIGATOR_050], nifedipi[INVESTIGATOR_050], nilvadipi[INVESTIGATOR_050], nisoldipi[INVESTIGATOR_050], verapamil  
Antimigraine Agents  Diergotamine, eletriptan, ergotamine  
Corticosteroids  Dexamethasone, methylprednisolone, oral budesonide  
Erectile Dysfunction Agents  Sildenafil, tadalafil, vardenafil  
HMG -CoA Reductase 
Inhibitors  Atorvastatin, lovastatin, simvastatin  
Hypnotics and Sedatives  Alprazolam, brotizolam, diazepam, estazolam, midazolam, triazolam, zolpi[INVESTIGATOR_6730], zopi[INVESTIGATOR_482973], sirolimus, tacrolimus  
Miscellaneous  Aprepi[INVESTIGATOR_053], cisapride, darifenacin, disopyramide, leflunomide, 
methohexital, oral contraceptives, quinine, ranitidine, solifenacin, 
sulfasalazine, tramadol, tolvaptan, chloroquine, zopi[INVESTIGATOR_800832]: Co -administration of drugs that increase gastric pH should be used with 
caution when administered with dabrafenib..  
pH altering agents  dexlansoprazole. esomeprazole, famotidine, ilaprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole, ranitidine  
Abbreviations: CYP = cytochrome P450; HMG -CoA = 3-hydroxy -3-methylglutaryl -coenzyme A.  
 S1221  
  Page 105  
Version Date 8/21/17  
 
  
 
* Therapeutic level dosing of warfarin can be used with approval by [CONTACT_800870]/INR by [CONTACT_779].  Exposure may be decreased due to enzyme induction when on treatment, thus warfarin dosing may need to be adjusted based upon PT/INR.  Consequently, when discontinuing dabrafenib, warfarin exposure may be increased and thus close monitoring via PT/INR and warfarin dose adjustments must be made as clinically appropriate.  Prophylactic low dose warfarin may be given to maintain central catheter patency.  
 Because the list of these agents are constantly changing, it is important to regularly consult a 
frequently -updated list such as http://medicine.iupui.edu/clinpharm/ddis/ main -table/ ; medical 
reference texts such as the Physicians’ Desk Reference may also provide this information. 
As part 
of the enrollment/informed consent procedures, the patient will be counseled on the risk of 
interactions with other agents, and what to do if new medications need to be prescribed or if the 
patient is considering a new over -the-counter medicine or herbal product.  Section 18.6 is a 
patient information sheet that can be used for this specific protocol and presented to the patient.  
 S1221  
  Page 106  
Version Date 8/21/[ADDRESS_1105489]*  To Work**   
 
I None  None  None  Full Time  
 
II Only moderate  Slight  Usually only slight  Usually full time 
   or occasional  
 III Defined, with less  Marked Usually  moderate  Usually part time 
 than ordinary  
 activity  
 IV May be present  Extreme  Marked Unable to work  
 even at rest, & any  
 activity increases  
 discomfort      
 * To control or relieve symptoms, as determined by [CONTACT_102], rather than as advised by [CONTACT_099].  
 
** At accustomed occupation or usual tasks.   
 
 S1221  
  Page 107  
Version Date 8/21/17  
 
  
 
18.6 Information on Possible Drug Interactions  
 
Information on Possible Interactions with Other Agents for Patients and Their Caregivers and Non- Study Healthcare Team  
 
[Note to investigators:   This appendix consists of an “information sheet” to be handed to 
the patient at the time of enrollment.   Use or modify the text as appropriate for the study 
agent, so that the patient is aware of the risks and can communicate with their regular prescriber(s) and pharmacist.   A convenient wallet -sized information card is also included 
for the patient to clip out and retain at all times.]  
 The pat ient is enrolled on a clinical trial using the experimental agents dabrafenib , 
trametinib, and [COMPANY_004]2141795.  This clinical trial is sponsored by [CONTACT_6808].  This form is addressed to the patient, but includes important information for 
others who care for this patient.  
 
Drug  Interactions : 
Dabrafenib, trametinib, and [COMPANY_004]2141795 interact with many drugs that are processed by 
[CONTACT_6813].   Because of this, it is very important to tell your study doctors about all of your 
medicine before you start this study.   It is also very important to tell them if you stop 
taking any regular medicine, or if you start taking a new medicine while you take part in this study.   When you talk about your medicine with your study doctor, include medicine 
you buy without a prescription at the drug store (over -the-counter remedy), or herbal 
supplements such as St. John’s W ort. 
 Many health care prescribers can write prescriptions.   You must also tell your other 
prescribers (doctors, physicians’ assistants or nurse practitioners) that you are taking part in a clinical trial. Bring this paper with you and keep the attached information card in 
your wallet .  These are the things that you and they need to know:  
 Liver Enzyme Interactions : 
Dabrafenib, trametinib, and [COMPANY_004]2141795 interact with certain specific enzymes in your 
liver.  
 • The enzymes in question are CYP450 3A4, 2C8, 2C9, 2C19, 2B6, P- gp, BCRP and 
OATP1B1 . Dabrafenib, trametinib, and [COMPANY_004]2141795 levels are affected by [CONTACT_800871].  
 
• Dabrafenib, trametinib, and [COMPANY_004]2141795 must be used very carefully with other 
medicines that need these liver enzymes to be effective or to be cleared from your 
system.  
 • Other medicines may also affect the activity of the enzyme.  
 
• Substances that increase the enzyme’s activity (“inducers”) could reduce the 
effec tiveness of one or more of the drugs , while substances that decrease the 
enzyme’s activity (“inhibitors”) could result in high levels of the drugs , increasing the 
chance of harmful side effects.   Dabrafenib mesylate should not be taken with any 
other drugs  that are strong inducers or inhibitors of CYP 3A4 or 2C8.   Prohibited 
medications include azole antifungals, some antiepi[INVESTIGATOR_006], some antibiotics 
and some immunosuppressants.   Please check with the study investigator before 
prescribing or dispensing strong inhibitors/inducers of CYP 3A4 or 2C8. 
Mild/moderate inhibitors/inducers should be used with caution.  
 
 S1221  
  Page 108  
Version Date 8/21/17  
 
  
• Dabrafenib mesylate is considered an inducer of CYP 3A4, 2B6 and possibly 2C8/9 and 2C19, meaning that it can decrease the levels of other drugs that are processed 
by [CONTACT_36918].   This can lead to harmful side effects and/or reduce the 
effectiveness of those medications.  
 
• [COMPANY_004]2141795 is a moderate inhibitor of CYP 2C8 and 3A4.  Drugs th at are 
substrates of these CYP 2C8 and 3A4 should be used with caution and ones with a narrow therapeutic index should be avoided.  
 
• [COMPANY_004]2141795 is a substrate of p- glycoprotein (P -gp) and breast cancer protein 
(BCRP).  It is also an inhibitor of BCRP and OATP1B1.  Administration of sensitive BCRP substrates should be prohibited, such as topotecan.  
 
You and healthcare providers who prescribe drugs for you must be careful about adding 
or removing any drug in this category.  
 
Before you start the study, your study doctor will work with your regular prescriber to 
switch any prohibited medicines that are considered strong inducers/inhibitors or substrates of CYP 3A4, CYP,  2C8, P -gp, or BCRP . 
 Your prescribers should look at this web site  
http://medicine.iupui.edu/clinpharm/ddis/table.aspx or consult a medical reference to see 
if any medicine they want to prescribe is on a list of drugs to avoid.  
 
Please be very careful!  Over -the-counter drugs have a brand name [CONTACT_159964] —it’s 
usually big and catches your eye. They also have a generic name—it’s usually small and located above or below the brand name, and printed in the ingredient list.   Find the 
generic name [CONTACT_159965], with the pharmacist’s help, whether there could be an 
adverse interaction.  
 
Be careful:  
 • If you take acetaminophen regularly:   You should not take more than 3 grams a day if 
you are an adult or 2.4 grams a day if you are older than 65 years of age. Read 
labels carefully! Acetaminophen is an ingredient in many medicines for pain, flu, and 
cold.  
 
Speak to your doctor about any medications you think may contain 
acetaminophen in order to find a dose that is safe for you.  
 
• If you take herbal medicine regularly: You should not take St. John’s wort while you are taking dabrafenib mesylate.  
 
Other medicines can be a problem with your study drugs.  
 
• You should check with your doctor or pharmacist whenever you need to use an over -
the-counter medicine or herbal supplement.  
 
• Your regular prescriber should check a medical reference or call your study doctor 
before prescribing any new medicine for you.   Your study doctor’s name [CONTACT_800872][CONTACT_6811] __________________.  
 
 
 S1221  
  Page 109  
Version Date 8/21/17  
 
  
18.7 Information on Possible Drug Interactions – Patient Wallet Card  
 
 
 
 
   
 
     
 
     
 
    
 
     
 
     
 INFORMATION ON POSSIBLE DRUG 
INTERACTIONS  
You are enrolled on a clinical trial using the 
experimental agents dabrafenib mesylate , 
trametinib DMSO , and [COMPANY_004]2141795.   This 
clinical trial is sponsored by [CONTACT_6812].  
Dabrafenib mesylate interacts with drugs that 
are processed by [CONTACT_6813].   Because of this, 
it is very important to:  
 Tell your doctors if you stop taking regular 
medicine or if you start taking a new medicine.  
 Tell all of your prescribers (doctor, 
physicians’ assistant, nurse practitioner, 
pharmacist) that you are taking part in a clinical trial.  
 Check with your doctor or pharmacist whenever you need to use an over -the-
counter medicine or herbal supplement.  
Dabrafenib mesylate interacts with a specific 
liver enzymes called CYP 3A4 and 2C8 , and 
must be used very carefully with other medicines  that interact with this enzyme.   
 Before you start the study, your study doctor will work with your regular 
prescriber to switch any prohibited 
medicines that are considered “strong inducers/inhibitors or substrates of CYP 
3A4 and 2C8.”  
 [COMPANY_004]2141795 is a moderate inhibitor of 
CYP 2C8 and 3A4. Drugs that are 
substrates of these CYP 2C8 and 3A4 
should be used with caution and ones 
with a narrow therapeutic index should be avoided.   
 
 [COMPANY_004]2141795 is a substrate of p -
glycoprotein (P -gp) and brea st cancer 
resistant protein (BCRP). It is also an 
inhibitor of BCRP and OATP1B1. 
Administration of sensitive BCRP 
substrates should be prohibited, such as 
topotecan.  
 
 Before prescribing new medicines, your 
regular prescribers should go to http://medicine.iupui.edu/clinpharm/ddis/table.aspx for a list of drugs to avoid, or 
contact [CONTACT_6814].    
 Your study doctor’s name [CONTACT_832] _____________________________  and 
can be contact[CONTACT_6811] _____________________________ . 
 
 S1221  
  Page 110  
Version Date 8/21/17  
Appended 3/25/15  
 
  
 
18.8 Instructions for Patients for Storage of Trametinib Tablets  
 
Patient Storage Instructions:  
 
- Study drug can be transported home in the bottle(s) that were dispensed to the 
patient at room temperature.   Avoid exposing the bottle(s) to prolonged temperature 
extremes (i.e.  do not leave bottle(s) in a hot car while doing errands)  
 
- At home, store the study drug in the refrigerator,  2°C – 8°C (36°F - 46°F).  Do not 
freeze the bottles.  
 
- Keep the tablets in the original bottle(s).   Do not remove tablets from the bottle(s) and 
put them in a pi[INVESTIGATOR_800809].  
 
- Keep desiccant cylinder in the bottles in order to keep tablets dry .  
 
 